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ABSTRACT
Liu, Yue Ph.D., Purdue University, December 2016. Structural Studies on Cell Entry
of Respiratory Enteroviruses. Major Professor: Michael G. Rossmann.
Enteroviruses (EVs) represent a group of non-enveloped, positive strand RNA
viruses with an icosahedral capsid shell of about 300 A˚ in diameter. A variety of
EVs are notable for human infections, such as polioviruses, rhinoviruses, EV-A71,
and EV-D68. EV-D68 causes childhood respiratory infections worldwide and has also
been associated with neurological diseases. A lack of knowledge on the mechanisms
of EV-D68 infection has hindered the development of antiviral interventions. Specif-
ically, it remains obscure how the virus enters into host cells. Here, cell surface sialic
acid has been identified to be indispensable for EV-D68 to attach onto and infect
host cells. X-ray crystal structures of EV-D68 on its own and in complex with sialic
acid receptor analogues show that binding of the sialic acid receptor to a depression
on the virus outer surface destabilizes the virus. Receptor binding induces a cas-
cade of conformational changes of the virus to eject a fatty-acid like molecule, the
“pocket factor”, that regulates virus stability. Furthermore, exposure of EV-D68 to
an acidic environment triggers virus uncoating whereby the viral genome is released
into host cell cytosol for replication and translation. In comparison with the native
EV-D68 structure, the cryo-electron microscopic (cryo-EM) structure of an uncoating
intermediate formed at late endosomal pH (pH 5.5) shows an expanded capsid where
pores are formed at icosahedral two-fold axes and where segments of polypeptides
are externalized to interact with host membranes. Because of the low stability of
EV-D68, cryo-EM analyses of the virus at neutral pH indicate the involvement of
multiple structural intermediates in the uncoating process. More importantly, a cap-
sid binding compound, pleconaril, effectively inhibits EV-D68 infection by blocking
xix
virus attachment and uncoating. Pleconaril replaces the pocket factor in occupying
a hydrophobic pocket in viral protein 1. Thus these results illuminate structural
rearrangements of EV-D68 during cell entry and open up an avenue for developing
antiviral treatments of EV-D68 infections.
11. INTRODUCTION
Part of the text in this chapter is taken from [1–3] and is highlighted by a black,
vertical line in the right margin. Macmillan Publishers Ltd: Nature Communications
[3], copyright 2015. The text from [2] is reprinted with permission from AAAS.
1.1 Enterovirus Infection
The Picornaviridae consist of a variety of non-enveloped, icosahedral viruses with
a single, positive-stranded RNA genome. The family encompasses pathogens that
are notable for many human and animal diseases [4], such as poliovirus (PV) and
foot-and-mouth-disease virus. Out of the 26 genera of Picornaviridae, the genus
Enterovirus (EV) is classified into twelve different species, including EV-A to EV-
J and rhinoviruses (RV)-A to RV-C [5, 6]. EVs that cause human infections have
been primarily found in seven species, EV-A to EV-D as well as RV-A to RV-C [5].
These phylogenetically distinct species are classified according to a number of criteria
concerning sequence information (e.g., amino acid sequence conservation of structural
proteins and some non-structural proteins) and biological characteristics (e.g, receptor
usage) [5]. Historically, EVs that belonged to a single species were typed by variation
of surface antigens as determined using specific anti-sera, which is time-consuming
and depends upon the availability of anti-sera [7–9]. Currently, a widely-adopted
typing approach relies on complete or partial nucleotide sequence of the VP1 (viral
protein 1) gene [10]. EVs are responsible for a wide range of human diseases. These
include respiratory illnesses, hand, foot, and mouth disease (HFMD), myocarditis
and a number of neurological diseases such as encephalitis and poliomyelitis (Table
1.1) [11]. The major transmission modes of EVs are fecal-oral route and respiratory
route (e.g., airborne transmission or droplet transmission) [11].
2Table 1.1
Selected EVs that infect humans and common diseasesa
Species Number of types Key members Diseases
EV-A 24 EV-A71 HFMD, neurological complications
EV-B 61 Coxsackievirus B3 Myocarditis
Echovirus 7 Aseptic Meningitis
EV-C 23 Poliovirus 1-3 Poliomyelitis
EV-D 5 EV-D68 Respiratory illnesses
EV-D70 Acute hemorrhagic conjunctivitis
RV-A 77 RV-A2 Respiratory illnesses
RV-B 30 RV-B14 Respiratory illnesses
RV-C 55 RV-C15 Respiratory illnesses
a Table content was based on [5, 11,12] and http://www.picornaviridae.com.
1.1.1 Virion structure
Similar to many other picornaviruses, EVs have an outer diameter of approxi-
mately 300 A˚ [13, 14]. The atomic structures of a rhinovirus (RV-B14) and a po-
liovirus (PV type 1), as determined by X-ray crystallography, were the first ever
three-dimensional (3D) stuctures of animal viruses [13, 14]. The determination of
these virus structures represented a milestone in structural and molecular virology.
Since then, extensive efforts in the past three decades have led to high resolution
structures of native virions for a large number of EVs [15–32]. These viruses include
members of five different species, EV-A to EV-C and RV-A to RV-B. All of these
viruses exhibit pseudo T=3 icosahedral symmetry. The triangulation number T was
proposed by Caspar and Klug to describe the number of structurally similar protein
subunits in each icosahedral asymmetric unit [33]. Specifically, 60 copies of VP1,
VP2, and VP3, each of which has a length of about 250-300 amino acids, form the
capsid shell (Fig. 1.1), whereas 60 copies of VP4, a small polypeptide (about 70
amino acids), reside in the capsid interior [13]. The N-terminal glycine residue of
VP4 is covalently linked to myristic acid (a fatty acid with 14 carbon atoms) [34,35].
The N-termini of VP1, VP2, and VP3 are also located inside the virus and, together
3with VP4, participate in viral RNA binding [16]. Moreover, VP1, VP2 and VP3
all possess an eight-stranded antiparallel -barrel ”jelly roll” fold (Fig. 1.1), which is
an evolutionarily conserved fold shared by the capsid proteins of various plant and
animal viruses [36–39].
Fig. 1.1. The structure of enteroviruses. A. Diagrammatic repre-
sentation of the virus. VP1, VP2 and VP3 are colored blue, green, and
red, respectively. Each pentagonal icosahedral vertex is surrounded
by a surface depression or “canyon” colored black. The epitopes for
neutralizing antibodies for RV-B14 are labelled as NIm-I, NIm-II and
NIm-III, where NIm is neutralizing immunogenic site. B. The VP1
jelly roll is shown as a ribbon diagram. If the β-strands along the
polypeptide are identified sequentially as A to I, then one of the sheets
is composed of the anti-parallel strands BIDG and the other by the
anti-parallel strands CHEF. From [1]. Reprinted with permission from
AAAS.
1.1.2 Genome organization
Enteroviruses contain a positive sense RNA genome of about 7.5 kb [40,41]. One of
the unique features is that a protein, namely VPg (virion protein genome linked, about
22 amino acids long), resides at the 5’ end of the genome [42]. VPg is covalently linked
to the 5’-uridylylate moiety of the RNA through a tyrosine residue and acts as a primer
4for viral RNA synthesis [43]. Furthermore, the 5’ untranslated region (UTR) is highly
structured and contains the internal ribosome entry site (IRES), which is crucial for
internal ribosome binding and efficient translation of viral messenger RNA (mRNA)
[44, 45]. For the 3’ end, like cellular mRNAs, the viral RNA possesses a stretch
of poly (A), known as poly (A) tail. The protein coding region has a single open
reading frame. It is translated into a polyprotein (approximately 2200 amino acids
long) [46] that is initially processed by viral protease to give three precursor proteins,
P1, P2 and P3 [47]. P1 is further cleaved to produce the structural proteins VP0
(the precursor protein of VP4 and VP2), VP3, and VP1 for virus assembly [47,48], as
will be discussed below. P2 and P3 are processed into a number of intermediate and
final products that are functionally critical nonstructural proteins for viral replication
and for virus-host interactions [4, 47]. These protein products include 2Apro, 2B, 2C
(nucleoside triphosphatase), 3A, VPg, 3Cpro, and 3Dpol (Fig. 1.2) (11), where pro and
pol denote protease and polymerase, respectively. The proteins 3AB (the precursor
to 3A and VPg), 2BC (the precursor to 2B and 2C), and 3CDpro (the precursor to
3C and 3D) are also produced. In addition, 2B, 3A, 2BC, and 3AB contribute to
membrane rearrangements, formation of membrane replication complex, and viral
RNA replication [49].
1.1.3 Life cycle
Current knowledge of the infectious cycle of EVs in a host cell is largely based
on studies of polioviruses over the past six decades (reviewed in [52]). As illustrated
by Fig. 1.3, EV infection is initiated by viral attachment onto cell surface via spe-
cific receptor molecules [53, 54]. This step is followed by virus internalization into
host cells primarily via endocytosis. EVs can utilize different endocytic pathways
(e.g., clathrin-mediated endocytosis) for internalization and end up uncoating from
membrane bound organelles (e.g., endosomes) within a host cell [54]. The uncoat-
ing process is facilitated by structural changes of the capsid [53]. Once the viral
5Fig. 1.2. The genome organization of enteroviruses. A viral
protein, VPg, is covalently linked to the genome RNA. The viral RNA
encodes a polyprotein, which is processed by viral proteases to form
precursor proteins P1, P2, and P3. P1 is further processed into capsid
proteins, whereas P2 and P3 are cleaved into non-structural proteins.
The cleavage sites of viral proteases 2A and 3C (or 3CD [50]) are
indicated by yellow and blue triangles. The figure was taken from [51]
with some modifications.
genome is released into the cytoplasm, VPg is removed that allows for the translation
of viral mRNAs. This process leads to the production of a polyprotein that is then
processed by viral proteases into a number of individual viral proteins as mentioned
above. The capsid P1 precursor is cleaved to form a biological protomer (VP0, VP3,
and VP1). Protomers then assemble into capsid protein pentamers [48]. Viral RNA
synthesis takes place inside membranous vesicles, known as membranous replication
complexes [55–57], which are formed with the help of a number of viral non-structural
proteins as mentioned above. The viral polymerase 3Dpro [58, 59] catalyzes the pro-
duction of a full length negative strand RNA that is complementary to viral RNA
in the first step [60], which serves as a template to synthesize new positive sense
RNAs [61]. In the early phase of infection, these positive sense RNAs are translated
into viral proteins [62]. At the late stage of infection, these viral RNA molecules be-
come associated with capsid protein pentamers to assemble into infectious, progeny
6virions [48]. In this process, VP0 is autocleaved into VP4 and VP2 when the viral
RNA is present [63, 64]. Native empty particles containing uncleaved VP0 have also
been found in infected cells, which might be abortive products during viral assem-
bly [48]. The progeny virions are usually released upon the lysis of host cells [4].
Alternatively, these virions can exit from infected cells in a non-lytic manner [65].
In essence, they are released through secreted vesicles that encapsulates a cluster of
viral particles [65]. The ratio of particle number to plaque forming unit for EVs is
about 100 - 1000 [4], which is high. It indicates that a large portion of virus particles
might not successfully undergo a complete cycle of infection.
1.1.4 Prevention and control
The first EV, poliovirus, was discovered more than a century ago [66]. The mech-
anisms of EV replication have been studied for more than 50 years [67]. The only
vaccines that have been approved are those for PVs and for EV-A71. Vaccines for
PVs, including the inactivated PV vaccine [68] and the oral PV vaccine [69,70], have
been available since 1955 and have played an instrumental role in a significant de-
crease of cases of PV infections. The oral PV vaccine utilizes live attenuated PVs and
is currently the major cause of vaccine associated acquisition of PV infections, which
prevents the global eradication of PVs [71]. Furthermore, two inactivated vaccines
for EV-A71 were recently licensed in China [72, 73]. Nevertheless, a major challenge
of developing vaccines against all EVs is the presence of a diversity of EVs [11]. For
instance, there are more than 160 types of rhinoviruses that exhibit distinct surface
immunogenecity [12]. A very recent breakthrough was the development of an effec-
tive polyvalent inactivated RV vaccine against infections of a range of RVs in animal
models [74]. This vaccine was a cocktail of multiple types of inactivated RVs.
Despite some successful attempts in vaccine developments, there are still no ef-
fective antiviral therapeutics for prevention and treatments of EVs infections. In
principle, it is possible to develop antiviral compounds that are directed against a
7Fig. 1.3. The life cycle of enteroviruses. Enteroviruses attach
onto a host cell via receptor binding, which is followed by virus in-
ternalization into internal membrane organelles such as endocomes.
Then the positive sense viral genome is released into the cytoplasm,
where translation occurs. A polyprotein is produced in the first
step. It is subsequently processed by proteases into structural and
non-structural proteins. Viral RNA synthesis operates via a nega-
tive sense RNA intermediate and takes place in membrane replication
complexes of which the formation is facilitated by non-structural pro-
teins. Progeny virions are then assembled from structural proteins
and newly synthesized viral RNAs. These virions are mainly released
upon lysis of the host cell. The figure was taken from [51] with some
modifications.
conserved target or mechanism shared by a broad spectrum of EVs. In the past, two
major classes of anti-EV reagents entered into at least phase II clinical trials but ended
up not being approved. Pleconaril [75], a capsid binding reagent, was not approved
because of side effects especially in pregnant women ( [76]). An inhibitor of viral 3C
8protease, rupintrivir [77], showed poor oral bio-availability and was not clinically ef-
fective against natural RV infections [78]. In addition, some other virus proteins (e.g.,
2A protease and RNA-dependent RNA polymerase (reviewed in [76]) and host factors
(e.g., oxysterol-binding protein that facilitates viral RNA replication [79]) have been
explored as antiviral targets. Currently, the only anti-EV reagents under clinical de-
velopment are two capsid binding reagents, BTA-798 (against RVs) [80] and V-073
(against PVs) [81].
1.2 Cell Entry of Enteroviruses
1.2.1 General principles of viral entry into cells
Viruses are obligate parasites of host cells in that they rely on the host for repli-
cation of viral genome, production of viral proteins, and assembly of viral particles.
A general task for all viruses is the successful delivery of viral genome to sites where
viral genome replication occurs within a host cell. This is true no matter whether
the viral genome being released is in the form of naked nucleic acids, ribonucleopro-
teins or a subviral core containing nucleic acids inside. Nevertheless, in this process,
there are hurdles that a virus would need to overcome. These are physical barriers
presented by the host cell and energy barrier for changes of the virus structure that
primes viral genome release.
The first physical barrier is the cell plasma membrane. In order to attach onto the
surface of a susceptible cell, viruses have evolved to bind cellular receptors through
specific physical interactions (reviewed in [82]). Recognition of viruses by host cells
is frequently dependent on multivalent virus-receptor binding. There are various
types of cell surface receptors, including carbohydrate molecules, lipids and proteins.
Receptor specificity is largely attributed to long-term host-virus co-evolution [83].
Viral receptors are molecular determinants of the host range [84] and/or tissue tropism
(i.e., preference for specific tissues) of a virus [85]. Additionally, a co-receptor [86,87]
may exist that works with the primary receptor on viral entry in a synergistic manner
9[88,89]. Upon receptor dependent recognition by a host cell, the virus, in many cases,
triggers cell signaling so as to be internalized [90]. Alternatively, receptor binding
leads to structural changes of the virus that facilitate penetration of the plasma
membrane and subsequently genome release into cytosol [91]. In both ways, the virus
circumvents the plasma membrane barrier.
Viruses are often internalized via endocytosis (reviewed in [92]), a process involves
invagination of the plasma membrane and formation of membrane bound compart-
ments called endosomes. In addition to endosomes, viruses can also be taken up
to other internal compartments when hijacking specific endocytic pathways. Then
in the process of endosome maturation, cytoplasmic transportation of endosomes by
motor proteins ensures that the virus bypasses the crowding in cytoplasm [93], which
is another physical barrier of the host cell. This hitchhiking mechanism also allows
the virus to arrive at a destination that is close to the site of viral genome repli-
cation. With the help of endosomal acidification, many viruses can get around the
intervening endosomal membrane and be primed for uncoating [92]. In the case of en-
veloped viruses, fusion occurs between the viral membrane and host endosomal mem-
brane [94]. Non-enveloped viruses, instead, penetrate endosomal membrane by means
of pore formation or membrane rupture using specific viral polypeptides [34, 95–98].
Additionally, many DNA viruses and some RNA viruses need to circumvent another
barrier at the boundary between cytoplasma and nucleus in order to import viral
genome into the nucleus (reviewed in [99]).
When a virus enters a host cell, the virus also needs to cross the energy barriers
that limit structural changes of the virus. Viruses are generally stable being trans-
mitted in between hosts, but becomes unstable during cell entry in order for genome
release. Therefore, host cues, e.g., receptor binding, low pH, proteases, or redox con-
ditions, are critical to trigger conformational changes of the virus [100]. For many
enveloped viruses, an energy barrier lies in the fusion of two membranes that are dis-
tant from each other. The process requires insertion of viral fusion peptides into the
host membrane upon structural rearrangements of viral enveloped proteins [94]. The
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structural changes are usually triggered by low pH [101], receptor binding [102] or pro-
teolysis [103,104]. Non-enveloped viruses can use multiple mechanisms. Host factors
can induce destabilization of the virus [105–108], release of viral components from the
virions [109–113], externalization of specific regions of structural proteins [96,114], or
a series of complicated structural changes [113,115,116].
Therefore, viral entry is dependent on the interplay between the virus and the
host cell. Determination of the role of host factors and structural changes of the virus
in the entry process would open up opportunities for antiviral interventions.
1.2.2 Major approaches to study viral entry
A comprehensive view of the viral entry process often requires a variety of com-
plementary approaches. The following are a few key aspects of studying the entry
process: identification of viral receptors, analysis of virus-receptor binding, dissection
of viral internalization pathways, study of structural changes of the virus necessary
for penetration and uncoating, and kinetics of viral entry.
The first viral receptor, a carbohydrate moiety named sialic acid, was discovered
using an enzymatic approach [117, 118]. Nevertheless, it was not until the 1980s
that the field boomed with the advent of molecular cloning [119] and monoclonal
antibodies [120]. Proteinaceous receptors were identified for a number of impor-
tant animal viruses including human immunodeficiency virus [121–126]. In the post-
genomic era, quantitative proteomics and transcriptomics approaches have become
prevalent. The proteomics method utilizes mass spectrometry coupled with immuno-
precipitation [127] or affinity purification [128]. It is based on specific interactions
between a cellular receptor and the receptor binding components of a virus. The tran-
scriptomics approach relies on comparison of transcription levels in susceptible over
non-susceptible cell lines [129]. Most recently, genome-wide genetic screening tech-
niques have been applied to discover viral receptors that were previously challenging.
These include RNA interference (RNAi) [130], haploid screening [131], and CRISPR
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(clustered regularly interspaced short palindromic repeats) [132]. The general idea is
disruption of the function of individual genes by means of silencing gene expression,
insertional mutagenesis or knock out of genes. All these genetic screening approaches
are followed by functional validation of positive hits. Particularly, haploid screening
showed that intracellular viral receptors that are present in internal compartments of
a host cell can facilitate virus entry [133].
Multiple endocytic pathways for virus uptake have been found, including clathrin
mediated endocytosis, macropinocytosis, caveolar/lipid raft mediated endocytosis,
and some alternative mechanisms [92]. A combination of live cell imaging, genetic
methods, and pharmacological inhibition can be employed. In general, there are sev-
eral critical aspects concerning a specific pathway: virus induced host signaling events,
the route by which viral internalization occurs, intracellular trafficking of cytoplasmic
membranous compartments that carry the virus, and host factors that trigger virus
penetration and uncoating. Multicolor live cell imaging using fluorescence microscopy
is crucial to dissect different steps of viral entry and to track the dynamic process of
each step. Due to its high sensitivity as well as good spatial (better than the diame-
ter of a virion) and temporal resolution (often at the level of seconds), this approach
provides spatiotemporal analysis of fluorescent dye-labeled single virus particles [134].
Furthermore, the other two approaches offer advantages in identification of host fac-
tors and study of molecular mechanisms. Specifically, knockdown of host genes by
genetic methods (e.g., RNAi) has been utilized for discovering novel host factors that
define novel pathways and for clarifying the functional role of a known factor (e.g.,
clathrin, caveolin, or other factors) so as to differentiate between established path-
ways [135]. Pharmacological inhibition takes advantage of chemical compounds that
specifically target individual host factors and can be useful to determine host triggers
of virus penetration and uncoating (e.g., bafilomycin is an inhibitor of endosomal
acidification) [135].
Biochemical and biophysical approaches in vitro are suited to provide a clearer and
often quantitative understanding of specific molecular events, including virus-receptor
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binding, virus penetration, and genome release. Many of these molecular events have
been reconstituted in vitro using purified macromolecules with or without artificial
membrane systems (e.g., liposomes) that mimic native biological membranes [136].
General principles of the interactions of a virus with receptor molecules and of the
conformational changes of viruses associated with viral entry have been illustrated by
structural studies of the entire viral particles or isolated viral components at low reso-
lution (about 30-40 A˚) to near atomic resolution (4 A˚ or better). The major structural
tools were X-ray crystallography, single particle cryo-electron microscopy (cryo-EM),
cryo-electron tomography (cryo-ET), or hybrid methods (e.g., a combination of x-
ray crystallography with cryo-EM [137]). One of the first examples was the crystal
structure of influenza virus hemagglutinin in complex with sialic acid [138]. Studies
using complementary biophysical techniques, such as surface plasmon resonance [139]
and fluorescence correlation spectroscopy [140], have contributed to knowledge on the
kinetics of virus-receptor binding and of genome release. Moreover, the application of
mass spectrometry has been instrumental to study the stoichiometry of virus-receptor
binding as well as compositional and conformational changes of viral particles [141].
Additionally, single molecule techniques have characterized the dynamics of intact
viruses or viral protein structures concerning receptor binding and fusion [142,143].
More recently, an emerging technique, namely cryo correlative light and electron
microscopy (cryo-CLEM), has begun to show new details of the viral entry process
by studying interactions of virus with host cells at close-to-native state [144]. CLEM
combines the spatial resolution of cryo-ET (i.e., at the scale of several nanometers)
with the temporal resolution (i.e., at the scale of seconds) of light microscopy and
achieves spatially precise correlation using markers [145]. Although technical issues
like specimen thickness await further developments, CLEM holds the promise for
visualizing ultrastructural details and dynamics of virus-cell interactions that span
different spatial scales.
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1.2.3 Current knowledge of enterovirus entry into cells
Over the past several decades, structural and functional studies have defined some
of the molecular mechanisms of EV entry into host cells. As will be discussed be-
low, general principles underlying attachment and internalization of multiple EVs
have been established, whereas the penetration and uncoating processes are less well
understood.
Beginning in the 1980s, a diversity of specific cellular receptors have been iden-
tified for EVs (Table 1.2) [124–126, 146–169]. A depression on the virion surface,
the “canyon”, that encircles each five-fold vertex (Fig. 1.1), is frequently the bind-
ing site for EV receptors [28, 108, 170–182]. Many of these receptors belong to the
immunoglobulin (Ig) superfamily (Table 1.2) [183]. This region also has limited acces-
sibility to neutralizing antibodies [13]. In most EV structures, a hydrophobic pocket
in the VP1 jelly roll is located underneath the canyon and accommodates a “pocket
factor (Fig. 1.1), which is a fatty-acid like molecule that contributes to stabilize the
virion [16, 184]. Many EVs interact with the N-terminal Ig-like domain of their cog-
nate Ig-like receptors. This process proceeds via a two-step mechanism [172,185–187],
which involves a competition between the pocket factor and the receptor [188]. In
essence, receptor binding depresses the base of the canyon to squeeze the VP1 pocket,
expelling the pocket factor [188]. Thus, binding of Ig-like receptors destabilizes the
virus that primes the uncoating process. Nevertheless, receptors of some EVs, such
low density lipoprotein receptor of the minor group rhinoviruses, bind to other loca-
tions on the viral surface and do not induce viral uncoating (Table 1.2) [29,189–191].
Depending on the virus and the cell type, EVs are known to be internalized into
host cells via different routes. Multiple types of distinctive endocytic pathways have
been found for EV entry [54]. A large number of rhinoviruses utilize clathrin-mediated
endocytosis and end up uncoating in endosomes [197]. In these cases, endosomal
acidification is an important trigger for virus uncoating, of which the pH threshold




























































































































































































































































































































































































































































































































































































dosomes). Many viruses from the species EV-B can follow either caveolae-dependent
endocytosis or macropinocytosis [198]. Low pH is not a trigger for uncoating of these
viruses. There are also known examples of EVs (e.g., EV-A71) that take two different
endocytic pathways when using two separate cellular receptors [199, 200]. In addi-
tion, PV appears to be a special case, because binding of cell surface PV receptor
CD155 to the virus at physiological temperature is sufficient to cause genome release
directly through the plasma membrane or through vesicles near the plasma membrane
shortly after internalization [201]. More importantly, binding of EVs onto host cell
surface induces a series of signaling events that result in viral internalization. This is
because that virus-receptor binding can lead to phosphorylation of the cytoplasmic
region of receptor molecules [202] or cause clustering of receptor molecules into spe-
cific microdomains on the cell surface [203]. In both ways, downstream intracellular
signaling can be activated that involves the participation of kinases, adaptor proteins,
cytoskeletal proteins, and a number of other cellular proteins.
The penetration and uncoating of EVs rely on structural changes of the virus.
Upon induction by host factors, the native virion (with a sedimentation coefficient of
160S) of many EVs is converted into an altered particle or subviral A-particle (135S)
[105–107, 178, 182, 204, 205]. The trigger is often Ig-like receptor molecules and/or
endosomal acidification. Furthermore, A-particles were also known to be formed by
heating native virions in vitro [206–209]. A-particles are featured by expansion of the
capsid shell, externalization of the N-terminal amphipathic region of VP1 (the first
about 25 amino acids [114]), and release of myristoylated VP4, as compared with
native virions [209–213]. A line of in vitro and cell-based evidence indicated that the
A-particle is an intermediate during EV entry.
(1) A-particles were found in the supernatants upon increasing temperature to 37 °C
after attachment of native viruses to cells at 4 °C [214–216];
16
(2) Pre-formed A-particles retain the ability to infect host cells despite with dramati-
cally reduced efficiency and, more importantly, A-particles complexed with a non-
neutralizing antibody infect cells in an Fc receptor-dependent manner [217,218];
(3) A-particles were isolated from infected cells at the stage of internalization into
cytoplasmic membranous compartments [114,194,219];
(4) Inhibition of conformational changes necessary for both thermal inactivation and
uncoating correlates with the antiviral activity of capsid binding compounds [220].
Myristoylated VP4 and the N-terminal amphipathic helix of VP1 are critical for
EV penetration through the membrane of intracellular vesicles, which are often endo-
somes. The mechanism of penetration is either pore formation (e.g., RV-A2) [221–223]
or lysis of membrane (e.g., RV-B14) [224]. VP1 N-terminal amphipathic helices,
which are probably externalized through the base of the canyon or two-fold axes on
A-particles [209, 211, 212, 225], might act as anchors for A-particles to directly at-
tach onto target membranes [114, 136, 226, 227]. Thus binding of A-particles to lipid
membranes is independent of receptor molecules. An icosahedral two-fold axis of the
A-particle appears to face the membrane [227]. Myristoylated VP4 molecules have
been proposed to exit through icosahedral two-fold axes [228] or five-fold axes [229]
in the transition of native virions to A-particles. The VP4 molecules are oligomer-
ized and form channels in model membranes, as demonstrated by electrophysiological
experiments and EM analysis [230, 231]. The functional importance of VP4 in virus
penetration and uncoating was further confirmed by the observation that mutation
of VP4 changes its ability to form pores in vitro and to allow RNA release during
infection [232–234].
Enteroviruses uncoat from cytoplasmic membrane compartments such as endo-
somes. A-particles were proposed to release genomic RNA into cytosol, resulting in
the formation of subviral emptied particles (80S) [114, 219]. Furthermore, emptied
particles were found in isolated endosomes derived from infected cells [219]. Much
like A-particles, emptied particles can be produced in vitro by heating and share
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considerable similarity to the cell-derived equivalent in terms of composition and
sedimentation coefficient [206, 229, 235–238]. Structural studies of in vitro produced
emptied particles showed that the capsid shell of these particles is structurally similar
to that of A-particles [31, 238]. They are both expanded relative to native virions.
These observations support the idea that emptied particles is another intermediate
(in addition to A-particles) during cell entry of EVs [53, 114, 219]. In the process of
RNA release, the viral RNA is protected from RNA degrading enzymes by a shield
that is possibly composed of the VP1 N-termini and perhaps VP4 molecules [226].
Using cross-linking reagents that capture the virus when releasing the genomic RNA,
recent studies indicated that viral RNA exits from the virus through two-fold axes
and that the exiting of genomic RNA begins with its 3’-end [239–241]. When RV-A2
was incubated at 56°C, the exiting of viral RNA 3’-end completed in about 3 min,
and release of free viral RNAs into solution occurred about 7 min later. The whole
process of RNA release took only around 20 min [240]. Similarly, viral RNA was first
detected in the cytosol of cells infected by RV-A2 at about 10 min post infection when
using a multiplicity of infection of 15 [242]. Nevertheless, the trigger for RNA release
during EV infection remains unknown. It has been suggested that the disruption
of viral RNA secondary structures is required for RNA release [201] and that inter-
actions of uncoating intermediates with lipid membranes is a prerequisite [226]. In
addition, negatively charged amino acid residues on the inner surface of EV capsids
could expel genomic RNA from the virus via charge-charge repulsion [212]. Taken to-
gether, a wealth of information on EV penetration and uncoating has primarily been
derived from work on PVs and RVs. Nevertheless, it is not clear whether other EVs,
including the circulating EV-A71 and EV-D68, adopt the same molecular mechanism
as what have been established for PVs and RVs.
Delineation of the mechanism of EV entry has aided the design and development
of anti-EV reagents. A series of capsid-binding antiviral compounds (e.g, pleconaril)
have been and are being developed to inhibit infections by a broad spectrum of
EVs [76]. These inhibitors bind to the VP1 pocket of EVs often by replacement
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of the pocket factor [243–246]. The major mechanisms of action are blocking of
virus uncoating [246–249] and, in some cases, inhibition of receptor dependent virus
attachment [249–252]. Capsid binding reagents also impede transient and reversible
externalization of internal polypeptides at physiological temperature, an event named
as virus “breathing” [253–255].
1.3 X-Ray Crystallography and Electron Microscopy
Two breakthrough discoveries in the 1950s ushered in a new era of biology. The
double helical structure of DNA was deduced in 1953 [256]. Only several years later,
the first three-dimensional structures of proteins, myoglobin [257] and hemoglobin
[258], were solved. These pioneering works in structural and molecular biology pro-
vided a structural view of the functions of biological macromolecules and began to
decipher the atomic secret of biological processes. Since then, nearly six decades
of effort have led to the experimental determination of more than 120,000 biologi-
cal macromolecular structures. These structures were made possible by three major
techniques: X-ray crystallography, electron microscopy (EM), and nuclear magnetic
resonance (NMR). NMR has the advantage of studying protein dynamics in solu-
tion but generally proves difficult for structure determination of biomolecules with a
molecular weight of more than 50 kilodaltons (kDa). This section will focus on the
other two approaches, X-ray crystallography and EM.
1.3.1 X-ray crystallography
In 1912, the phenomenon of X-ray diffraction by crystals was discovered by Max
von Laue (reprinted in [259]). The diffraction pattern was subsequently interpreted by
William Lawrence Bragg as being derived from the reflection of incident X-ray waves
by parallel planes within a crystal [260]. This interpretation was expressed as an
equation that became known as Bragg’s law. These and many early crystallographic
studies had dealt with crystals of inorganic compounds such as sodium chloride.
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It was not until 1934 when John Bernal obtained the very first X-ray diffraction
pattern of a crystalline protein (pepsin) [261]. Nevertheless, the application of X-ray
crystallography to structure determination of proteins was challenging. It took more
than 20 years for Max Perutz to solve the structure of hemoglobin [258]. The central
problem was the phase problem. In essence, in an X-ray diffraction experiment, the
phases of diffracted x-ray waves are unknown, whereas the amplitudes of diffracted
X-ray waves are known according to experimentally measured reflection intensities.
The aim of structure determination is to determine the electron density ρ(xyz) at
each point with the coordinates (x, y, z) in the crystallographic unit cell. An electron
density map in real space is the inverse Fourier transform of structure factors in
reciprocal (Fourier) space. Structure factor is a complex number that describes the
amplitude and phase of a diffracted X-ray wave.







|F(hkl)|exp(−2pii(hx+ ky + lz))exp(iα(hkl)) (1.1)
where V represents the unit cell volume. |F(hkl)| and α(hkl) are the amplitude and
phase of the structure factor with miller indices (hkl), respectively. i is the square
root of -1.
One of the first ideas to tackle the phase problem was isomorphous replacement
[262], which was crucial to structure determination of hemoglobin and myoglobin.
This approach requires preparation of heavy atom derivatives, which refer to crystals
of native protein complexed with heavy atoms (e.g., mercury). Heavy atoms are
usually incorporated into protein crystals by means of soaking or cocrystallization
with heavy atom compounds. The assumption is that the native protein crystal
is isomorphous to the heavy atom derivative. It means that the two crystals have
identical unit cell parameters. Depending on the number of heavy atom derivatives
used for phasing, there are two variations: single isomorphous replacement (SIR) that
uses one heavy atom derivative and multiple isomorphous replacement (MIR) that
uses multiple heavy atom derivatives [263].
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Heavy atoms diffract X-rays better than the light atoms (e.g., carbon) present
in the native protein. Thus the structure factors of heavy atoms, FH(hkl), have
relatively large amplitudes, which contribute to the difference between the structure
factors of native protein and of heavy atom derivative. Assuming that there are
two heavy atom derivatives, heavy atom locations can be determined by calculation
of difference Patterson maps with Fourier coefficients (|FPH1(hkl)| − |FP(hkl)|)2,
(|FPH2(hkl)| − |FP(hkl)|)2, and (|FPH1(hkl)| − |FPH2(hkl)|)2, in which FP(hkl),
FPH1(hkl), and FPH2(hkl) are the structure factors of native protein and two heavy
atom derivatives, respectively [264]. The Patterson function is essentially the inverse
Fourier transform of intensities and is a function of interatomic vectors in real space
[265]. Information of heavy atom locations is used to compute the structure factors
of heavy atoms, FH1(hkl) and FH2(hkl).
Structure factors are usually expressed as vectors in an Argand diagram, where
the x and y axes represent the real and imaginary parts of a complex number, re-
spectively. Thus, FPH(hkl) is the vector sum of FP(hkl) and FH(hkl). The phases
for native protein can be determined geometrically using a Harker construction (Fig.
1.4) [266]. There are two possible phase angles when only one heavy atom derivative
is considered. This uncertainty is often resolved by the use of multiple heavy atom
derivatives or by taking advantage of anomalous signals of heavy atoms (as will be
descried below) [267]. However, there are experimental errors in structure factor am-
plitudes. Additionally, |FH(hkl)| is small in many cases. These factors cause some
ambiguities in determining phases using MIR. Blow and Crick developed a method
where any phase angle has a probability to be the correct solution [268]. In MIR,
an individual probability distribution is calculated for α(hkl) concerning each heavy
atom derivative. The product of individual probabilities gives a joint probability for
every possible phase angle, which is employed to calculate a probability-weighted av-
erage phase or the “best phase”. A “figure of merit” is used as a metric to evaluate
the goodness of phase determination. Nevertheless, the bottleneck of isomorphous
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replacement is preparation of suitable heavy atom derivatives, which is generally dif-
ficult and time-consuming.
Fig. 1.4. A Harker construction for phase determination us-
ing multiple isomorphous replacement. The red and blue circles
intersect at two positions, showing an uncertainty of phase determi-
nation when using single isomorphous replacement.
The anomalous dispersion (scattering) effect of heavy atoms offers another ap-
proach to solve the phase problem [269]. When the energy of incident X-ray beam
reaches a transition energy (often referred to as absorption edge), electrons in an
inner shell (e.g., K shell) of atoms become ejected due to the absorption of photon
energies. This causes alterations of the amplitude and phase of the atomic scattering
factor.
f = f0 + f
′
(λ) + if ”(λ) (1.2)
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where the total atomic scattering factor f is a complex number, and f0 is the normal
atomic scattering factor when the energy of X-ray beam is well below the absorption
edge. f
′
and f ” are components due to anomalous scattering, which are wavelength
(λ) dependent. f
′
is often negative and has the same phase as f0, whereas f
” is out
of phase by 90° relative to f0.
Early work had focused on combining anomalous dispersion with isomorphous
replacement [267, 270–272]. Hendrickson and coworkers developed a practical ap-
proach, namely multiwavelength anomalous dispersion (MAD) [269], that has fueled
structure determination of proteins without prior information about the structure.
MAD is made possible by finely tunable synchrotron radiation. Selenium (Se) is a
commonly used heavy atom, because its absorption edge is located within the range
of usable X-ray wavelengths [273]. Se atoms are introduced into the native protein
by protein expression in the presence of a surrogate of methionine named selenome-
thionine [273]. The aforementioned phase shift of the atomic scattering factor breaks
down the Friedel’s law, where the Friedel pair, F(hkl) and F(hkl), have an identical
amplitude. Heavy atom locations are determined by calculation of an anomalous
difference Patterson map with coefficients (|FPH(hkl)| − |FPH(hkl)|)2 [274]. Thus,
phases for native protein can be determined in a similar way as in isomorphous replace-
ment. Given that the anomalous scattering components are wavelength dependent
(Equation 1.2), data collection in MAD is performed at several selected X-ray wave-
lengths [269]. These include that of the absorption edge and of the peak absorption,
which give the largest magnitudes of f
′
and f ”, respectively, and maximize anomalous
signals for phasing. In most cases, a wavelength being remote from the absorption
edge is also included. Nevertheless, one disadvantage of MAD is the need to pro-
duce selenomethionine substituted proteins in a large amount and suitable crytals of
selenium labeled proteins. A workaround of these problems is to rely on anomalous
signals of sulfur atoms in unlabeled proteins [275].
Another approach, namely molecular replacement (MR), originated from the con-
cept of non-crystallographic symmetry (NCS) [276]. Crystallographic symmetry op-
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erators are applicable to the infinite crystal lattice, whereas NCS operators are only
applicable to a locally defined volume. NCS defines the rotational and translational re-
lationship between structurally similar (or identical) subunits in one crystallographic
asymmetric unit or between structurally similar subunits that are present in different
crystals.
The use of NCS for determination of initial phases is described here. MR takes ad-
vantage of known structures of proteins that have a homologous amino acid sequence
to the target protein for which the structure is unknown. Phases are calculated based
on a properly oriented and positioned search model that is a homologous structure.
Thus, the problem can be divided into two steps, rotation determination and trans-
lation determination. Rossmann and Blow worked out a rotation function that was
expressed as the overlap of a Patterson function with a rotated version of the Patter-
son function [277]. This rotation function R has the form






where h (h = (h, k, l)) and p (p = (p, q, r)) are vectors in reciprocal space. F(h) and
F(p) are structure factors with miller indices (hkl) and (pqr), respectively. Here they
can be considered as structure factors of the unknown structure and of the search
model, respectively. h’ describes the position of p after applying a rotation matrix
[C], which is specified by three Euler angles or polar angles. U is the volume of an
integration sphere (by assumption) whose center is at the origin of the unit cell and
whose radius is r. In such case, G is a sinc function with the argument |h + h’|r. A
maximum of R would indicate that the search model is correctly rotated to match
the orientation of the unknown structure. To determine the translation needed to
correctly position the search model (at the determined orientation) in the unit cell,
translation search can be performed to minimize the difference between the observed
structure factors and the calculated structure factors (calculated using the search
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hkl |(Fo(hkl)|− < |Fo(hkl)| >)(|Fc(hkl)|− < |Fc(hkl)| >)√∑
hkl (|Fo(hkl)|− < |Fo(hkl)| >)2
∑
hkl (|Fc(hkl)|− < |Fc(hkl)| >)2
(1.4)
where Fo(hkl) and Fc(hkl) are the observed and calculated structure factor ampli-
tudes, respectively. There are also several other criteria for translation search (re-
viewed in [278]), e.g., the overlap of the observed Patterson map with the calculated
Patterson map [279].
Averaging of NCS related identical subunits within one crystallographic asym-
metric unit represents a useful method for phase improvement [36, 37, 280, 281] and
for phase extension [13, 14, 282, 283]. For instance, icosahedral viruses have an NCS
redundancy of at least five, where the NCS redundancy refers to the number of iden-
tical subunits in a crystallographic asymmetric unit. This redundancy leads to an
effective decrease of the size of the structure to be determined. The idea is explained
by the application of real space NCS averaging and phase extension to virus structure
determination below [14, 284–290]. The assumption is that initial phases have been
determined at a low resolution using one of the methods mentioned above. First, a
molecular envelop is defined in which the NCS relationship of subunits is valid. The
envelop might be a hollow spherical shell or based on a homologous atomic structure.
Electron densities outside the envelop are set to low, constant value (such as zero), a
procedure known as “solvent flattening” [291]. Electron densities within the envelop
is averaged using the NCS operator. The averaged map is Fourier back transformed
to produce more accurate phases than the original ones. A new map can be calculated
when the observed structure factor amplitudes (appropriately weighted) are combined
with the new phases. Iterative cycles of these procedures improve the phases until no
further improvements are observed. Structure factors computed from the map (after
density modifications) contain phase information at slightly higher resolution than
the resolution limit used for calculating the current map. Such phase information
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can be combined with the observed structure factor amplitudes to calculate a new
map, thus extending the resolution limit. Phases at the current resolution limit are
then improved by multiple cycles of NCS-averaging and solvent flattening. Thus,
phases can be gradually extended in small incremental steps to the resolution limit
that the data allow. Phase extension using large step sizes often results in erroneous
phases [13]. An appropriate step size, as determined based on a similar sinc function
to the G function in the rotation function mentioned above, is about one or two re-
ciprocal space lattice units [292, 293]. In this process, better defined NCS operators
and molecular envelop can be used. Convergence is usually monitored the difference
between observed and calculated structure factors using correlation coefficient as an
indicator.
1.3.2 Electron microscopy
The electron microscope (EM) was invented in the 1930s by Ruska [294] and
initially used to characterize inorganic chemical materials. Unlike these materials,
biological samples, which are made up of light elements like carbon, have intrinsically
low contrast. These samples are hydrated and prone to radiation damage [295].
Sample thickness is also a concern when cells or tissues are used. Beginning in late
1950s, biological samples were negatively stained by electron dense reagents such as
heavy metal salts in order to improve the image contrast [296]. The resultant samples
were also tolerant to radiation damage. Nearly a decade later, DeRosier and Klug
developed a general approach to computationally reconstruct the three dimensional
(3D) structure of an object from two dimensional (2D) EM images that represent
multiple views of the object [297]. The idea was based on the assumption that each
of the 2D EM images is a projection of the 3D density distribution of the object (the
effect of contrast transfer function (CTF) should be taken into account [298].) In
principle, the Fourier transform of a projection is a central slice of the 3D Fourier
transform of the object. Thus, a 3D density map of the object can be reconstructed
26
by Fourier synthesis using all available 2D slices, each of which is computed from one
of the experimental images. This approach is particularly powerful when the object
has screw or rotational symmetry, because different views of an asymmetric unit of
the object are present in one experimental 2D image. The development of the 3D
reconstruction method marked the birth of biomolecular structure determination by
EM. However, the method had been applied only to images of negatively stained
particles at the time. Heavy metal stains cause uneven staining and distortions of
the objects present in the sample. Furthermore, the resolution of 3D reconstructions
is limited by the grain size of heavy metal salts and can not go beyond about 20 A˚
resolution [299].
In an attempt to preserve samples at close-to-native state, to minimize radiation
damage, and to keep the sample under high vacuum within the microscope, Taylor and
Glaser obtained high resolution (up to 3.4 A˚) electron diffraction patterns of frozen,
hydrated 2D crystals (about several protein layers in thickness) of catalase [300]. This
was achieved in 1974 when the field of cryo-EM began. Moreover, a general approach
for producing unstained, hydrated, frozen samples was introduced by Dubochet in
the 1980s [301]. Plunge freezing of a tiny volume (several nanoliters or less) of sample
solution into a suitable cryogen such as liquid ethane resulted in dispersed, single
molecules (or particles) being embedded within a layer of vitreous ice, which is distinct
from hexagonal or cubic ice. This approach is still widely used today for a variety
of samples, including cells, crystals, helical assemblies, and single particles such as
icosahedral viruses and other macromolecular assemblies with or without symmetry.
Imaging of radiation sensitive, unstained biomolecules requires low electron ex-
posures (e.g., about 16-25 e-/A2 for single particles [302]), because the extent of
radiation damage depends on the total electron doses for imaging. For these samples,
one event of elastic electron scattering is often accompanied by about three to four
events of inelastic electron scattering [295]. The former does not change the energy
of the incident electron and contributes to signals present in images. The latter de-
posits energy onto biological samples, causing ionization of the sample and formation
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of radials that disrupt the chemical structures of biomolecules. This leads to a high
amount of noise in experimental images and a low signal-to-noise ratio (SNR). Thus
structure determination often requires averaging of multiple images. Two dimensional
crystals and helical assemblies (also known as one dimensional crystals) were the first
objects of which the structures were determined to 4 A˚ resolution or better [303–305].
These objects benefit from enhanced SNR by averaging of many repeating units. For
instance, the first structure of a membrane protein, bacteriorodopsin, was determined
by Unwin and Henderson in 1975 [306], whose effort subsequently yielded an atomic
structure of the seven-helix protein [303]. Determination of a 1.9 A˚ resolution struc-
ture of aquaporin 0 using 2D crystals further showed the power of averaging in EM
structure determination [307].
Icosahedral viruses represented the first samples that consist of single particles to
reach subnanometer (better than 10 A˚) resolution in 1997, which made it possible
to assign α-helices in the structure [308, 309]. In comparison to particles with low
symmetry or no symmetry, the large size (at least 260 A˚ in diameter) and high sym-
metry of icosahedral viruses are favorable to determining the orientations and centers
of experimental projection images. The advantage of averaging multiple icosahedral
asymmetric units reduces the number of particles needed for 3D reconstruction. Only
about a decade later, determination of the first near-atomic resolution virus struc-
tures [310,311] were made possible in part because of improved transmission electron
microscopes. The improvements included mechanically stable column and cryo-stage,
better vacuum, and the introduction of the field emission gun (FEG). In particular,
the FEG produces a much brighter beam with smaller size and better coherence than
what had been conventionally used (e.g., LaB6 crystals).
Nevertheless, it proved challenging to work with single particles that have low
or no symmetry and that are smaller than icosahedral viruses. For instance, the
ribosome structure was limited to about 6 A˚ resolution [312] before the advent of
direct electron detectors (DED), as will be mentioned below. It was in part because
EM images have low contrast. Unstained biomolecules in a thin (no more than 1000 A˚
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thick) layer of vitreous ice are essentially transparent to the electron beam. The thin
specimen scatters electrons weakly and causes a slight phase shift of electron weaves.
Thus such specimen is considered as a weak-phase object [298]. Images are formed
due to the interference of the unscattered and scattered electron waves. In-focus (or
close-to-focus) images generally have low contrast. In practice, image contrast at low
resolution can be enhanced by defocusing the objective lens, which modulates the
CTF of the microscope. However, a full recovery of high resolution signals by CTF
correction is difficult when dealing with highly defocused images [313].
The central problem in single particle cryo-EM is the accurate determination of
the orientation and center of each experimental projection image. The particle orien-
tation is specified by three rotation angles including one in-plane rotation angle and
two out-of-the-plane rotation angles, where the plane refers to the plane where the
projection image lies. The particle center is specified by the position (x and y) of
a point in the plane of the projection image. This is hampered by the low contrast
of experimental images. Crowther and coworkers developed a common line method
mainly for icosahedral viruses in the 1970s [314,315]. A common line is defined as the
line shared by a pair of 2D sections in Fourier space. For a given 2D section, an icosa-
hedral symmetry related 2D section intersects with it along one common line, and
another 2D section generated using the inverse of this symmetry operator intersects
with the original 2D section along another common line. These two common lines
represent a pair of self-common lines. The center of a projection image can be esti-
mated based on the cross correlation between the image and its rotational averaged
derivative or by calculation of the center of mass. The orientation of a projection im-
age is determined by searching for the best orientation in an icosahedral asymmetric
unit that minimizes the sum of phase residuals for all 37 pairs of self-common lines of
the icosahedral particle image. Phase residual is an indicator of the phase difference
between a pair of common lines. 3D reconstruction using projection images with the
determined centers and orientations produces an initial 3D model, from which a few
reference projections are usually generated. The Fourier transform of an experimen-
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tal image and that of a reference projection (or an experimental image for which the
orientation has been determined) give rise to a pair of cross-common lines. There are
60 pairs of cross-common lines when icosahedral symmetry is considered. The sum of
phase residuals for all pairs of cross-common lines is used as a criterion to determine
the orientation (and subsequently the center on the basis of the determined orien-
tation) of an experimental image. Reconstruction of all experimental images with
known orientation and center produces a 3D model that serves as the initial model
for the next iteration. Thus, this iterative process allows for accurate determination
of particle orientations and centers. Recently, a new implementation of the common-
line method in the EMAN program package has achieved simultaneous determination
of all five parameters for orientation and center using a Monte Carlo optimization al-
gorithm [316]. In addition, initial 3D models can be reconstructed using experimental
images to which orientations are randomly assigned. Furthermore, the angular recon-
stitution method [317] developed by van Heel is essentially the real-space equivalent
of the aforementioned common-line approach and has been extended to objects with
other point group symmetries. This method relies on using 2D class averages for
determining particle orientations and centers, because class averages have a much
improved SNR compared to individual experimental images. Experimental particle
images with similar orientations are clustered into a class, and they are averaged to
produce a 2D class average [318].
Projection matching is a model based approach developed by Frank and cowork-
ers [319]. The prerequisite is that an initial 3D model has been built using the afore-
mentioned methods or other approaches that require multiple images of the same area
being recorded at different tilt angles [320]. The initial 3D model is used to generate
a series of reference projections that are sampled at a suitable angular step and that
represent all possible different views. The centers of the experimental images are then
roughly determined in a similar way as what was described above. Each experimental
image is compared to every one of the reference projections. The orientation of the
experimental image is determined by that of the reference projection to which it best
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matches. The initially determined particle centers can also be improved in this way.
Several criteria such as cross correlation can be used as an indicator of the degree of
matching between images. CTF correction of the experimental images needs to be
performed in the process. As in the cross-common line method, iterative cycles of
projection matching and subsequently 3D reconstruction employing the current best
particle orientations and centers can improve the accuracy of orientation and center
determinations. This is in part because a finer angular size used to generate reference
projections can potentially result in a higher resolution 3D reconstruction. There are
several different implementations of the projection matching principle [302]. In these
implementations, the determinations of the two out-of-the-plane rotation angles, of
the in-plane rotation angle, and of particle center are generally treated separately
to reduce the amount of computation. This idea is explained by the Polar Fourier
Transform (PFT) method developed by Baker below [321]. For each of the experi-
mental images and of the reference projections, the image is converted from Cartesian
coordinates (x, y) to polar coordinates (γ, r), where γ and r represent angular coordi-
nate and radial coordinate. The resultant image represents a series of annuli of data
with each having a specific radius. The Fourier transform (along the direction of γ)
of the image presented in polar coordinates, namely the PFT, consists of a series of
one dimensional Fourier transforms, of which each is calculated from an annulus of
data. The two out-of-the-plane rotation angles can be determined based on the cross
correlation between the PFT of an experimental image and the PFT of each of the
reference projections. Given these two rotation angles, the in-plane rotation angle
is determined according to the rotational correlation of the experimental image with
its best matching reference projection as determined in the previous step. Thus, the
knowledge of all three rotation angles can be applied to the refinement of the initially
determined particle centers.
There are three major factors that affect the contrast of cryo-EM images, in-
cluding beam-induced motion, noise during detection, and the CTF of the micro-
scope [322]. Inelastic scattering events result in emission of electrons from the sample
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and a buildup of positive charges on the sample [323]. This causes deflection of elec-
trons which increases the blurriness of EM images [324]. Translation and rotation of
the sample can occur probably due to electrostatic force [324]. The sample movement
is also caused by the mechanical instability of the supporting film (e.g., amorphous
carbon film) [325]. Furthermore, charge coupled device (CCD) cameras convert elec-
trons into photons, which are then transformed into electric charges. Noise can arise
from scattering of electrons or photons, a large spread of electron signals over multi-
ple pixels, and integration of electric charges [326]. These factors limits the detective
quantum efficiency (DQE) of CCD cameras, where DQE reflects the performance of
a detector and shows how much signal present in the original image is preserved after
detection.
Recent advances in direct electron detection technologies have partially resolved
the first two issues mention above [327–329]. DEDs show much reduced read-out
noise via detection of single electron events and have an improved DQE (particularly
at low spatial frequencies) over CCD cameras and photographic films [330]. DEDs
locate single electron events at a precision of one quarter of a pixel. Because of a high
frame rate (e.g., up to 400 frames per second for a K2 Summit DED), these cameras
allow for recording EM data in a movie like mode. Thus computational alignments
of frames lead to motion correction that deblurs experimental images [331,332]. Fur-
thermore, because electron doses can now be fractionated into frames, images are
often recorded using a high electron dose (e.g., up to 130 e-/A2) such that a high
contrast is achieved even at low defocus [333]. These factors result in experimental
images with an enhanced SNR. A direct outcome is that the number of asymmetric
units needed to reach a near atomic resolution reconstruction has now been reduced
from millions to tens of thousands [334]. There have also been advancements of image
processing approaches [335–339] and automated data collection [340]. For instance,
the application of maximum likelihood (ML) approaches [337, 341] has been instru-
mental to deal with noisy cryo-EM images and to classify a heterogeneous particle
population into conformational (or compositional) homogenous subpopulations. Un-
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like the aforementioned approaches where a single, best orientation is assigned to a
particle image based on certain criteria of similarity, the idea of ML approaches is
that a probability is calculated for any possible orientation with regard to each par-
ticle image. Thus ML approaches are advantageous when there is an ambiguity in
assigning particle orientation based on a noisy and low resolution 3D reference. With
these developments, single particle cryo-EM has become a powerful approach to de-
termine near atomic resolution structures of macromolecular assemblies. Concerning
crystallizable and conformational homogeneous samples, there have been a number
of better than 3 A˚ resolution cryo-EM structures [333, 342–347], of which one was
determined to 1.8 A˚ resolution [347]. Furthermore, the technique shows advantages
over X-ray crystallography when the following types of samples are concerned. These
include membrane proteins that can hardly be crystallized [348,349], conformational
flexible macromolecular assemblies [350–352], samples that have limited production
yield [353–355], complex assemblies (e.g., many bacteriophages) where symmetry mis-
match is present [356–358], as well as transient and unstable molecular assemblies or
structural intermediates that are difficult to capture [359–361]. Nevertheless, in many
cases, a project takes advantage of a hybrid approach. For example, available X-ray
crystal structures can be fitted into cryo-EM density maps [137,362]. Mass spectrome-
try provides information of the interactions between components in a macromolecular
assembly [363,364], facilitating the interpretation of a cryo-EM density map.
There are new challenges that lay ahead. One of theses challenge is to break
the lower limit of molecular size. The development of phase plate technologies [365]
holds some promise for structure determination of biomolecules that have a molecular
weight of less than about 200 kDa. Phase plates, which are situated at the back focal
plane of the objective lens, cause a phase shift (e.g., 90° in the case of Zernike phase
plates) of the scattered electron waves and alters the CTF to increase image contrast
at low spatial frequencies that allows in-focus or close-to-focus imaging. One of the
latest examples is structure determination of a 260 kDa protein to 4.4 A˚ resolution
using a Volta phase plate [366, 367]. To overcome the hurdle, further improvements
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of detectors are also needed to make detection faster and to increase the DQE (at
low spatial frequencies) close to 1. The issue of beam induced motion can be further
mitigated by employing mechanically stable supporting films such as graphene [368]
and/or by neutralization of the positive charges on the specimen [369]. A controllable
way of producing a layer of vitreous ice with a desirable thickness during sample
preparation would be an additional benefit [370].
Another direction is the study of pleomorphic (i.e., variable in size and shape)
molecular assemblies and organelles. These objects often contain membranes and
have a large size (e.g., more than 800-1000 A˚ in at least one dimension). One promis-
ing technique is cryo-electron tomography (cryo-ET) developed by Baumeister and
coworkers [371]. Projection images that represent multiple different views of a 3D
object are acquired by tilting the sample holder. Thus cryo-ET is distinct from single
particle cryo-EM that relies on randomly oriented single molecules. Without averag-
ing, the current achievable resolution of cryo-ET is perhaps about 40 A˚. Furthermore,
the resolution can be improved for certain components by aligning and averaging of
structurally similar 3D subvolumes that are extracted from tomograms. This process
is generally referred to as subtomograpm averaging [372]. One of the most successful
examples is the capsid structure of human immunodeficiency virus determined to near
atomic resolution [373].
The third challenge has to do with thick samples, including large double strand
DNA viruses (e.g., the mimivirus capsid has a diameter of about 5000 A˚) [374],
subcellular organelles [375], and cells (at the scale of µm) [376]. In these cases,
dynamic scattering (i.e., electrons scatter for multiple times) is involved, making it
complicated to determine the relationship between the experimental 2D image and
the projection of the 3D object. The electrons also loss energy in this process, leading
to images with a low SNR [377]. The idea of reducing sample thickness has long been
pursued. One of the current techniques is cryo-focused ion beam (cryo-FIB) [378,379],
which produces less artifacts than conventional methods such as sectioning. A high
energy ion (e.g., gallium ion) beam is used to remove materials above and below a
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target region in a cell, resulting in a thin section (e.g., about 2000-5000 A˚ thick)
for imaging by EM. Gallium ions collide with atoms on the surface of the sample
and remove materials in a layer-by-layer manner. A combination of complementary
techniques including cryo-FIB, phase plates, direct electron detectors, and cryo-ET
have now opened up a new avenue for structural studies of biomolecules in the context
of cells [376,380].
1.4 Scope of the Current Thesis
The current thesis focuses on structural rearrangements of enterovirus D68 (EV-
D68) during cell entry. The major approaches are X-ray crystallography and single
particle cryo-EM. Chapter 2 concerns determination of the X-ray crystal structure
of EV-D68. Chapter 3 describes the discovery of sialic acid as a cellular receptor for
EV-D68 and receptor induced conformational changes of the virus. Chapter 4 details
the cryo-EM analysis of a rhinovirus C that helps establish a workflow of cryo-EM
structure determination of similar viruses. Chapter 5 deals with structural changes of
EV-D68 in the process of virus uncoating and molecular basis of the acid sensitivity of
EV-D68. Chapter 6 describes the discovery of a capsid binding inhibitor against EV-
D68 infections. Taken together, the present thesis defines structural mechanisms of
EV-D68 entry into host cells. It also paves the way for developing antiviral compounds
that interfere with virus entry.
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2. X-RAY CRYSTAL STRUCTURE OF HUMAN
ENTEROVIRUS D68
Part of the data and text in this chapter are taken from [2] (reprinted with permission
from AAAS) and are highlighted by a black, vertical line in the right margin below.
2.1 Chapter Abstract
Enterovirus D68 (EV-D68) is a member of Picornaviridae and is a causative agent
of recent outbreaks in the USA of respiratory illness in children. Here, the crystal
structure of EV-D68 has been determined to 2.0 A˚ resolution. The hydrophobic drug
binding pocket in viral protein 1 contained density that is consistent with a fatty
acid of about 10 carbon atoms. Many rhinoviruses that cause common cold contain
a similarly short fatty acid like molecule in the VP1 pocket. Thus EV-D68 shares
considerable structural similarity with rhinoviruses.
2.2 Introduction
The enterovirus (EV) genus includes medically-important human pathogens, such
as rhinoviruses (RV), polioviruses (PV) and coxsackieviruses (CV) [5, 6]. Many of
these viruses have been characterized structurally and functionally [13, 14, 16–18, 21,
30,31]. However, the species EV-D remains poorly characterized.
Human enterovirus D68 (EV-D68) was first isolated from children who were hospi-
talized due to respiratory infection in California in 1962 [381]. The virus was identified
sporadically ever since until 2000s [382]. A global upsurge of EV-D68 cases since late
2000s has reminded the world of considerable threats of this human pathogen [383].
Particularly, in the summer and fall of 2014, an outbreak of mild to severe respiratory
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illnesses occurred among thousands of young children in the United States of which
more than 1000 cases was confirmed to be caused by EV-D68 [384]. EV-D68 mainly
causes respiratory diseases among children [385]. There were also some cases of se-
vere respiratory illnesses seen among adults [386]. In addition, this virus has been
associated with occasional neurological diseases [387], including acute flaccid myelitis
(AFM) [388]. To date, there are still no effective vaccines or antiviral treatments
available. This is in part due to a lack of three-dimensional structural information on
EV-D68.
This chapter details X-ray crystal structure determination of the prototype EV-
D68 strain Fermon CA62-1.
2.3 Materials and Methods
2.3.1 Cells and viruses
HeLa cells (H1-HeLa cells, ATCC CRL-1958) were maintained in Minimum Es-
sential Medium (Life Technologies) supplemented with 10% Fetal Bovine Serum
(FBS), L-glutamine, and non-essential amino acids (NEAA). Human rhabdomyosar-
coma (RD) cells (ATCC CCL-136) were maintained with Dulbecco’s Modified Eagle
Medium (DMEM) (Sigma-Aldrich) supplemented with 10% FBS, L-glutamine, and
NEAA. Cells were grown at 37°C with 5% CO2. EV-D68 virus (prototype strain)
was kindly supplied by Dr. M. Steven Oberste at the Centers for Disease Control
and Prevention (United States). EV-D68 stock was propagated in RD cells. Both
the supernatant and infected cells were harvested. After multiple freeze-and-thaw
cycles, the mixture was spun down. The resultant supernatant was stored at -80°C.
The virus titers were determined by a plaque assay using HeLa cells.
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2.3.2 Plaque assays
A series of 10-fold dilution were made for each sample. The resultant sample
with a given dilution was added to confluent HeLa cells in a 6-well plate. After
virus absorption at room temperature for 1h, cells were covered with an overlay of
0.9% agarose in MEM and 5% FBS per well. Plates were allowed to be incubated at
33°C for approximately 5 days. Plaques were visible and counted after neutral red or
crystal violet staining.
2.3.3 Virus production and purification
The prototype strain Fermon CA62-1 of EV-D68 (GenBank: AY426531.1), which
was isolated in 1962 in California [381], was grown in RD cells at 33°C using an
MOI (multiplicity of infection) of approximately 0.01. When an obvious cytopathic
effect was observed 3-4 days post infection, cells and supernatant were harvested at
the same time. The mixture was centrifuged to separate cell debris from the super-
natant. The cell debris were then thawed and frozen multiple times, and homogenized
and centrifuged to remove the pellets. All supernatant was pooled up and pelleted
using a Ti 50.2 rotor (277,937 x g for 2h at 4°C). The pellets were resuspended
and treated sequentially with 0.01 mg/ml DNAse (Sigma-Aldrich), 7.5 mg/ml RNase
(Sigma-Aldrich) and 0.8 mg/ml trypsin (Sigma-Aldrich) to remove impurities. After
centrifugation and removing the pellet, the sample was further applied to a potassium
tartrate gradient (10%-40%, w/v) in 250 mM HEPES, 250 mM NaCl (pH 7.5) using
a SW 41 Ti rotor (221,830 x g for 2h at 4°C). The virus concentration was finally
estimated by measuring the absorption at a wavelength of 260 nm (assuming a mass
extinction coefficient of 7.7 ml/mg/cm because picornaviruses often consist of about
25% (mass percentage) RNA and 75% protein) using UV spectroscopy.
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2.3.4 Crystallization and data collection
Because the yield of EV-D68 production was limited, crystallization conditions
used for the purpose of screening were confined to a few previously reported condi-
tions for crystallizing picornavirues in the literature. Cubic, shiny crystals with a size
of approximately 0.1 mm for each dimension were grown using a hanging drop vapor
diffusion technique within 2-3 days at room temperature from a drop consisting of 0.5
µl of virus (2-3 mg/mL in PBS (phosphate buffered saline): 10 mM phosphate buffer,
2.7 mM KCl, 137 mM NaCl, pH 7.4) and 0.5 µl of reservoir solution (0.1 M sodium
acetate (pH 4.5) with 3.5 M sodium formate) [389]. The pH of the reservoir solu-
tion was about 6.0. When the crystals were looped out, washed twice with reservoir
solution and then re-dissolved in water, the crystals contained viruses as verified by
SDS-PAGE with silver staining. Crystals were soaked in reservoir solution contain-
ing glycerol by gradually increasing the concentration from 0% to 20% (v/v). The
soaking time was approximately 1-2 min. They were then flash frozen in liquid ni-
trogen. Both glycerol and ethylene glycol were found to be effective cryoprotectants.
X-ray diffraction data were collected at 100K using an ADSC Q315 CCD (charge
coupled device) detector at beamline 14-BM-C of the Advanced Photon Source. The
oscillation angle was 0.2 degrees.
2.3.5 Structure determination
Diffraction data were processed using the program HKL2000 [390]. The space
group for native EV-D68 virus crystals was I222. Calculation of the Matthews coef-
ficient suggested the presence of two particles per unit cell. Therefore, the particles
should be sitting on 222 symmetry special position. Determination of which of the
two possible orientations was accomplished with a self-rotation function using the
program GLRF [391]. The correctly oriented and positioned RV-2A model (PDB
accession number 1FPN) without the pocket factor was used for an initial phase
calculation to 8.0 A˚ resolution. Phases were improved by 10 cycles of 15-fold non-
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crystallographic symmetry (NCS) averaging using the program AVE [392] of the USF
software package based on the convergence of the correlation between observed and
calculated (from the Fourier transform of the averaged map) structure amplitudes.
The mask defining the volume of the NCS was generated by selecting all grid points
within a radius of 5 A˚ from each atom of the RV-A2 coordinate using the program
MAMA [393]. Phases were then iteratively extended to 2.0 A˚ resolution using a step
size of 1/c A˚-1. Each step was followed by 3 cycles of NCS averaging at the current res-
olution limit. Manual model building was performed using the program Coot [394].
The resultant structure was subjected to atomic position and B factor refinement
with simulated annealing using the program CNS [395]. The quality of the averaged
electron density map was judged by visual inspection. The R factor was also used as
criterion to evaluate the refinement. Water molecules were finally added and checked
with the program Coot [394]. The EV-D68 structure was validated by the criteria of
Molprobity [396] in the program package Phenix [397]. Other calculations were done
using CCP4 [398]. Pentamers were generated using VIPERdb [399]. Figures were
made with Pymol (http://www.pymol.org/) and UCSF Chimera [400].
2.3.6 Cryo-electron microscopy
3.5µl of EV-D68 samples (about 1 mg/ml in PBS) was applied onto Quantifoil
holey carbon grids R 2/2 (200 mesh, EMS). After manual blotting for about 1.5s,
the sample was immediately plunge frozen into ethane which was pre-cooled by liquid
nitrogen. The resultant grid was kept at close to liquid nitrogen temperature using
a Gatan 626 cryo holder. It was then imaged under a Phillips CM200 transmission
electron microscope (TEM) (FEI) with a 1K X 1K CCD camera at a nominal mag-
nification of 38,000x. The microscope was operated at an accelerating voltage of 200
kV.
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2.4 Results and Discussion
2.4.1 Virus growth and purification
The EV-D68 prototype strain Fermon CA62-1 was propagated in human rhab-
domyosarcoma cells at 33°C, which had previously been shown to be the optimal
growth temperature for EV-D68, indicating that EV-D68 behaves much like viruses
from the RV-A and RV-B species that are responsible for common colds [401]. In
the process of virus purification, density gradient centrifugation of a crude EV-D68
sample showed the presence of two major bands. Both bands were characterized by
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis), UV spec-
troscopy (by analyzing the ratio of absorbance at 260 nm to that at 280 nm), and
electron micrographs of the particles. The lower band corresponded to viral genome
containing native virions, whereas the upper band probably represented native empty
particles that contain uncleaved VP0 (Fig. 2.1).
2.4.2 Structure determination
The native virion was crystallized to yield cubic looking crystals, which had a size
about 0.1 mm in each dimension. After soaking in glycerol, they were flash frozen
in liquid nitrogen before data collection. The data extended to 2.0 A˚ resolution
(Table 2.1). The crystal symmetry was I222 with two particles per unit cell, implying
that the particles were located on a 222 symmetry position (Fig. 2.2). A rotation
function [391] differentiated between the two orthogonal possible orientations of the
icosahedron (Fig. 2.2). Initial phases were calculated based on the structure of
RV-A2 (27) (PDB accession number 1FPN) after removing the pocket factor. EV-
D68 and RV-A2 share about 45% amino acid sequence identity concerning the P1
capsid region. The phases were then extended in small steps to 2.0 A˚ resolution
using 15-fold averaging and solvent flattening. A sharp drop of correlation coefficient
beyond the resolution limit (2.0 A˚) was observed, indicating that phase extension
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Fig. 2.1. Chracterization of two types of EV-D68 particle.
Cryo-EM images of full (A) and empty (B) particles that were sepa-
rated by gradient centrifugation. Scale bar: 100 nm. C. Crystals of
full particles or native virions. D. SDS-PAGE analysis of the compo-
sition of full and empty particles. The ratio between the VP0/VP1
band and the VP2/VP3 band indicates that empty particles might
have uncleaved VP0.
was successful (Fig. 2.3), where correlation coefficient is the correlation between the
observed structure factor amplitudes and the calculated structure factor amplitudes.
A model of the structure was built using the program Coot [394] and refined with
the program CNS [395]. The final value of Rwork was 27.5%. Rfree is essentially the
same as Rwork in the presence of high non-crystallographic symmetry redundancy
for a randomly selected set of reflections as is the case here (Table 2.1).
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Fig. 2.2. Packing and orientation of particles in crystallo-
graphic unit cells. A. Packing of viral particles (red sphere-like
object) in an orthorhombic unit cell (blue). Self-orientation function
was calculated for the EV-D68 crystallographic data, where 15 A˚ - 8 A˚
resolution data and an integration radius of 150 A˚ were used. Shown
are plots of self-rotation function peaks as a function of ψ and φ for
the sections κ=180° (two-fold, B), κ=72° (five-fold, C), and κ=120°
(three-fold, D). The contours start from 2.2σ with increments of 2σ.
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Fig. 2.3. Phase extension and representative electron densities
A. A plot of correlation coefficient (CC) as a function of the inverse
of resolution for selected cycles during phase extension. CC is defined
as in Equation 1.4. B. Representative electron densities of NCS av-
eraged 2Fo-Fc map at a contour level of 1.5σ. Fo is the observed
structure factor and Fc is the structure factor determined after back
Fourier transform of the previously NCS averaged map. Panel B was
taken from [2] (http://science.sciencemag.org/content/347/6217/71).
Reprinted with permission from AAAS.
2.4.3 Biological implications
Comparison of the amino acid sequences of EV-D68 with other enteroviruses shows
that VP3 has a short, C-terminal α-helix not present in other enteroviruses (Fig.
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Table 2.1
Data collection and refinement statisticsa
EV-D68
Data collection
Oscillation angle (°) 0.2
No. of crystals (No. of frames) 1 (171)
Space group I222
Cell dimensions
a, b, c (A˚) 327.0, 347.8, 357.1
α, β, γ (°) 90.0, 90.0, 90.0
Resolution (A˚) 50.0-2.00 (2.07-2.00)b
No. of unique reflections 748623 (55656)
Completeness (%) 55.7 (41.6)
Redundancy 2.1 (2.0)
Rmergec 0.105 (0.754)
I /σ(I ) 8.71 (1.08)
Refinement
Resolution (A˚) 50.0-2.00 (2.07-2.00)
No. of reflections 748174 (54156)






RMSD bond (A˚) 0.006
RMSD angle (°) 1.393
Mean B-factor (A˚2) 27.5





a From [2]. Reprinted with permission from AAAS










2.4). The EV-D68 electron density map showed that this helix decorates the north
side of the canyon in the neighboring, 5-fold related, icosahedral asymmetric unit.
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As a result, the canyon is narrower than in other enteroviruses (Fig. 2.4) and might,
therefore, not be large enough to accommodate immunoglobulin-like receptors.
Fig. 2.4. Surface features. A. The canyon of EV-D68 is shallower
and narrower than the canyon of RV-A16. Pentamers are colored
by radial distance (A˚) to virus center. B. Structure based sequence
alignments of EVs with known structures. These sequences are of
EV-A71 (species EV-A), CVB3 (species EV-B), PV1 (species EV-C),
EV-D68 (species EV-D), bovine EV (species EV-G), RV-A16 and RV-
A2 (species RV-A), and RV-B14 (species RV-B). The PDB accession
numbers are given above. The secondary structural elements were
based on EV-D68 native structure and the numbering of amino acids
was according to EV-D68 amino acid sequence. This figure was gen-
erated using Espript [402]. Red amino acids on a white background
indicate conservation only in chemical properties. From [2]. Reprinted
with permission from AAAS
The BC and DE loops of VP1 are structurally the most variable among known pi-
cornaviruses. The EV-D68 VP1 has two disordered regions corresponding to residues
80-86 (EV-D68 numbering) in the BC loop and 129-136 in the DE loop, both of
which are near five-fold axes. These regions harbor the neutralizing immunogen sites,
NIm-IA and NIm-IB, on RV-B14, respectively [13]. Thus the flexible immunogenic
regions around the five-fold axes might be an alternative mechanism for evading host
humoral immune responses.
The electron density map of EV-D68 showed density in the VP1 pocket (Fig. 2.5).
The height of this pocket factor density was about 3 standard deviations above the
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mean of the non-crystallographic symmetry averaged map, as compared with about
5 standard deviations of most of the main chain density. As in other enteroviruses
that have a pocket factor, the conformation of the GH loop of VP1, which defines
the interface between the VP1 pocket and the floor of the canyon, is pushed into the
pocket relative to the empty pocket in RV-B14 [13,243] or RV-B3 [20].
Fig. 2.5. The pocket factor. A. One icosahedral asymmetric unit of
the EV-D68 structure, showing the Cα backbone for VP1, VP2, VP3
in blue, green and red, respectively. The pocket factor electron density
outline is shown in grey. B. Enlargement of the pocket factor density
with a fitted putative C10 fatty acid. Shown also are the amino
acids lining the pocket. C. Comparison of the putative pocket factor
structures in six known EV structures. Shown also is the residue I184
in EV-D68 that alters the orientation of the shorter pocket factors in
some of the viruses as compared to others with longer pocket factors
and a smaller residue at the equivalent position of 184. Atoms at
the head of the pocket factors and of the VP1 residue side chains
are colored red (oxygen), dark blue (nitrogen) and yellow (sulfur).
From [2]. Reprinted with permission from AAAS
The length of the pocket factor density in the EV-D68 map corresponded to a
fatty acid with an aliphatic chain of about 10 carbon atoms (Fig. 2.5). Similarly, 12
carbon atom long pocket factors were observed for RV-A16 [17] and RV-A2 [24]. In
contrast, the well-formed pocket factors in PV1 [14,16], CVB3 [18], and EV-A71 [30]
corresponded to longer fatty acids with 18, 16 and 18 carbon atoms, respectively.
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Furthermore, the orientation of the pocket factor tails in EV-D68, RV-A16 and RV-
A2 are slightly different than that of the long pocket factors of EV-A71, PV1 and
CVB3 (Fig. 2.5). The orientation is controlled in part by VP1 residue 184, which
is Leu or Ile for the viruses with small, short pocket factors and Val for viruses with
longer pocket factors. The larger Leu and Ile residues might push the pocket factor
sideways. The similarity between the properties of the pocket factor in EV-D68 and
that in the RVs might partially explain why these viruses are less stable.
These results show that EV-D68 shares considerable structural similarities to the
well-studied rhinoviruses, in particular, members of the species RV-A.
48
3. SIALIC ACID DEPENDENT CELL ENTRY OF
HUMAN ENTEROVIRUS D68
Most of the data and text in this chapter are taken from [3] and are highlighted by
a black, vertical line in the right margin below. Macmillan Publishers Ltd: Nature
Communications [3], copyright 2015.
3.1 Chapter Abstract
Human enterovirus D68 (EV-D68) has now emerged as a global public health
threat. Nevertheless, knowledge of the tissue tropism and pathogenesis of EV-D68
has been hindered by a lack of studies on the receptor-mediated EV-D68 entry into
host cells. This chapter shows that cell surface sialic acid is indispensable for EV-
D68 to bind to and infect susceptible cells. Crystal structures of EV-D68 in complex
with sialylated glycan receptor analogues show that they bind into the canyon on the
virus surface. The sialic acid receptor induces a cascade of conformational changes of
the virus to eject a fatty-acid like molecule, which regulates the stability of the virus.
Thus virus binding to a sialic acid receptor and to immunoglobulin-like receptors used
by most other enteroviruses share a conserved mechanism for priming viral uncoating
and facilitating cell entry.
3.2 Introduction
EV-D68 is a causative agent of childhood respiratory infections [385, 401] and
occasionally leads to neurological diseases [387]. Recent outbreaks of EV-D68 indicate
that this virus has now emerged as a global public health threat [383,403]. However,
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the tissue tropism and pathogenesis of EV-D68 is poorly understood. Specifically,
there is a lack of knowledge on the receptor-mediated EV-D68 entry into host cells.
For many EVs, binding of Ig-like receptor molecules to the virus at physiological
temperatures leads to an irreversible conformational switch to an expanded A par-
ticle [105, 106], an intermediate during viral entry. Thus binding of Ig-like receptors
facilitates viral genome release into the cell cytosol for successful replication. Carbo-
hydrate receptors including sialic acid and heparin sulfate have also been identified
as receptors for a number of EVs [159–164, 168, 169]. Nevertheless, it is not known
whether these receptors can also initiate virus uncoating to facilitate virus infection.
EV-D68 belongs to the poorly characterized species EV-D. However it had been
reported that EV-D70, a close relative of EV-D68, utilizes sialic acid as a cellular
receptor [160, 404]. An early report suggested the possible usage of sialic acid as
a receptor by a strain of EV-D68 [405]. Nevertheless, the complete sequence for
its capsid region is currently not available, which limits further studies using this
strain.Furthermore, a glycan array analysis showed that multiple EV-D68 strains can
bind to synthetic glycoproteins with a terminally linked sialic acid [406]. In addition,
sialic acid terminated molecules are widely distributed and abundantly expressed in
the human respiratory tract [407].
3.3 Materials and Methods
3.3.1 Viruses and cells
Human embryonic lung fibroblast (HELF) cells were supplied by M. Steven Ober-
ste at the Centers for Disease Control and Prevention (US). CMAS knockout HAP1
cells were obtained from Haplogen GmbH (Vienna, Austria). RD and HeLa cells were
maintained as described in Chapter 2. HELF cells were maintained in DMEM sup-
plemented with 10% FBS and NEAA. CMAS knockout HAP1 cells, a near-haploid
human cell line that was derived from the human myeloid leukemia cell line KBM7,
were grown in Iscoves Modified Dulbeccos Medium (IMDM, Life Technologies) sup-
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plemented with 10% FBS. Cells were grown at 37°C with 5% CO2 An isolate of
EV-D68 from the 2014 outbreak in the United States, US/MO/14-18947 (GenBank:
AIS73051.1), was also provided by M. Steven Oberste through BEI Resources, Na-
tional Institute of Allergy and Infectious Diseases, National Institute of Health. All
EV-D68 stock was propagated in RD cells and stored at -80°C. Procedures for Virus
growth and purification was the same as that in Chapter 2. Plaque assays were
performed as previously described in Chapter 2.
3.3.2 Crystallization and soaking and data collection
Cubic-looking crystals (about 0.1 mm in each dimension) were grown within 3
days at room temperature using the hanging vapor diffusion technique, as previously
described in Chapter 2. Crystal soaking experiments were performed in a soaking
solution that contains a given concentration of a sialylated trisaccharide in reservoir
solution at room temperature for approximately 8h. The concentration used for 3’-
sialyl-N-acetyl-lactosamine (3’SLN, V-Labs Inc.), 6’-sialyllactose (6’SL, V-Labs Inc.)
and 6’-sialyl-N-acetyl-lactosamine (6’SLN, V-Labs Inc.) were 10 mM, 20 mM and
10 mM, respectively. Crystals were cryo-protected in the aforementioned soaking so-
lution containing glycerol (with gradually increased concentration from 0% to 20%
(v/v)) and then flash-frozen in liquid nitrogen. X-ray diffraction data on single crys-
tals were collected at 100K at beamline 14-BM-C of the Advanced Photon Source.
The detector was an ADSC Q315 CCD. The oscillation angle was 0.2°.
3.3.3 Structure determinations
Procedures for determining all three complex structures were the same, as de-
scribed in Chapter 2. X-ray diffraction data were processed using the program
HKL2000. The space group for all crystals was I222. Calculation of the Matthews co-
efficient indicated that there are two particles present in each unit cell. The particles
must be sitting on 222 symmetry positions. Calculation of a self-rotation function
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differentiated between the two possible 90° related orientations of the particle. The
atomic model of EV-D68 (PDB accession number 4WM8) excluding the pocket fac-
tor and water molecules was employed to calculate initial phases to 8.0 A˚ resolution.
NCS averaging and phase extension using a step size of 1/a A˚-1 were employed to
determine phases up to the resolution limit of the dataset. Roadmaps were generated
using the program RIVEM [408] with the help of Chuan Xiao (University of Texas
at El Paso, US)
3.3.4 Virus infection assays
Each of the three cell lines, HeLa, RD and HELF cells, grown to about 90% con-
fluency in 24-well plates were treated with either 100 mU/ml neuraminidase (NA)
from Clostridium perfringens (Sigma) in DMEM and 1XNEAA (solution A) or solu-
tion A only at 37°C for 1h. Cells were then washed with DMEM once and infected
with the EV-D68 strain Fermon CA62-1. The MOI for HeLa, RD and HELF cells
were 0.3, 0.001 and 0.01, respectively. After absorption at 33°C for 1h, the inoculum
was removed and cells were washed twice with DMEM. Cells were incubated at 33°C
in a medium of DMEM supplemented with 5% FBS and NEAA for 0h, 24h, 48h or
72h post attachment. Samples were collected at each of these time points. These
samples were freeze-thawed multiple times and then subjected to virus titer deter-
mination using plaque assays (as described in Chapter 2). For the EV-D68 strain
US/MO/14-18947, infection experiments on RD cells were performed in the same
way as described above for the Fermon prototype strain. All experiments were done
in at least triplicate.
Experiments concerning virus infection of HAP1 cells were performed by Jim
Baggen and Hendrick Jan Thibaut (Utrecht University, the Netherlands). HAP1 WT
and CMAS-KO cells were seeded in a 96-wells plate at 20000 cells per well. Cells were
treated with NA (from Clostridium perfringens, New England Biolabs) 1:50 diluted in
IMDM for 30 min at 37°C. After NA was removed, EV-D68 (strain Fermon CA62-1)
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was added to the cells at an MOI of 1 and incubated for 1 hour at 37°C. Virus was
removed and NA (or only medium) was added again to the cells. Cells were frozen
immediately (T=0) or 10h after addition of the virus. Virus titers (expressed as
TCID50/ml) were determined by an end-point dilution assay using RD cells at 33°C.
TCID50 (50% Tissue Culture Infectious Dose) is defined as the titer of virus that
results in cytopathic effect in 50% of tissue culture cells that have been inoculated
with virus.
3.3.5 Competition experiments
Cytopathic effect inhibition assays [409] were conducted in the following way. For
each of the three glycans, 6’SL, 6’SLN and 3’SLN, EV-D68 (strain Fermon CA62-1)
diluted in DMEM was incubated with a series of concentrations of glycans ranging
from 0 mM to 4 mM at 33°C for 1h, where 0 mM was designated as the non-treated
virus control. For each given concentration of glycan, a control was performed in
which DMEM was incubated with glycan. The resultant mixture was added into
90% confluent RD cells in each well of a 96-well plate. The MOI was 0.001. After
virus absorption at 33°C for 1h, the inoculum was removed and cells were washed
twice with DMEM. Cells were allowed to be incubated in DMEM supplemented with
5% FBS and NEAA at 33°C for three days, which ensured that almost all cells
became detached in the non-treated virus control. After removal of the medium,
cell viability was assayed using a Quick Cell Proliferation Colorimetric Assay Kit
(BioVision). The optical density for each well was recorded at a wavelength of 450 nm
using a SpectraMax M5 Microplate Reader (Molecular Devices). Percent inhibition
was calculated as (ODcg − ODvg)/(ODc − ODv) × 100, where ODcg and ODvg are
the optical density of the uninfected and infected cell cultures treated with a given
concentration of glycan, respectively. ODc and ODv are the optical density of the
uninfected and infected cells treated with water only but no glycan, respectively. All
experiments were done in triplicate.
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3.3.6 Viral attachment assays
RD cells with approximately 90% confluent in 24-well plates. These were treated
with 100 mU/ml NA in solution A or solution A only at 37 °C for 1h. After washing
with cold DMEM once, each well was treated with 500 µl of DMEM containing
1% bovine serum album (blocking solution) at 4°C for approximately 15 min. The
blocking solution was then removed and purified EV-D68 (strain Fermon CA62-1)
diluted in cold DMEM was added onto cells with an MOI of 10. After incubation at
4°C for 1h, the wells were washed three times with cold DMEM to remove unbound
virus.
Competition assays were performed using purified virus incubated with either
3’SLN or 6’SLN in a series of concentrations ranging from 0-3.2 mM, where 0 mM
represents the virus only control in which virus was incubated with water alone. The
resultant mixture was cooled down on ice and added to about 90% confluent RD cells
in a 24-well plate after each well was blocked with the blocking solution as described
above. The MOI was 10. After incubation at 4 °C for 1h, the wells were washed three
times with cold DMEM to remove unbound virus.
For all virus attachment experiments, the RNA in each well was extracted us-
ing an RNeasy Mini Kit (Qiagen) per manufacturers protocol (RNA extraction was
performed by Ju Sheng). The viral RNA of the bound virus in each sample was quan-
tified using a quantitative real-time RT-PCR protocol. All experiments were done in
triplicate.
3.3.7 Quantitative real-time RT-PCR
Quantitative real-time RT-PCR was performed (together with Ju Sheng) using a
Superscript III Platinum SYBR Green One-step qRT-PCR Kit with ROX (Life Tech-
nologies) on an ABI 7300 real time PCR system. A 25 µl reaction mixture containing
RNA template, SYBR green reaction mix, SuperScript III RT/Platinum Taq Mix,
primers and RNAse-free water was used, where the forward and reverse primers tar-
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geting the EV-D68 5’-untranslated region were EQ-1 (5’-ACATGGTGTGAAGAGT-
CTATTGAGCT-3’) and EQ-2 (5’-CCAAAGTAGTCGGTTCCGC-3’) [410]. The
thermal profile was 50°C for 3min, 95°C for 5min followed by 40 cycles at 95°C for
15s and at 60°C for 30s. Glyceraldehyde-3-phosphate dehydrogenase, a housekeeping
gene, was used as an internal control for normalization purpose. The primers for
GAPDH were 5’-CCCACTCCTCCACCTTTGACG-3’ (forward) and 5’-CACCACC-
CTGTTGCTGTAGCCA-3’ (reverse). The relative levels of EV-D68 RNA in different
samples were determined using a comparative 2−44Ct method [411].
3.4 Results
3.4.1 Identification of sialic acid as a receptor for EV-D68
The possible use of sialic acid as a cellular receptor by EV-D68 was examined
by performing attachment and infectivity assays. Removal of cell surface sialic acid
by neuraminidase (NA) treatment of HeLa cells, human rhabdomyosarcoma (RD)
cells and human lung embryonic fibroblast (HELF) cells was found to significantly
reduced infectivity of the EV-D68 Fermon prototype strain (Fig. 3.1). These results
suggest that sialic acid might be a receptor for EV-D68 in these cell lines. To obtain
further evidence that sialic acid is a functional receptor for EV-D68, human HAP1
cells were used in which the sialic acid activating enzyme cytidine monophosphate N-
acetylneuraminic acid synthase (CMAS) had been knocked out. These cells are devoid
of sialic acids on their surface and had previously been shown to be highly resistant
to influenza A virus infection [412]. It was found that these cells were resistant to
EV-D68 (Fermon strain) infection, further confirming the importance of sialic acid
for EV-D68 infection (Fig. 3.1). Moreover, NA treatment of RD and HELF cells led
to significantly decreased virus attachment (Fig. 3.1).
In view of these results as well as the previous glycan array analysis [407], and
also because N-acetylneuraminic acid (Neu5Ac) is a frequently occurring sialic acid
in humans, the sialylated trisaccharides Neu5Ac2-3Gal1-4GlcNAc (3’SLN), Neu5Ac2-
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6Gal1-4GlcNAc (6’SLN), and Neu5Ac2-6Gal1-4Glc (6’SL) were used as potential re-
ceptor analogues. Preincubation of EV-D68 with these sialylated trisaccharides inhib-
ited viral attachment and prevented killing of RD cells in a concentration-dependent
manner (Fig. 3.1). Therefore, sialic acid has a crucial role in EV-D68 attachment
and infection.
3.4.2 The binding site of sialylated receptor analogues
The crystal structures were determined of EV-D68 when in complex with 3’SLN,
6’SL or 6’SLN. The resolution of these structures ranged from 2.2 to 2.3 A˚ (Table
3.1). The procedures for the structure determination of these complexes were based
on non-crystallographic symmetry averaging and step-by-step phase extension. All
three receptor analogs were observed to bind near the eastern end of the canyon
(Fig. 3.2). The EV-D68 canyon is unusually shallow and narrow compared to other
picornaviruses that bind Ig-like receptor molecules [2, 183]. In all three structures
the Neu5Ac moiety is well accommodated in a wide crater formed by VP1 and VP3
within the same protomer [13] (Fig. 3.2).
The sialic acid moiety (Neu5Ac) of these ligands is stabilized by a series of in-
teractions provided by the surrounding residues Arg3104, Asp3232, Pro3231, Asn
1275, Pro1274, Arg1270, Asp3091, Arg3095 and Ile3233 (Fig. 3.3) (The EV-D68
amino acid numbering system is based on the Fermon strain amino acid sequence.
Residues in VP1, VP2 and VP3 are defined by adding 1000, 2000 and 3000 to their
sequence number). Thus, like other viral attachment proteins that bind terminal
Neu5Ac [413], EV-D68 makes polar interactions with the carboxylate group and the
acetamido group nitrogen atom of Neu5Ac (Fig. 3.3). The residues that interact with
Neu5Ac in EV-D68 are conserved except for an Arg to Lys change at position 1270
among 51 EV-D68 isolates collected from sources on four continents between 1962 and
2014. These isolates have been classified as belonging to three lineages [383,403,414],
although lineage 1 was the most dominant. It is, therefore, significant that these
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Fig. 3.1. Cell surface sialic acid plays a crucial role in EV-D68
attachment and infection. A-C. Growth curve of EV-D68 in sus-
ceptible cell lines cells. Neuraminidase treatment of susceptible cell
lines inhibits EV-D68 (Fermon) infection. D. HAP1 cells (WT and
CMAS KO) were infected with EV-D68 (Fermon) at an MOI of 1 and
virus titers were determined at 0h (T=0) or 10h post infection. E-F.
Histograms showing virus binding to susceptible cells. P<0.0001 by
Student’s t test. G. Neuraminidase treatment of RD cells inhibits
the infectivity of a current EV-D68 strain (US/MO/14-18947). H.
Preincubation of 6’SL, 6’SLN or 3’SLN with EV-D68 (Fermon) pre-
vents killing of RD cells caused by virus infection. I. Preincubation
of 6’SLN or 3’SLN with EV-D68 (Fermon) inhibits viral attachment
to RD cells. All data are represented as mean±SD. Experiments were
performed at least in triplicate.
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Fig. 3.2. Sialylated receptor analogues bind to the EV-D68
canyon. A. An EV-D68 virus particle in an icosahedral cage (black).
The white triangle represents one icosahedral asymmetric unit. The
surrounding white rectangular outline represents the limits of the fig-
ures shown in B and C. The thick white contour outlines the sum-
mation of five superimposed footprints of Ig-like receptors on the
virus, whereas the thinner white contour represents the consensus
footprint of at least four footprints. The receptors are intercellu-
lar adhension molecule-1 for human rhinovirus 14 [179], human rhi-
novirus 16 [179], and coxsackievirus A21 [28], CD155 for poliovirus
1 [108], and coxsackievirus and adenovirus receptor for coxsackievirus
B3 [182]. Shown also is the footprint of the sialylated trisaccharides
(yellow). The background is a map of the EV-D68 surface residues
colored by polypeptide in A and C or colored by radial distance from
the virus center in B. D. The VP1 GH loop is invariably in the foot-
print of Ig-like receptors used by EVs. Residues in the contact region
are highlighted. Black arrows represent -strands.
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Table 3.1
Data collection and refinement statistics
EV68 – 6’SL EV68 – 6’SLN EV68 – 3’SLN
Data collection
Wavelength (A˚) 0.9787 0.9787 0.9787
Oscillation angle (°) 0.2 0.2 0.2
No. of frames 150 170 160
Space group I222 I222 I222
Cell dimensions
a, b, c (A˚) 325.6, 347.1, 356.4 325.7, 347.4, 356.5 325.8, 347.2, 356.9
α, β, γ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Resolution (A˚) 50-2.32 (2.40-2.32)a 50-2.15 (2.23-2.15) 50-2.15 (2.23-2.15)
Unique reflections 526043 (55652) 803405 (80335) 823936 (84149)
Completeness (%) 61.4 (65.3) 74.6 (75.0) 76.3 (78.3)
Redundancy 1.9 (1.8) 1.8 (1.6) 1.7 (1.6)
Rmergeb 0.175 (0.722) 0.152 (0.865) 0.124 (0.529)
I /σ(I ) 4.16 (1.04) 5.37 (0.89) 6.05 (1.45)
Refinement
Resolution (A˚) 50-2.32 (2.40-2.32) 50-2.15 (2.23-2.15) 50-2.15 (2.23-2.15)
No. of reflections 525999 (55490) 802817 (79585) 823388 (84396)
R factor 0.246 (0.333) 0.254 (0.327) 0.244 (0.314)
CCc 0.886 0.922 0.921
No. of atoms 6610 6647 6679
Protein 6296 6303 6317
Ligand 43 46 46
Water 271 298 316
RMSD bond (A˚) 0.006 0.006 0.006
RMSD angle (°) 1.378 1.393 1.392
Mean B-factor/A˚2 19.3 25.1 20
Ligand B-factor/A˚2 51.6 70.6 63.7
Ramachandran plot
Favored (%) 96.1 96.2 95.9
Allowed (%) 3.9 3.7 4.1
Outliers (%) 0 0.1 0











residues are also conserved in EV-D70, which is known to bind sialic acid as a cellu-
lar receptor [404]. However, enteroviruses that bind Ig-like molecules in the canyon
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have quite different kinds of residues at the sialic acid binding site of EV-D68 (Table
3.2). In addition, CVA24, which utilizes sialic acid as a receptor [163], also has dif-
ferent kinds of residues at the EV-D68 sialic acid binding site, suggesting that sialic
acid would bind to a different site on CVA24 than on EV-D68. This is consistent
with the fact that Coxsackievirus A24 binds to sialic acid at a site near each five-
fold axis, as shown by a previous study on the structures of CVA24 complexed with
sialic acid or sialylated glycans [32]. Moreover, the infectivity of the EV-D68 strain
(US/MO/14-18947) from the 2014 US outbreak (which has a lysine in position 1270)
was significantly reduced in NA-treated RD cells as compared with non-treated RD
cells (Fig. 3.1), suggesting that sialic acid might be a common receptor for a broad
spectrum of EV-D68 strains.
Fig. 3.3. Binding of sialylated receptor analogues to EV-D68
displaces the pocket factor. A. Superimposition of the amino
acids lining the VP1 hydrophobic pocket in the native structure (light
grey) and the receptor bound complex (green). The pocket factor in
the native structure is colored grey. B. Two protomers of the EV-D68
capsid are represented as Cα backbones with VP1, VP2, and VP3 col-
ored blue, green and red, respectively. The pocket factor (native struc-
ture) and the receptor analogue (receptor bound complex) are colored
grey and cyan, respectively. C. The sialic acid moiety (Neu5Ac) (cyan
carbon atoms) interacts with surrounding amino acids (green carbon
atoms). A water molecule is represented by a red sphere. Dash lines
indicate polar interactions. Oxygen, nitrogen and sulfur atoms in A















































































































































































































































































































































































































































































































































































Different conformations were observed between the 6’SLN and 3’SLN receptor ana-
logues that might explain why EV-D68 preferentially recognizes sialic acid receptors
with an α-2,6 linkage [406] (Fig. 3.4). These are consistent with the fact that 6’SLN
prevents EV-D68 attachment and inhibits killing of RD cells more efficiently than
does 3’SLN. This suggests that EV-D68 might have a tropism towards the human
upper respiratory tract, where α-2,6 linked sialic acid molecules are more abundant
and the temperature is optimal for EV-D68 growth than in the lower respiratory
tract [401].
The receptor analogues used here are trisacchrides and presumably could be a
component of the glycoconjugate on the authentic receptor that might be a glycopro-
tein or glycolipid. However, a previous glycan array analysis [406] used 3’SLN and
6’SLN covalently linked to bovine serum albumin (BSA) through the GlcNAc moiety.
This analysis found that the Fermon strain has a limited binding affinity for 3’SLN
linked to BSA compared to 6’SLN linked to BSA. In the present study, structures of
EV-D68 complexed with these sialylated glycans showed that 3’SLN adopts a linear
conformation such that it is lying against the eastern rim of the virus canyon (Fig.
3.4). Thus, if 3’SLN linked to BSA were to bind to the same binding site, the virus
would impose a large steric hindrance that would not accommodate the BSA. In con-
trast, 6’SLN (as also 6’SL) adopts a bent conformation such that the GlcNAc moiety,
which is furthest away from the Neu5Ac moiety, is well clear of the virus surface
which, therefore, permits the presence of BSA (Fig. 3.4). Therefore, steric hindrance
might limit the binding of the virus to α-2,3 but not α-2,6 linked sialic acid on the
authentic sialylated receptors.
3.4.4 Sialic acid receptor binding causes the ejection of the pocket factor
The root mean square deviation (r.m.s.d.) between all the equivalent atoms of
the EV-D68 native structure and the EV-D68 bound with any of the three receptor
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Fig. 3.4. Receptor specificity. Receptor analogues 6’SL (A-B),
6’SLN (C-D), and 3’SLN (E-F) are colored using green (carbon), red
(oxygen) and blue (nitrogen). A, C, and E show these compounds
in their NCS averaged difference map densities (3.0σ) all oriented to
place the icosahedral two-fold axis perpendicular to the page. B, D,
and F show their interaction with the virus, oriented to resolve the
projected atoms. Dashed lines indicate polar interactions.
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analogues is about 0.4 A˚ (Table 3.3). Nearly all main chain atoms that were displaced
by more than four r.m.s.d. were in the loops that form the connecting region between
the sialic acid binding site and the VP1 hydrophobic pocket. The same conforma-
tional changes occurred in each of the three complexes. The conformational changes
included the VP1 GH loop located at the boundary between the VP1 hydrophobic
pocket and the canyon. Similar changes in the VP1 GH loop occur when CD155
binds to poliovirus [108]. In particular, the Cα atom of residue Ile1217 moves 2.2
A˚ into the pocket (Fig. 3.3). This results in a conformation of the VP1 GH loop
much like that in the RV-B14 structure where no pocket factor is present [13]. Thus
binding of sialylated receptor analogues onto EV-D68 causes a partial collapse of the
pocket, leading to the displacement of the pocket factor (Fig. 3.5). However, in these
sialylated receptor analogue bound structures, the VP4 density is still present and
the particle size is not altered, indicating that sialylated glycan binding of EV-D68 at
room temperature represents an initial event of the viral entry process. In contrast
to the conformational changes that occur when a sialic acid receptor binds into the
canyon, binding of glycan receptors to other binding sites on picornaviruses do not
cause further conformational changes [32,415–417] (Fig. 3.6).
Table 3.3
Root mean square deviationsa between two given structures with or
without a bound receptor analogue
Structure A Structure B Overall 3086-91b 3178-79b 1149-53b 1211-19b
D68-6’SL D68 0.40 1.93 2.28 2.72 1.91
D68-3’SLN D68 0.36 1.78 2.31 2.65 1.81
D68-6’SLN D68 0.35 1.80 2.19 2.24 1.83
D68-6’SL D68-3’SLN 0.10 0.24 0.05 0.21 0.20
D68-6’SL D68-6’SLN 0.11 0.21 0.48 0.48 0.21
D68-3’SLN D68-6’SLN 0.06 0.09 0.33 0.34 0.09
a r.m.s.d. values (A˚) were calculated using main chain atoms (N, Cα, C, O).
b Numbered according to the amino acid sequence of the EV-D68 strain Fermon CA 62-1.
The contact region for all three receptor analogues is the VP1 C-terminus, VP3
C-terminus and VP3 CD loop. This site is about 28 A˚ from the VP1 hydropho-
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Fig. 3.5. Competition between the sialic acid receptor and
the pocket factor. A. The conformational changes of the virus
when sialylated receptor analogues bind the virus and eject the pocket
factor. Amino acids in the native and in the receptor bound structures
are shown in yellow and cyan, respectively. A water molecule is shown
as a red sphere. Dash lines represent polar interactions. Red arrows
indicate movements of the four loops. B. Enlarged component of
marked region in a shown in a slightly different orientation.
bic pocket in the same protomer and about 30 A˚ away from the VP1 hydrophobic
pocket in a neighboring protomer (Fig. 3.3). In contrast, all Ig-like molecules interact
directly with the VP1 GH loop in the canyon (Fig. 3.2). Thus, binding of the sia-
lylated receptor analogues displaces the pocket factor through long range structural
rearrangements of the virus. The region connecting the sialic acid receptor bind-
ing site and the VP1 hydrophobic pocket is formed by the VP3 CD loop, the VP3
GH loop, the VP1 EF loop and the VP1 GH loop. These loops undergo the only
significant conformational changes mentioned above (Table 3.3). Thus the signal of
receptor binding must be transmitted to the hydrophobic pocket through the struc-
tural rearrangements of these loops (Fig. 3.5). These conformational changes might
be initiated by charge repulsion between the negatively charged carboxylate group of
Neu5Ac and the main chain carbonyl group of Gln3089. In partial agreement with
this mechanism, two of the five mutations that resulted in the resistance of EV-D70 to
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neuraminidase treatment of HeLa cells occur in the VP1 EF loop and GH loop [418].
Furthermore, the pocket factor was missing and the hydrophobic pocket was collapsed
in A particles of other enteroviruses [212], while three of the four loops mentioned
above undergo dramatic conformational changes during virus expansion to A particle
in the uncoating process [209]. In summary, binding of sialic acid receptor analogues
to EV-D68 ejects the pocket factor and therefore presumably destabilizes the virus
to facilitate viral uncoating.
Fig. 3.6. Comparison of carbohydrate receptor binding sites
on picornaviruses. All known picornaviruscarbohydrate receptor
structures were superimposed. Two adjacent protomers of the EV-
D68 capsid are represented as Cα backbones. The triangle outlines
an icosahedral asymmetric unit of the virus capsid. VP1, VP2, and
VP3 are colored blue, green, and red. Carbohydrate receptors are
shown as sticks. Cyan, Neu5Ac (CVA24 variant, PDB 4Q4X); ma-
genta, 3-sialyllactose (equine rhinitis A virus, PDB 2XBO); yellow,
6’-sialyllactose (EV-D68, PDB 5BNN); dark green, heparan sulfate
(foot-and-mouth disease virus, PDB 1QQP).
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3.5 Discussion
In the present study, a recent clinical isolate of EV-68 (US/MO/14-18947 from
the 2014 US outbreak) was shown to have sialic acid dependency, as is the case for
the prototype Fermon strain and another early strain isolated in the 1970s [405].
Furthermore, RD and HeLa cells were found to be susceptible to infection by both
the Fermon and US/MO/14-18947 strains. In particular, these two strains exhibited
similar growth kinetics when using RD cells (Fig 3.1). Thus the similarities between
these two strains suggest that the results described here might be equally applicable
to at least some of the recent isolates. However, the Fermon strain is likely to have
undergone some changes since its isolation in 1962 due to a lengthy passage history,
which may have changed its receptor binding properties and/or fitness in susceptible
cell lines [419]. Therefore, it is possible that some recent strains may have potentially
altered receptor usage. It is also probable that some recent strains may not replicate
as efficiently as the Fermon strain in cells lines such as RD, HeLa and HELF cells
examined here.
Although EV-D68 mainly causes respiratory infections, some recent isolates were
associated with neurological illness such as acute flaccid myelitis (AFM) [420–425].
These recent clinical isolates are all in the same clade as US/MO/14-18947 isolated
from a patient with respiratory illness but who did not have a neurological disease
[421]. The amino acid sequences of the structural proteins of these isolates share
approximately 99% sequence identity to that of US/MO/14-18947. Furthermore, the
51 strains used for sequence alignment, as mentioned above, include strains that were
associated with neurological diseases. This suggests that these strains might also be
sialic acid dependent, consistent with the fact that most EV-D68 associated AFM
cases had respiratory infections [421].
Complementary to the biochemical and structural data presented here, a recent
report found that host proteins involved in sialic acid biosynthesis, transport, and
conjugation play crucial roles in EV-D68 infection using a haploid genetic screening
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[426]. It was also discovered that three recent strains of EV-D68 did not appear
to depend on cell surface sialic acid for infections [426]. These results suggested
the presence of potential alternative receptors for EV-D68. Ongoing studies have
shown that one of the three strains can use both sialic acid and glycoamineglycans
(particularly heparan sulfate (HS)) as a receptor. The property of binding to HS
has been found to be acquired in the process of virus adaptation to growth in RD
cells (Personal Communications with Jim Baggen). These observations support the
point that sialic acid represents a common receptor for many EV-D68 strains, while
alternative receptors may be utilized by some EV-D68 strains. Nevertheless, sialic
acid is only an essential moiety on the authentic cellular receptor molecules, which
might be sialic acid containing glycoproteins or glycolipids. A glycoprotein, namely
ICAM-5, has recently been identified as a cellular receptor for EV-D68 [427]. Both the
protein component and the sialic acid terminated glycan component of ICAM-5 are
important for ICAM-5 dependent EV-D68 infection. ICAM-5 is specifically expressed
in neurons, which might have some relevance to the pathogenesis of EV-D68.
In summary, the structural and functional analyses showed that sialic acid is a
functional cellular receptor for EV-D68. The prevalence of sialic acid in the human
respiratory tract might allow efficient replication of EV-D68 that leads to human
respiratory infection. Despite chemical and structural differences from the Ig-like re-
ceptors, the sialic acid receptor binds to the virus canyon and causes the expulsion
of the pocket factor, suggesting that the enterovirus canyon is a sensor for recep-
tors. Thus, the canyon transmits signals initiated by receptor binding to release the
pocket factor, regulating the conformational state of EVs from being stable for virus
transmission to being unstable during virus entry.
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4. CRYO ELECTRON MICROSCOPIC ANALYSES OF A
HUMAN RHINOVIRUS C
Most of the data and text in this chapter are taken from [428] and have been high-
lighted by a black, vertical line in the right margin below.
4.1 Chapter Abstract
Isolates of rhinovirus C (RV-C), a recently identified Enterovirus (EV) species,
are the causative agents of severe respiratory infections among children. Moreover,
the RV-C have been linked to 50-85% of hospital-level childhood asthma exacerba-
tions that can lead to significant adult respiratory problems. Nevertheless, there are
currently no effective antiviral treatments or vaccines available. The RV-C have been
refractory to structure determination because they are difficult to propagate in vitro.
This chapter presents the cryo-EM atomic structures of the full virion and native
empty particle (NEP) of RV-C15a. The virus has 60 “fingers, on the virus outer
surface that probably function as dominant immunogens. Since the NEPs also dis-
play these fingers, they may have utility as vaccine candidates. A sequence-conserved
surface depression adjacent to each finger forms a likely binding site for the sialic
acid on its receptor. The RV-C, unlike other EVs, are resistant to capsid-binding
antiviral compounds because the hydrophobic pocket in VP1 is filled with multiple
bulky residues. These results define potential molecular determinants for designing
anti-viral therapeutics and vaccines. This work also provides a common work flow for
cryo-EM structure determination of similar viruses.
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4.2 Introduction
A number of enteroviruses have been structurally characterized by X-ray crystal-
lography [2, 13, 14, 429], establishing the general mechanisms for virus infection and
for the development of effective anti-EV therapeutics. Nevertheless, rhinovirus C
(RV-C), a newly discovered species among the EVs, remains enigmatic.
RV-C viruses (55 types), together with RV-A and RV-B viruses (about 108 types),
are the leading cause of common colds [12]. However, the RV-C might be associated
with more severe respiratory infections among children than any other known rhi-
noviruses [430,431]. In contrast to other RV, the RV-C utilize cadherin related family
member 3 (CDHR3) as a cellular receptor [432]. This childhood asthma susceptibility
gene product is expressed in the human lower respiratory tract [433]. In line with
this etiology, the RV-C cause a significantly higher rate of lower respiratory tract
infections in children than in adults [434] and are directly associated with childhood
asthma exacerbations [431]. Similar to influenza viruses, RV-C infections peak in
winter months [435]. Currently, there are no vaccines or effective antiviral treatments
available.
RV-C isolates have been refractory to structural characterization since their dis-
covery in 2006 [436] because of an inability to infect standard tissue culture (e.g.,
HeLa) [437]. Only modeled structures, based on amino acid sequence comparisons,
have been available to aid biological investigations [437–440]. single-particle cryo-
electron microscopy (cryo-EM) has now emerged as a powerful method for deter-
mining near atomic resolution (better than 4 A˚) structures of macromolecular as-
semblies [441]. Cryo-EM requires only limited amount of sample without intensive
purification, offering advantages over X-ray crystallography in structural studies of
samples that are difficult to produce.
This chapter reports atomic cryo-EM structures of the full and native empty par-
ticles (NEP) of the cell-adapted RV-C15a strain. These structures highlight novel
immunogenic surfaces, a probable binding site for the glycosylated CDHR3 receptor
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molecule and the requirements for antiviral compound resistance. The external sur-
face of both types of particles is almost identical. Thus the RV-C NEPs represent
potential vaccine candidates. The present findings also identify targets for designing
anti-RV-C therapeutics.
4.3 Materials and Methods
4.3.1 Growth and purification of RV-C15a
The following experiments were performed by Marchel Hill at the Palmenberg
laboratory (University of Winsconsin - Madison). The seed of RV-C15a was provided
by Yury Bochkov from the same Institute. RV-C15a (adapted) is a virus preparation
derived by serial passage (10x) of recombinant C15 virus (12), in HeLa-E8 cells, a
lentivirus-transduced line expressing the full-length human CDHR3 gene (Tyr529)
linked to a GFP reporter sequence [432]. To produce viruses for structure determi-
nation, HeLa-E8 cells were infected with RV-C15a at 34°C. At 40h post infection
after complete cytopathic effect (CPE) was observed, infected cells (2.4 x 1010) were
supplemented with HEPES (to 50 mM, pH 7.2) and then subject to multiple freeze-
thaw cycles (3x). Clarified supernatants were treated with RNAse A, then concen-
trated by pelleting through 30% sucrose, before resuspension and being assayed for
titer [432, 442]. The procedure gave a sample of RV-C15a at about 1.2 x 1010 PFUe
(by quantitative reverse transcription PCR (qRT-PCR) using HeLa-E8 cells) that
is equivalent to 125 µg RNA-containing, infectious particles, assuming a particle-to-
PFU ratio of 200 PFUe is the PFU-equivalent calculated based on calibrated standard
curves for RV-A16/RV-B14 viruses. .
4.3.2 Characterization of two forms of RV-C15a particles
The following experiments were performed by Kelly Watters from the Palmenberg
laboratory. A sample of RV-C15a, as prepared for structure determination, was sed-
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imented through a 10-40% sucrose gradient (103,600 x g (Beckman SW41 Ti rotor)
for 3h at 4°C). Fractions (1 ml) were collected (from the top) and then probed for
VP2/VP0 content by Western blot analyses using anti-RV-C15-VP2 mouse mono-
clonal antibody, clone No. 517 (kindly provided by MedImmune Inc., Gaithersberg
MD). The fractions were also tested for infectivity according to CPE (38), and for
RNA content by qRT-PCR (8).
4.3.3 Cryo-electron microscopy
Aliquots of 2.8 µL of purified RV-C15a sample were applied onto glow-discharged
holey carbon EM grids (400 mesh, Ted Pella Inc.). Grids were blotted for about
8s at a relative humidity of 80% and then plunge-frozen in liquid ethane cooled
down by liquid nitrogen using a Cryoplunge 3 system (Gatan). Movies of frozen RV-
C15a particles embedded in vitreous ice were collected at liquid nitrogen temperature
using a Titan Krios transmission electron microscope (FEI) operated at 300 kV and
equipped with a Gatan K2 Summit direct electron detector (3838 x 3710 in physical
pixels). All the movies were automatically recorded in super resolution mode using
Leginon [340] at a nominal magnification of 14,000x and with a defocus range of 0.7-
3.5 µm. This resulted in a super resolution pixel size of 1.04 A˚/pixel. The dose rate
was approximately 8e-/pixel/s. For each movie, the total electron dose was about
25.7 e-/A˚2 that was fractionated into 70 frames with an exposure time of 200 ms per
frame.
4.3.4 Image processing
Cryo-EM data were collected of the RV-15a particles. A total of 2,979 movies were
subjected to whole-frame motion correction using a modified version of MotionCorr
[331] as modified by Wen Jiang (Purdue). This process was integrated into the
Appion data processing pipeline [443]. Aligned frames were subsequently summed to
obtain individual micrographs. Micrographs that had ice contamination or severe drift
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were discarded. The remaining micrographs were used for estimating of the contrast
transfer function (CTF) parameters using CTFFIND3 [444]. For a part of the data set
particles were selected semi-automatically. In this process the program e2boxer.py in
the EMAN2 package [335] picked particles based on several templates (derived from
manually selected particles). The selection was then confirmed by visual inspection,
For the rest of the data set automatic particle selection was accomplished by using
DoG picker [445]. The final number of selected particles was 24,882. Individual
particle images were boxed, extracted and subjected to reference-free 2D classification
into 156 classes using the program Relion [337]. Some of these classes were clearly
composed of full particles, some of empty particles and some were just junk. This
yielded 13,390 full particles and 5,324 empty particles. Particles were re-boxed and re-
extracted from the micrographs using jspr [339,446]. CTF parameters of the particles
from each micrograph were estimated using fitctf2.py [447].
Images of the full particles were divided into two half data subsets. A truly inde-
pendent 3D reconstruction strategy, using the program jspr [339], was applied to each
of the two subsets assuming icosahedral symmetry. For each subset, eightfold binned
particle images (squares of 88 original pixels separated by 1.04 A˚ were averaged to
represent one pixel with a spacing of 8.32 A˚) were used to compute ten initial 3D
reconstructions by assigning random initial angles [316] to each of 150 particle images.
Refinements were performed by searching for the best orientation and particle center
of each particle image relative to the ten current 3D reconstructions. Three of these
structures were selected for further refinement with all the available particle images
in the half subset. After multiple iterations these structures converged to roughly
the same reconstruction. One of these structures was randomly chosen to extend
the refinement with 4-binned, then 2-binned data and finally unbinned data. At this
point, anisotropic magnification distortion remained the major resolution limiting
factor. Ten images of polycrystalline gold particles were taken at a nominal magnifi-
cation of 14,000x in super resolution mode. Fourier transform of these gold particle
images gave powder diffraction like patterns that were used to estimate parameters
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of anisotropic magnification distortion [448]. The estimated degree of distortion and
angle were 2.87% and 31.3°, respectively. These parameters were then employed
to correct anisotropic magnification distortion for individual particle images using
jspr [449]. Subsequent refinement of particle center, orientation, defocus, astigma-
tism, scale and beam tilt using jspr led to the final optimal reconstructions in terms
of resolution. The Fourier shell correlation (FSC) [450, 451] between the half maps
independently calculated from the two subsets was used to monitor convergence. The













where r is spatial frequency, and Fo(r) and Fe(r) are structure factors of the two half
maps. F∗e(r) is the complex conjugate of Fe(r), and ri represents a shell in Fourier
space. The same procedures were used for determining the 3D structure of the empty
particles. A 2.79 A˚ resolution map of the full particle was reconstructed using 8,973
particles, and a 3.16 A˚ resolution map of the empty particle was reconstructed using
3,614 particles. The map resolution was determined based on the FSC between the
two half maps (masked with a soft mask) independently calculated using the two half
data subsets following the 0.143 cut-off criterion [452, 453]. To further validate the
map resolution, phase randomized (beyond 5 A˚) data were refined using the same
procedures as were used for the original data that were not phase randomized. A
true FSC curve [454] was calculated using the FSC curve based on the original data
and the FSC curve based on the phase randomized data. The full and empty particle
maps were sharpened [452] using a B factor of -108.6 A˚2 and -122.2 A˚2, respectively.
The pixel size of the micrographs collected at 14,000x in superresolution mode was
verified in the following way. In essence, a map was calculated the homologous RV-
A16 (or RV-B14) coordinates of the capsid by specifying 2.8 A˚ resolution. Real space
correlation coefficients were calculated between the resultant RV-A16 map and the
EM map of RV-C15a (full particle) by varying the pixel size of the RV-A16 map
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from 0.94 A˚/pixel to 1.14 A˚/pixel (with an increment of 0.01 A˚/pixel). This was
performed using Chimera [400]. The highest correlation coeffcient was achieved when
the RV-A16 map had a pixel size of 1.04, thus verifying the pixel size of the RV-C15a
electron micrographes.
4.3.5 Model building and refinement
For the full particle structure, a predicted atomic structure of the RV-C15 (13)
(including coordinates for a protomer, VP1-VP4) was manually fitted into a region
of the final EM map that corresponds to one protomer of the capsid using Chimera
[400]. Atomic positions were refined using Phenix [397] in real space. The correlation
coefficient between the final EM map and a map calculated based on the coordinates
was improved in this process. Model statistics including bond lengths, bond angles
and all-atom clash, rotamer statistics, and Ramachandran plot statistics were also
monitored. This was followed by model rebuilding with the program Coot [394]. The
combination of real space refinement in Phenix and model rebuilding in Coot were
repeated multiple times to achieve an optimized fit between the coordinates and the
final EM map. At this point, the coordinates fit well into the densities by visual
inspection.
Next, a mask, which included all grid points within a radius of 5 A˚ around each
atom, was employed to cut out densities from the final EM map using the CCP4 [398]
program suite. The resultant segment of the final EM map was placed into a pseudo
crystallographic unit cell (P1 space group) and was back transformed into pseudo
structure factors (including both amplitudes and phases). The coordinates were then
subjected to refinement of individual B factors, atom positions and occupancy against
the pseudo structure factors using standard reciprocal space refinement procedures
in Phenix [397]. R factors were monitored during the refinement cycles. Only the
coordinates were refined, whereas the map was kept constant. Subsequently, the
coordinates were refined in real space against the final EM map by applying non-
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crystallographic symmetry (60-fold) constraints using Phenix [397]. Validation of the
final coordinates was based on the criteria of MolProbity [396]. The full particle
atomic model (excluding VP4 and the VP1 N-terminal residues 1101-1160) was used
as a starting atomic model for model building and refinement of the empty particle
structure.
As a further validation of the EM map resolution and of the fitting between the
atomic model and the final EM map, a density map was calculated based on the
atomic model specifying a resolution of 2.79 A˚ for the full particle structure and 3.16
A˚ for the empty particle structure. An FSC was computed between the resultant
density map and the final EM map. The resolution determined using 0.5 FSC as
a cut-off was 2.85 A˚ (full particle) and 3.24 A˚ (empty particle). Oligomers were
generated using VIPERdb [399]. Figures were made using Chimera [400] and Pymol
(https://www.pymol.org/).
4.4 Results
4.4.1 Production of RV-C15a viruses
Recently, a recombinant RV-C15 virus [437], adapted for tissue culture growth by
serial passage in HeLa-E8 cells [432] (a transduced HeLa cell line expressing CDHR3)
led to new protocols for enhanced virus yields. The derivative, RV-C15a, represents a
cell-adapted, uncloned population. The consensus sequence of this population differs
in the capsid region from that of RV-C15, primarily by a single, high-frequency,
nucleotide polymorphism. The substitution converts residue 1125 from Thr to Lys.
(The numbering convention follows what was described for EV-D68 in Chapter 3.) In
this chapter, an RV-C15a sample, purified only by sucrose cushion sedimentation, was
used for cryo-EM structure analysis. To obtain a minimum of five to six particles per
micrograph, given the high dilution of the sample, data collection was carried out at a
low magnification. Specifically, movies of frozen RV-C15a particles within a thin layer
of vitreous ice were recorded at a nominal magnification of 14,000x using a Gatan
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K2 Summit direct electron detector. However, the trade-off was a low signal-to-noise
ratio and a high anisotropic magnification distortion compared to what would be the
case were high magnifications used for data collection.
4.4.2 Biochemical characterization of two forms of particles
Cryo-EM micrographs of RV-C15a showed the presence of two major forms of par-
ticles. One form lacked density at their centers and another form had density at their
centers (Fig. 4.1). When fractionated on sucrose gradients, these types of particles
separated from each other. One form was full, infectious virions that contained VP1,
VP2, VP3 and VP4 whereas the other form (about 30% of all particles) was native
empty particles (NEP) that had VP1, VP3, and uncleaved VP0, as shown by western
blot analyses using an antibody against VP2 (Fig. 4.1). Unlike the full virions, NEPs
were devoid of viral RNA and had no infectivity to HeLa-E8 cells (Fig. 4.1).
4.4.3 Cryo-EM structure determination
The procedures for cryo-EM structure determination is shown in Fig. 4.2. In
essence, images of full and empty particles were separated by reference-free 2D clas-
sification using the program Relion [337]. A truly independent procedure of 3D re-
construction was employed to avoid overfitting to noise [339, 446]. Essentially, ini-
tial model calculations, low resolution refinements and high resolution refinements
were performed independently for each of the two half-data subsets. Parameters
of anisotropic magnification distortion, a major resolution limiting factor for large
assemblies (e.g., viruses), were estimated using powder diffraction patterns of poly-
crystalline gold particles [448]. The resultant parameters were used in the program
jspr for correcting anisotropic magnification distortion on individual particles [449]
(Fig. 4.3). Refinements of particle center, orientation, defocus, astigmatism, scale,
and beam tilt resulted in icosahedral reconstructions of 8,973 full particles and 3,614
empty particles at 2.8 A˚ and 3.2 A˚ resolution, respectively (Table 4.1 and Fig. 4.4).
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Fig. 4.1. Characterizations of two forms of RV-C15a particles.
A. A typical region of a cryo-EM micrograph shows the presence of
full and empty RV-C15a particles. The micrograph was recorded at
a defocus of 3.1 µm. It was four-fold binned and low passed to 15 A˚
resolution for better visualization. The scale bar indicates 100 nm.
A sample of RV-C15a was sedimented through a sucrose gradient.
Fractions (1 ml) were collected (from the top) and then probed for
VP2/VP0 content by Western blot analyses (B) using mouse anti-RV-
C15-VP2. These fractions were also tested for infectivity according
to cytopathic effect (C), and for RNA content by qRT-PCR (C)
The resolution of the maps was estimated by calculating the Fourier shell correlation
between the two half maps, using 0.143 as a cut-off [452] (Fig. 4.5).
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Fig. 4.2. Workflow of cryo-EM structure determination in
the current thesis. Heterogeneity analysis refers to classification
of experimental EM images based on similarity at the level of 2D
image or at the level of 3D reconstruction [455]. The assumption is
that all datasets show a certain degree of particle heterogeneity. This
process allows for “virtual” purification of a heterogeneous particle
population to yield homogeneous subpopulations of particles. These
subpopulations are then treated as independent particle sets in the
following image processing procedures. Included in typical high res-
olution refinements are parameters for particle center, particle ori-
entation, astigmatism, defocus, scale, and anisotropic magnification
distortion.
4.4.4 RV-C15a has a spiky structure
The structure of the RV-C15a full particle has 60 dominant spike-like protrusions,
or fingers, on the outer surface of the virion (Fig. 4.6). In contrast, all other EV
structures have smoother, spherical surfaces (Fig. 4.6). Each RV-C15a finger, located
at the juncture between VP1, VP2 and VP3 that form a protomer, is formed by the
VP1 C-terminal residues 1252-1265 as well as residues 2136-2138 and 2160-2165 that
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Fig. 4.3. Anisotropic magnification distortion is a major reso-
lution limiting factor. Resolution of EM reconstructions was esti-
mated using FSC (0.143 as a cut-off) between two independent half-
maps. Shown are FSC curves for reconstructions that were computed
by varying parameters during refinement process. All parameters refer
to a combination of those for for particle orientation, particle center,
defocus, scale, astigmatism, beam tilt, and anisotropic magnification
distortion (or aniso in short). Red: only parameters for particle ori-
entation and center were included; green: all parameters but no aniso
were included; blue and black: all parameters were included, where
aniso was determined computationally by matching projections of a
3D EM reconstruction with experimental particle images (blue) or
experimentally (black) using polycrystalline gold particles.
form part of the VP2 EF loop (Fig. 4.6). The quality of the density for the finger
is not as good as is typical for the rest of the virus, presumably because this density
is on the periphery of the virus. It is noteworthy that residues 2160-2165 are highly
variable among alignments of RV-C sequences [439]. This segment corresponds to the
neutralizing immunogenic site NIm-II on the RV-B14 structure [13, 439]. The VP1
contribution to the finger, residues 1252-1265, is an RV-C-specific insertion. This




Data collection and refinement statistics
RV-C15a full RV-C15a empty
Data collection and processing
Microscope Titan Krios Titan Krios
Accelerating voltage (kV) 300 300
Camera Gatan K2 Summit Gatan K2 Summit
Pixel sizea (A˚/pixel) 1.04 1.04
Dose rate (e-/pixel/s) 8 8
Total dose (e-/A˚2) 25.7 25.7
Particle No. for final reconstruction 8973 3614
Resolutionb (A˚) 2.79 3.16
Map sharpening B factor (A˚2) -108.6 -122.2
Model Statistics




Avg. B-factor (A˚2) 24.1 31.7
r.m.s deviationsd
Bond lengths (A˚) 0.01 0.01
Bond angles (°) 0.96 0.944
Ramachadran plotd
Favored (%) 93.4 92
Allowed (%) 6.5 7.6
Outliers (%) 0.1 0.4
a Pixel size in super resolution mode. The physical pixel size is 2.08 A˚/pixel
b Resolution was determined by Fourier shell correlation between two half-maps using 0.143 as a
cut-off.
c Real space correlation coefficient (around atoms) between final EM map and a density map
calculated based on the coordinates.
d Based on the criteria of Molprobity
Because of relatively large deletions (21-35 residues) in parts of the VP1 BC, DE
and HI loops, the RV-C15a structure lacks a protruding plateau around each of the
5-fold vertices, a characteristic feature of other EV (Fig. 4.6). Thus the RV-C do not
have the analogous surface mass near the 5-fold vertices to form immunogenic sites
equivalent to NIm-IA (VP1 BC loop) and NIm-IB (VP1 DE loop) on RV-B14 [13].
Instead, the finger regions, as mentioned above, probably function as the dominant
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Fig. 4.4. Typical densities of the full (A-C) and empty (D-F)
particle EM maps.
antigenic sites [439]. As another consequence of these finger regions, the RV-C15a
particles have narrow, non-continuous canyons, much like the surface of EV-D68, a
virus that also causes respiratory illnesses [2, 456]. In each icosahedral asymmetric
unit, the C-proximal, RV-C15a VP1 insertion helps create a wall-like feature block-
ing the eastern end of the canyon (defined with respect to the usual orientation of
picornaviruses used in most figures) (Fig. 4.6).
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Fig. 4.5. The resolution of the empty (A) and full (B) parti-
cle maps is estimated based on FSC. The FSC curves between
two half subset maps calculated using the original images (Gold stan-
dard FSC) and using phase randomized (beyond 5 A˚) images (Phase
randomization) are colored red and blue. True FSC curves are col-
ored black. The FSC curves between the final EM map and a density
map computed based on the modeled atomic coordinates were colored
green.
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Fig. 4.6. The spiky structure of RV-C15a. A 10 A˚ resolution den-
sity map of RV-B14 (PDB 4RHV) (A) and RV-C15a (B) calculated
based on the respective coordinates is colored by radial distance (A˚)
to the virus center. A black triangle indicates an icosahedral asym-
metric unit on each of the two viruses. A rectangle (black dash line)
outlines the limit of a close up view of a finger in (C). Residues that
form the finger region, which are fitted into the EM map densities
(grey), are shown as Cα backbones and colored blue (VP1) and green
(VP2).
4.4.5 A sequence conserved depression could bind glycosylated CDHR3
Sialic acid is the glycan moiety recognized by EV-D68 when it interacts with its
cellular receptor [3]. Superposition of EV-D68 structure complexed with sialic acid
(Fig. 4.8) onto the structure of RV-C15a showed that the region near the eastern
end of the RV-C15a canyon has a similar surface electrostatic potential as the sialic
acid binding site on EV-D68 (Fig. 4.8). In the EV-D68, sialic acid can be bound
mainly by the Pro3231 carbonyl group and by the Arg3104 guanidinium group (Fig.
4.8). In RV-C15a, potentially those interactions would be replaced by the structurally
equivalent carbonyl group of Pro3226 and by the side chain amino group of Lys1271,
respectively (Fig. 4.8). Some of the nearby surface residues contributing to this region
are conserved among all RV-C (Fig. 4.7), and it is clear that the overall topography
could readily accommodate a sialic acid ligand. Therefore, this region, close to the
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Fig. 4.7. Sequence conservation of outer surface amino acid
residues. A surface representation of a pentamer of the RV-C15a
capsid is colored by radial distance (A˚) to the virus center (A) or by
conservation of amino acid sequences (B) among 33 types of RV-C
virus. A total of 67 sequences of RV-C viruses for which the complete
sequence of P1 region is available are used in sequence alignment.
Shown in the color key is the occurrence (%) of the most popular
residue at a given alignment position among the 67 sequences. A
surface representation of two protomers (C) is colored by conservation
of amino acid sequences. A black rectangle (dash line) outlines the
limit of a close-up view of the potential sialic acid (yellow) binding
site shown in (D).
base of each finger in the RV-C15a structure, is a likely binding site for a CDHR3
glycan. Consistent with this prediction, mutation of Asn186 a key glycosylation site
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on CDHR3, impairs RV-C15 binding to receptor-expressing cells [432]. Therefore,
glycans must play an important role in RV-C receptor interactions, as they do also
for EV-D68.
Fig. 4.8. A potential binding site for glycans on CDHR3. A.
A triangle indicates an icosahedral asymmetric unit. A red rectangle
(dash line) outlines the limit of the sialic acid binding site. Surface
electrostatic potential of EV-D68 (PDB 5BNO) (B) and RV-C15a
(C) is represented with a scale of -8kT/e (red) to 8kT/e (blue). D-E.
The sialic acid (yellow) interacts with surrounding residues on EV-
D68 (green) and as anticipated on RV-C15a (cyan). Red dash lines
indicate (potential) polar interactions. Oxygen and nitrogen atoms
are colored red and blue, respectively.
4.4.6 The hydrophobic pocket is unsuitable for capsid binding agents
Capsid-binding reagents that replace the pocket factor within VP1 are effective
antiviral therapeutics against many EV [457], but not RV-C [438]. Unlike many
86
EV structures the hydrophobic pocket within the VP1 jelly roll fold, where a pocket
factor is typically bound [2,16,429], is collapsed in RV-C15a (Fig. 4.9). The collapsed
structure is similar to the empty pockets found in purified RV-B14 [13] and RV-
B3 [20]. None of these three structures have sufficient space to accommodate a fatty-
acid pocket factor, because for each, the VP1 GH loop, located at the boundary
between the canyon and the entrance to the VP1 pocket, is in a conformation that
squeezes the pocket. Nevertheless, in RV-B3 and RV-B14, the flexibility of the VP1
GH loop allows enlargement of the pocket that then can bind antiviral reagents. The
RV-B14 pocket is lined with multiple small residues (e.g., Ala, Ser, Val, etc) that can
accommodate such compounds. In contrast, the collapsed RV-C15a VP1 pocket is
filled with bulky, hydrophobic residues (in particular, Trp1080, Phe1096, Met1116,
and Met1180) (Fig. 4.9 and Table 4.2). These amino acids are conserved in almost
all RV-C (14). Additionally, Ile1198 and Tyr1246 partially block the entrance to the
VP1 pocket. Therefore, as has been observed experimentally [438], no RV-C are likely
to be responsive to antiviral therapies based on pocket-binding compounds.
4.4.7 Comparison of the Full and Empty Particle Structures
RV-C15a full and empty particles differed mainly in regions on the inner surfaces
of their capsid shells (Fig. 4.10). In particular, the VP1 N-terminal residues 1017-
1053 are well-ordered in the full particle map, but disordered in the empty particle
map. This is consistent with other EV structures where the VP1 N-terminus is
involved in binding to viral RNA [16] and is externalized prior to ejecting the genome
during infection [114]. Thus the specific configuration of this internal region is RNA-
dependent and is likely to exert strong influence on VP0 cleavage when the RNA is
packaged [63]. In the empty particles, VP0 residues 4024-4050 form a hairpin loop
positioning the VP0 cleavage site in close proximity to His2191 (Fig. 4.10), a crucial
residue in the cleavage mechanism [64]. Nearby VP1 residues 1054-1064 interact with























































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 4.9. RV-C15a has a collapsed VP1 hydrophobic pocket.
RV-A16 (A) and RV-C15a (B) are colored by polypeptides: VP1
(blue), VP2 (green), and VP3 (red). The volume of the VP1
hydrophobic pocket, calculated using Pymol, is colored gold. C.
Residues lining the VP1 pocket of RV-C15a clash with pleconaril
when superimposing the structures of RV-C15a and RV-B14 com-
plexed with pleconaril. The VP1 GH loop (yellow) of RV-B14 is
shown as Cα backbones, which adopts a conformation that can ac-
commodate pleconaril. Red dash lines indicate a distance of closer
than 2.5 A˚ between a given atom of a RV-C15 residue (green) and a
given atom of pleconaril (yellow). Oxygen, nitrogen and sulfur atoms
are colored red, dark blue and dark yellow, respectively.
cleavage reaction. However, in the full particle structure, the VP1 N-terminal residues
1027-1053 (disordered in the empty particles) interact with the C-terminus of VP4
within the same protomer and participates in viral RNA binding (Fig. 4.10).
4.5 Discussion
The cryo-EM structure of RV-C15a showed a collapsed hydrophobic pocket in
VP1 that is filled with multiple bulky residues that inhibit the entrance of compounds
which inhibit other EV by binding into the VP1 pocket. This is reminiscent of the
collapsed pockets of non-EV picornaviruses, such as foot-and-mouth disease virus
(genus Aphthovirus) [286] and Mengovirus (genus Cardiovirus) [458]. Those pockets
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Fig. 4.10. The full and empty RV-C15a particle structures
differ in regions at the capsid interior. The VP1 N-terminus and
VP4 undergo structural rearrangements when the empty particle (A)
and full particle (B) structures are compared. Amino acid residues
are shown as Cα backbones. VP4, VP2, and VP1 are colored orange,
green and blue, respectively. In the RV-C15a full particle structure,
His1030, together with a conserved residue Trp2038 shared by many
EV, are involved in forming an RNA binding site [16,18,20].
are similarly occupied by multiple bulky, hydrophobic side chains and are unable to
serve as drug targets.
Inclusion of large hydrophobic residues into the VP1 pocket of RV-Cs and incor-
poration of a fatty-acid like pocket factor into the VP1 pocket of many other EVs
produce similar hydrophobic effects that favor the folding of the VP1 jelly roll β bar-
rel. On one hand large hydrophobic residues (e.g., Phe, Trp, Met) are more effective
than small residues (e.g., Val, Ala) at reducing solvent accessible surface areas in
the pocket. Likewise, a pocket factor with a long hydrophobic tail (more than eight
carbon atoms) plays a crucial role in expelling water out of the VP1 pocket of many
EVs that contain multiple small residues. On the other hand, the presence of large
hydrophobic side chains or a pocket factor in a VP1 pocket keeps the two sheets
(one with strands C, H, E, F and the other with strands B, I, D, G) in a favorable
90
distance for forming a barrel and offers hydrophobic interactions that stabilize the
jelly roll fold.
Concerning enteroviruses (e.g., EV-A71 and RV-A2) that have a pocket factor
bound in the VP1 pocket in the native form, a collapsed VP1 pocket is formed
when these viruses are converted into uncoating intermediates, including A(altered)-
particle [212] and emptied particle [31,238]. In this process, the VP1 GH loop changes
its conformation, whereas other residues lining the pocket remain nearly unchanged.
Specifically, the VP1 GH loop moves into and squeezes the pocket, adopting a con-
formation that resembles that in the RV-C15a, RV-B3, and RV-B14 structures. It
is thus probable that the collapsed pocket in RV-C15a, RV-B3 and RV-B14 might
facilitate virus uncoating. These viruses might undergo particle expansion to become
A-particles where pores are formed in the capsid, as was previously described for
other EV [209,212].
The large interior rearrangements characterizing the full and the native empty
particles of RV-C15a, contrast with the conserved external surfaces. Both particle
types have the same diameter, and display the same finger protrusions, truncated
5-fold vertices, and putative glycan binding regions. Presently, it is not clear whether
the observed high proportion (about 30%) of empty particles is a property of all RV-C,
or unique only to RV-C15a. Possibly the RV-C species use these native empty particles
as immunogenic molecular decoys during infections, or they are merely byproducts of
the assembly process [48].
The published atomic models of RV-C [439, 440] predicted the loss of VP1 mass
at the five-fold vertices, relative to the crystal structures of other RV virions. The
more rigorous one of these models [438] also predicted steric impediments in the VP1
pockets as the cause of drug binding failures. However, although the overall r.m.s.d.
between equivalent Cα atoms of this predicted model and the present cryo-EM struc-
ture was about 1.3 A˚, none of the bioinformatics-derived information correctly pro-
jected the finger-like features which dominate the particle surface. The relative VP1
insertion contributing to each protrusion is unique to the RV-C.
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The atomic structures of an RV-C virus, as reported here, show novel molec-
ular targets for designing anti-RV-C therapeutics. Furthermore the non-infectious
empty particles may have potential as vaccine candidates. These possibilities have
clinical relevance since many RV-C, including RV-C15, are associated with severe,
hospitalization-category infections in young children [431, 459], especially those with
asthma, and can also lead to significant adult respiratory problems, including chronic
obstructive pulmonary disease.
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5. ACID INDUCED STRUCTURAL CHANGES OF
HUMAN ENTEROVIRUS D68
The data and text in this chapter are part of a manuscript in preparation.
5.1 Chapter Abstract
Enterovirus D68 (EV-D68) mainly causes respiratory infections and is sensitive
to acid, much like rhinoviruses. The molecular basis of the acid sensitivity of EV-
D68 has not been studied. This chapter presents a 2.3 A˚ resolution cryo-electron
microscopy (cryo-EM) structure of a current strain of EV-D68. The structure shows
that the pocket factors is absent and that the VP1 hydrophobic pocket is partially
collapsed. This structural feature correlates with a low stability of EV-D68 under
acidic conditions, a characteristic that facilitates viral RNA release into host cells for
virus replication. Furthermore, the structure of an uncoating intermediate of EV-D68,
which was formed at late-endosomal pH (pH 5.5), has been determined to about 3.0
A˚ resolution. Acid treatment of EV-D68 leads to particle expansion and formation of
pores at two-fold axes through which the viral RNA might exit. Finally, as a result
of the low stability of the virus, cryo-EM analyses using a single specimen of EV-D68
at neutral pH show six distinct structural states of the capsid. These states differ
mainly in particle size and in regions at the capsid interior. Thus these results provide




Human enterovirus D68 (EV-D68) mainly causes respiratory infections [456]. The
optimum growth temperature of EV-D68 is 33°C, which is the temperature of the
human upper respiratory tract [401]. Furthermore, EV-D68 is sensitive to acid. These
are common biological characteristics shared by rhinoviruses (viruses from the species
RV-A , RV-B, and RV-C) but not by viruses from the species EV-A, EV-B and
EV-C [4]. Rhinoviruses primarily infect the human upper respiratory tract and are
transmitted through respiratory route. However, viruses from the species EV-A, EV-
B and EV-C, as exemplified by polioviruses, are transmitted through fecal-oral route
and need to be sufficiently stable to thrive in the acidic environment of the human
gastrointestinal tract [4].
Acid lability (virus instability at pH <6) has been explored as a potential anti-
rhinovirus therapeutic target [460], because acid treatment of rhinoviruses resulted in
partial or nearly complete loss of viral infectivity [461]. In the cases of RV-A2, RV-B3,
and RV-B14, early studies demonstrated that in vitro incubation of the virus at pH
5 led to the production of two different forms of subviral particles that had slower
sedimentation rates than native virions (150S) [106, 461]. The two forms exhibited
characteristics of what were later known as A-particles (135S) and emptied particles
(80S) [204, 205, 219, 229, 238], respectively. In essence, A-particles, which still retain
viral genome, are featured by externalization of VP1 N-terminal residues and by loss
of VP4 [205, 209, 212, 213]. Emptied particles have similar capsid structure but are
void of viral genome [31,205,238]. Crystallographic studies of RV-B14 crystals treated
immediately with acidic buffer showed that the VP1 GH loops, residues around the
five-fold cation sites, and the VP3 N-terminal regions became disordered [462], as
compared to the native virion structure. These acid induced structural changes were
proposed to facilitate release of VP4 [462]. Furthermore, in vitro treatment of RV-A2
at pH 5.6, which is close to the late endosome pH, led to the formation of A-particles
as characterized by X-ray crystallography [205]. This is consistent with the fact
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that endosomal acidification is important for successful cell entry of a number of
RVs [197, 463]. Comparison of the native RV-A2 structure and the 6.0 A˚ resolution
crystal structure of RV-A2 A-particle showed that the viral RNA loses contacts with
the VP1 N-terminus in A-particles and might form an ordered layer beneath the capsid
shell [205]. These results suggested a mechanism where global structural changes of
the virus are induced by acid. Given the structural similarity of EV-D68 to a number
of rhinoviruses, it is hypothesized that acid triggers EV-D68 uncoating.
This chapter characterizes structural changes of EV-D68 that are associated with
virus uncoating by cryo-EM analyses. The molecular basis of the acid lability of
EV-D68 (as also rhinoviruses) is also discussed.
5.3 Materials and Methods
5.3.1 Viruses and cells
EV-A71 (strain MY104-9-SAR-97, GenBank ABC69262.1) was provided by Jane
Cardosa (Universiti Malaysia Sarawak, Malaysia). In addition to the aforementioned
EV-D68 strain US/MO/14-18947, another isolate of EV-D68 from the 2014 outbreak
in the United States, US/KY/14-18953 (GenBank: AIS73057.1), was provided by M.
Steven Oberste through BEI Resources, National Institute of Allergy and Infectious
Diseases, National Institute of Health. Procedures for maintaining HeLa and RD cells
and for producing virus stocks have been described in earlier chapters.
5.3.2 Virus Growth and Purification
A sample (Prep A) for structure determination of full EV-D68 virion (strain
US/MO/14-18947) to 2.3 A˚ resolution was prepared as described in Chapter 2 with
slight modifications. After the crude virus sample was sedimented through a potas-
sium tartrate density gradient, a band in the middle of the tube was extracted and
subjected to buffer exchange. The resultant sample was further purified using an
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iodixanol (OptiPrep from Sigma) density gradient (10% - 51% (v/v) in 250 mM
HEPES, 250 mM NaCl, pH 7.5 (buffer A)) at 175274 x g (SW 41 Ti rotor) for 2h at
4°C. Electron micrographs of the final sample verified the presence of more than 95%
full particles. The sample was stored at 4°C.
A virus preparation (Prep B) that contained a heterogeneous population of EV-
D68 particles was used for structural studies at both neutral pH and acidic pH.
Briefly, RD cells were infected with EV-D68 (strain US/MO/14-18947) at an MOI
of about 0.01. Cells and supernantant were harvested at 3 days post infection and
were then separated by centrifugation. Cell pellets were subjected to multiple cycles
of freeze-and-thaw, and were centrifuged to remove cell debris. Polyethylene glycol
8000 (PEG8000) (40% w/v stock solution) and NaCl (powder) were added into the
original supernatants (after infection) to reach a final concentration of 8% PEG8000
and about 500 mM of NaCl. After low speed agitation at 4°C for about 6h, the
mixture was spun down. The resultant white pellets were resuspended in buffer A,
which was combined with the previous supernantant from the step concerning cell
pellets. All supernatant was centrifuged using a Ti 50.2 rotor at 277,937 x g for 2h
at 4°C. The resultant pellets were resuspended in buffer A and treated sequentially
as follows: 1) add 5 mM (final concentration throughout the treatments) MgCl2; 2)
add 10 µg/ml DNAse; 3) add 7.5 mg/ml RNase and leave at room temperature for 30
min; 4) add 0.8 mg/ml trypsin and incubate at 35°C for 10 min; 5) add 15mM EDTA;
6) add stock n-lauryl-Sarcosine (10%, w/v, in buffer A) to reach a final concentration
of 1% (w/v). Pellets were resuspended in buffer A and then purified through an
iodixanol density gradient mentioned above. The sample was stored at 4°C.
5.3.3 Infectivity Assay
Four different viruses were used, including the acid resistant EV-A71, the acid
labile EV-D68 strain Fermon CA62-1, and two EV-D68 isolates (US/MO/14-18947
and US/KY/14-18953) from the 2014 US outbreak. Purified viruses were treated
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with phosphate-citrate buffer (100 mM Na2HPO4 and 50 mM citric acid) at pH 4, 5,
6, or 7.2 at 33°C for about 40 min. The resultant samples were neutralized back to
about 7.2 using phosphate-citrate buffer (400 mM Na2HPO4 and 200 mM citric acid,
pH 7.3) before being assayed for viral titers using a plaque assay (Chapter 2).
5.3.4 Cryo Electron Microscopy
About 2.8 µl of virus sample was applied onto a 400 mesh continuous carbon grid.
Immediately after blotting for about 8s, the grid was vitrified in liquid ethane that
was pre-cooled by liquid nitrogen. Frozen particles within a thin layer of vitreous ice
were imaged with a Gatan K2 Summit direct electron detector using a Titan Krios
TEM (300 kV). All samples for EM data collection were of strain US/MO/14-18947.
The dose rate was kept at approximately 8e-/pixel/s for collecting all data, as will
be described below. For structure determination of native full virions using Prep A,
data (dataset A Native) were collected at a nominal magnification of 22,500x in super
resolution mode with defocus values ranging from 0.3 to 3.0 µm. A total electron dose
of about 36 e-/A˚2 was fractionated into 38 frames (200ms/frame). For initial low pH
studies using Prep B, viruses were treated with phosphate-citrate buffer (100 mM
Na2HPO4 and 50 mM citric acid) to reach a final pH of 5.5 (dataset B RT Acid)
or a pH of 7.2 (dataset B RT Neu), followed by incubation at room temperature
for 20 min and subsequently neutralization with 400 mM Na2HPO4 and 200 mM
citric acid (pH 7.8). Data were collected at a nominal magnification of 22,500x in
super resolution mode. The defocus range for datasets B RT Acid (144 micrographs)
and B RT Neu (87 micrographs) were 0.9-4.8 µm and 1.3-3.6 µm, respectively. For
dataset B RT Acid, a total electron dose of about 28 e-/A˚2 was fractionated into 30
frames (200ms/frame). For dataset B RT Neu, a total electron dose of about 25 e-/A˚2
was fractionated into 27 frames (200ms/frame). For low pH studies using Prep B to
mimic conditions during virus infection, viruses were treated at pH 5.5 similarly to
the aforementioned procedure except that the incubation temperature was at 33°C.
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Data (dataset B 33 Acid) were collected at a nominal magnification of 22,500x with
defocus values ranging from 0.5 to 3.5 µm. A total electron dose of about 38 e-/A˚2
was fractionated into 40 frames (200ms/frame). For analyzing the heterogeneous
particle population of Prep B (stored at 4°C) at neutral pH, data (dataset B 4 Neu)
were collected at a nominal magnification of 18,000x in electron counting mode with
defocus values ranging from 1.7 to 5.3 µm. A total electron dose of about 45 e-/A˚2
was fractionated into 60 frames (250ms/frame).
5.3.5 Image Processing
Procedures for image processing were similar to what had been described for
RV-C15a (Chapter 4). In essence, concerning all datasets, movie frames were sub-
jected to motion correction using a modified version of MOTIONCORR [331] (Wen
Jiang). The aligned frames were summed up to produce individual micrographs,
which were used to determine parameters of contrast transfer function (CTF) using
CTFFIND3 [444]. For some datasets, virus particles were picked up from the micro-
graphs manually using e2boxer.py in the EMAN2 program package [335]. For some
datasets, particle selection was performed first manually using e2boxer.py and subse-
quently automatically using the program DogPicker [445] based on templates derived
from manually selected particles. Particles were subsequently boxed and extracted
from the micrographs. The process was integrated into the Appion data processing
pipeline [443]. The resultant particle images were subjected to two dimensional (2D)
classification using the program Relion [337]. which identified and removed some low
quality particles and separated images of full particles from those of empty particles.
The following reconstruction procedures were employed for all datasets except
for dataset B 4 Neu using the program jspr [339, 446]. In brief, particle images (8x
binned, with a pixel size of 5.20 A˚/pixel) were divided into two halves. As described
in Chapter 4, for each half, a random initial model approach, specifying icosahedral
symmetry, was employed to generate multiple initial three dimensional (3D) models,
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from which a suitable initial model was selected. The best particle orientation and
center of each particle image was searched with respect to projections of the initial
reference model. The reference model for the next iteration was reconstructed from
particle images employing parameters for orientation and center determined in the
current iteration. The refinement procedure was then extended to 4x binned and then
2x binned data. Specifically, for dataset A Neu 2.3, the procedure was extended to
unbinned data. At this point, individual particles images were subjected to correc-
tion of anisotropic magnification distortion using the program jspr, which was done
with experimentally determined distortion parameters [449]. Subsequently, multi-
ple parameters were then included in the refinement process, which were parameters
for particle orientation, particle center, beam tilt, defocus, scale, astigmatism. To
achieve 3D reconstructions with the highest possible resolution, particle images were
re-extracted from micrographs that were generated by averaging aligned frames 3-16.
In this way, frames that underwent large motions and that contained limited high
resolution information due to radiation damage were discarded. Frames 3-16 were
selected using a trial-and-error approach where different combinations were tested,
including frames 3-9, 3-16, 3-23, and 3-30. Fourier shell correlation (FSC) of two
interdependently calculated half-maps (after masked with a soft mask) was used to
estimate the resolution of the final EM maps [452, 453]. The maps were sharpened
using a negative B-factor for better visualization during model building [452].
The following procedures were done for dataset B 4 Neu. After 2D classification
of all particle images in the dataset, the resultant full particle images (4x binned, 6.48
A˚/pixel) were used to generate initial three dimensional (3D) models, from which a
suitable initial model was selected. The refinement process was performed using a
projection matching approach as what was described above. After multiple iterative
cycles when the process converged, the resultant 3D model was essentially an average
of all possible structural states present in the collection of full particle images. The
model was low pass filtered to 60 A˚ resolution and then utilized as a reference model
for 3D classification of full particle images (4x binned) using the program Relion [337],
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where the number of classes was 4 and where icosahedral symmetry was imposed.
Particle images from two of the resultant four classes yielded 3D reconstructions that
were nearly identical to each other by visual inspection. Thus, particle images from
the two classes were combined into one class. The same process was also applied to
images of empty particles. Hence, all particle images in the dataset were classified
into a total of six classes (three for full particles and three for empty particles), which
represented six different structural states. Procedures for cryo-EM structure deter-
minations were the same when using each class of particle images, as were detailed
in the last paragraph.
5.3.6 Model Building and Refinement
Procedures for model building and refinement were essentially the same as what
had been done for the RV-C15a structure (Chapter 4). The same procedures were
employed for all atomic structures presented in this chapter. In brief, the coordinates
of Fermon strain excluding the pocket factor and water molecules (PDB accession
number 4WM8) were used as a starting atomic model. It was manually fit into the
EM map using Chimera [400]. Then multiple cycles of model rebuilding in Coot [394]
followed by real space refinement against the EM map using Phenix [397] yielded
an atomic model that fit well into the map density by visual inspection. A mask
that contained all grid points within a radius of 5 A˚ around each atom of the atomic
model was used to cut out a map segment from the EM map. The atomic model
was subjected to refinement of atomic coordinates, B factors, and occupancy against
pseudo crystallographic structure factors (defined as in Chapter 4) that were com-
puted from the map segment using Phenix [397]. In this reciprocal space refinement
procedure, R factors were monitored. The resultant atomic model was used for real
space refinement with NCS constraints using Phenix [397]. The final atomic model
was validated based on the criteria of MolProbity [454].
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5.4 Results
5.4.1 The EV-D68 strain MO is acid sensitive
The effect of acid treatment on virus infectivity was tested using a plaque assay.
EV-A71 is acid resistant and retained infectivity at low pH (pH 4-6). In contrast,
the tested EV-D68 strains are acid labile, including the prototype Fermon strain and
two strains (US/MO/14-18947 and US/KY/14-18953) from the 2014 US outbreak.
Hereafter, US/MO/14-18947 and US/KY/14-18953 will be referred as MO and KY,
respectively. Among these strains, strain MO is most sensitive to acid (Fig. 5.1).
Fig. 5.1. The EV-D68 strain MO is acid sensitive. Viruses were
treated using buffer with a series of pH values and then assayed for
viral titers. Shown is a plot of changes of virus infectivity in logarithm
scale as a function of buffer pH.
Cryo-EM analysis of the full virion of EV-D68 strain MO was performed similarly
as what was done for RV-C15a (Chapter 4), except that data collection was at a
nominal magnification of 22500x that gave a better signal-to-noise ratio and a finer
pixel size than in the case of 14000x. Cryo electron micrographs showed that there
were more than 95% of full virions in the sample (hereafter referred to as Prep A),
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which was prepared using two rounds of density gradient centrifugation. The virus
structure (dataset A Native) was determined to about 2.3 A˚ resolution using 11,344
particles (Fig. 5.2 and Table 5.1). The pocket factor was found to be absent in the
VP1 hydrophobic pocket, which is partially collapsed. This structural feature may
explain the low stability of strain MO under acidic conditions, a characteristic that
probably allows efficient virus uncoating within host cells.
5.4.2 Acid induces EV-D68 uncoating
In consistent with the low stability of strain MO, a virus sample (hereafter re-
ferred to as Prep B) that was not as intensively purified as Prep A yielded a mixture
of full virions and empty particles that co-existed within one fraction of about 0.7
ml. To study acid triggered structural changes of the virus, initial structural anal-
ysis was performed, where Prep B was treated with either a pH 5.5 buffer (dataset
B RT Acid) or a neutral pH buffer (dataset B RT Neu) at room temperature for 20
min. Two-dimensional (2D) classification of particle images in dataset B RT Neu
showed the presence of full and empty particles with a particle number ratio of about
1.9:1 (full:empty) (Fig. 5.3). In contrast, 2D class averages of particle images in
dataset B RT Acid showed the presence of empty particles as well as a particle form
that contained genome but exhibited a thinner capsid shell than native full virions.
The ratio between the new form of particles and empty particles was about 1.7:1 (Fig.
5.3), suggesting that acid triggered the conversion of native full virions to the new par-
ticle form. Icosahedral reconstructions of the new form of particles (3,708 particles)
and empty particles (2,150 particles) in dataset B RT Acid were calculated to about
3.3 A˚ and 3.8 A˚ resolution, respectively. The VP1 N-terminal residues 1001-1041
(numbering based on the amino acid sequence of the Fermon strain) and a majority
of VP4 residues are well ordered in the map of native full virion but become disordered
(or missing) in the map of the new particle form. This observation demonstrates that
the particle form represents A(altered)-particle, an uncoating intermediate known for
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Fig. 5.2. The cryo-EM structure of EV-D68 strain MO. A.
A typical portion of an electron micrograph (eight times binned) of
strain MO. The micrograph was collected at a defocus of 1.3 µm.
Scale bar: 100 nm. B. Typical cryo-EM map densities. C. Resolu-
tion estimation based on Fourier shell correlation (FSC) between two
independently calculated half-maps. Different kinds of FSC curves
are labeled as in Fig. 4.3. A fatty acid-like pocket factor is present
in strain Fermon (D), but is absent in strain MO (E). The volume
of the VP1 pocket, calculated using Pymol, is colored gold. F. Com-
parison of Amino acid residues lining the VP1 hydrophobic pocket in
the structures of strain Fermon (grey) and strain MO (green). The
pocket factor is colored black. Concerning strain MO, residue I1217
moves by 1.9 A˚ (Cα atom, red dash line) into the pocket that would
clash with the pocket factor.
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Table 5.1
Data collection and processing statistics
A Native B 33 Acid A-ptcl B 33 Acid emp
Data collection and processing
Microscope Titan Krios
Accelerating voltage (kV) 300
Camera Gatan K2 Summit
No. of micrographsa 642 950 950
Pixel sizeb (A˚/pixel) 0.65 0.65 0.65
Dose rate (e-/pixel/s) 8 8 8
Total dose (e-/A˚2) 36 38 38
Frame rate (ms) 200 200 200
Defocus (µm) 0.3-3.0 0.5-3.5 0.5-3.5
No. of ptcls for reconstruction 11344 23151 21132
Resolutionc (A˚) 2.33 2.96 3.08
Map sharpening B-factor (A˚2) -90.4 -150.8 -141.5
Model Statistics
Correlation coefficientd 0.850 0.845 0.862
No. of atoms
Protein 6264 5398 5149
Water 490 0 0
Avg. B-factor (A˚2) 14.1 20.7 27.3
r.m.s deviationse
Bond lengths (A˚) 0.009 0.010 0.010
Bond angles (°) 0.998 0.995 0.984
Ramachadran plote
Favored (%) 97.10 94.98 93.48
Allowed (%) 2.90 4.73 6.52
Outliers (%) 0.00 0.30 0.00
a No. of micrograhs where particles were extracted.
b Data collection was in electron couting mode. The physical pixel size is 1.62 A˚/pixel.
c Estimated by Fourier shell correlation between two half-maps using 0.143 as a cut-off.
d Real space correlation coefficient (around atoms) between final EM map and a density map
calculated based on the coordinates.
e Based on the criteria of Molprobity
many EVs (19-21). The capsid structure of empty particles is considerably similar
to that of A-particles (with a root mean square deviation (RMSD) of 0.2 A˚). The
RMSD values of two given structures were calculated based on equivalent Cα atoms
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throughout the chapter. This indicates that these empty particles are emptied parti-
cles that are formed after native full virions have released the viral genome. Emptied
particles are distinct from VP0 containing native empty particles that have nearly
the same capsid structure as native full virions.
Fig. 5.3. Acid induces structural changes of strain MO. Typical
electron micrographs (four times binned) show EV-D68 MO particles
treated with pH 7.2 buffer (A) and with pH 5.5 buffer (C). Scale bar:
100 nm. The corresponding 2D class averages of particle images are
shown in (B) and (D), respectively. On the far right, the percentage
of particle images that are classified to be full or empty is given.
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In order to mimic the environment for virus uncoating in host cells, Prep B
was treated with a pH 5.5 (late endosomal pH) buffer at 33°C for 20 min(dataset
B 33 Acid). Similar to the aforementioned observation in the case of room tempera-
ture incubation, A-particles and emptied particles were present in dataset B 33 Acid.
The cryo-EM structures of A-particles (23,151 particles) and emptied particles (21,132
particles) were determined to about 3.0 A˚ and 3.1 A˚ resolution, respectively (Table
5.1 and Fig. 5.4). Radial density distribution of spherically averaged EM maps show
that A-particles and emptied particles are similarly expanded by about 8A˚ in diame-
ter relative to native full virions (Fig. 5.4). Moreover, pores are opened up at two-fold
axes on A-particles (with a pore size of about 8A˚ x 14A˚) and emptied particles (pore
size of about 7A˚ x 29A˚). A VP2 helix (residues 2091-2098) and the equivalent helix
from a two-fold related VP2 molecule move away from each other (Fig. 5.4). These
pores might function as sites where the genomic RNA exits, partially because a sin-
gle strand RNA, assuming no secondary structures, has a size of slightly less than
8A˚ x 10A˚ (concerning the adenosine residue that is larger than other residues) by
looking in the direction normal to the planar aromatic ring of the nucleotide base.
More importantly, when native full virions are converted into A-particles, the VP1
N-terminal residues 1042-1051 undergo dramatic conformational changes, causing the
movement of residue 1042 and residue 1051 by about 35 A˚ (Cα) and 8 A˚ (Cα), re-
spectively. In native full virions, residues 1042-1051 reside in the virus interior. In
the A-particles, residues 1044-1051 traverse the capsid shell such that residue 1042
lies on the outer surface (Fig. 5.4). These changes cause the externalization of the
VP1 amphiphathic helix (disordered in the A-particle structure) through a pore at
the base of the canyon. The VP1 amphipathic helix was previously predicted as a
segment of about 25 amino acids at the extreme N-terminus [114]. Thus, acid induced
structural changes facilitate EV-D68 uncoating.
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Fig. 5.4. The structures of EV-D68 uncoating intermediates.
A. Resolution estimation of reconstructions using FSC (0.143 as a cut-
off) between two half-maps. B. Radial density distribution of spher-
ically averaged cryo-EM maps. C. For each one of the full native
and A-particle atomic structures, a half capsid shell is represented as
a slab of about 20 A˚. D. The Cα backbone representation of two
protomers is colored blue (VP1), green (VP2), and red (VP3). VP1
residues 42-52 are highlighted in black. E-F. Pores are formed at
two-fold axes in A-particles, as compared with native full virions.
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5.4.3 Multiple structural intermediates are involved in EV-D68 uncoat-
ing
At neutral pH, Prep B is made up of a heterogeneous particle population as
mentioned above. To analyze the sample heterogeneity at neutral pH in detail, 2D
classification and subsequently three-dimensional (3D) classification of particle images
(dataset B 4 Neu) resulted in six different structural states of the virus capsid. These
structures were determined to about 3.5-3.6 A˚ resolution (Table 5.2). These states
differ mainly in particle size and in internal regions including the VP1 N-terminal
residues 1001-1053 and VP4. The two predominant states are full native virions (ac-
counting for about 50% of all particles) and emptied particles (about 21%) (Fig. 5.5).
This observation suggests that a portion of native full virions might have undergone
uncoating to produce emptied particles during virus purification. Consistent with
this prediction, two uncoating intermediates have also been identified from the whole
particle population. One intermediate is A-particles (about 10%), whereas the other
one represents a previously undescribed structural state (about 5%), which is termed
“expanded 1 particle” (E1 particle) here. The VP1 N-terminal residues 1001-1053
and VP4 residues 4030-4057 are ordered in E1 particles, as is the case for full native
virions (Fig. 5.5). Nevertheless, the E1 particle is expanded by about 8 A˚ in diameter
relative to the native full virion as indicated by calculation of radial density distri-
bution. The RMSD between the two structures when aligning icosahedral symmetry
axes is about 4.0 A˚. There are pores formed at two-fold axes on E1 particles. The
size of the pores is about 6 A˚ in one direction and about 9-23 A˚ in the orthogo-
nal direction. This uncertainty of pore size is due to an ambiguity in building some
amino acid side chains into the EM map at about 3.6 A˚ resolution. It is probable
that virus uncoating is initiated by particle expansion of full native virions to form
E1 particles. Subsequent loss of the VP4 molecules and externalization of the VP1
N-termini through pores on the E1 particles result in A-particles. The genomic RNA
108
is ultimately released to yield emptied particles. These results show that multiple
structural intermediates are involved in EV-D68 uncoating (Fig. 5.5).
In addition, two other structural states, each of which accounts for about 7% of all
particles, were found to have similar capsid structures to the full native virion (Fig.
5.6). The RMSD between the full virion and each of the two states is slightly less
than 1.0 A˚ when aligning icosahedral symmetry axes. The two states either lack inner
densities or show rod-like densities in the particle. They might be abortive products
during virus assembly. Nevertheless, further studies are needed to unravel the true
identity of these states.
5.5 Discussion
In the present work, acid treatment was found to diminish or abolish EV-D68
infectivity (Fig. 5.1). This is primarily because A-particles, which are formed under
acidic conditions, have limited infectivity according to a previous report [217]. The
absent of VP4 in A-particles probably prevents pore formation on host cell membranes
[234]. Additionally, externalization of the membrane associated region of VP1 N-
terminal residues might impair receptor binding of A-particles. These factors would
render A-particles poorly infectious.
Differences of amino acid sequences in the P1 capsid region might explain why
the two current strains, MO and KY, are more sensitive to acid than the Fermon
strain. Strains MO and KY possess six more charged residues (Lys, Arg, Glu, and
Asp) on the virus surface than the Fermon strain. More importantly, the two current
strains have a His at position 2098, whereas the Fermon strain has a Tyr. There
is also a conserved His at position 2099 shared by enteroviruses. Histidine can act
as a pH sensor whose pKa is about 6. In particular, residue 2098 is located on the
aforementioned helix (residue 2091-2098) that is in close proximity to the icosahe-
dral two-fold axis and that contributes to the opening of pores at two-fold axes in






























































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 5.5. EV-D68 uncoating entails multiple structural inter-
mediates. A-D. A cut-way view of each of four different structural
states of the EV-D68 (strain MO) capsid by looking down an icosa-
hedral two-fold axis from particle exterior to particle interior. A red
triangle indicates an icosahedral asymmetric unit. RMSD values are
calculated based on equivalent Cα atoms using the native full virion
structure as a reference and by aligning icosahedral symmetry axes.
The percentage of particles images that are classified into a given state
is shown in parentheses.
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Fig. 5.6. Multiple structural states are present at neutral pH.
A-B. Two additional structural states represent probable abortive
products during virus assembly. Details for making the figure and for
labeling are the same as those in Fig. 5.5.
near two fold axes become protonated and might facilitate acid induced structural
changes of the virus. A similar mechanism was previously proposed for an animal
picornavirus, foot-and-mouth-disease virus (FMDV). The repulsive electrostatic in-
teractions at the pentamer-pentamer interface caused by protonated histidine residues
were suggested to trigger the dissociation of FMDV pentamers upon endosomal acid-
ification [286,464]. Furthermore, 25 out of 297 EV-D68 strains for which the (nearly)
complete genome sequence is available (as of October 2016) have a Tyr at position
2098 and were isolated in between 1962 and 2013. This indicates that current EV-D68
strains have evolved to acquire a His at position 2098, which might confer a high acid
sensitivity of the virus and the efficiency of virus uncoating.
Amino acid sequence alignments of multiple enteroviruses showed that EV-A71,
CVB3, PV, RV-A16, RV-A2, RV-B14, and EV-D68 (Fermon) contain a Tyr/Phe at
the equivalent position to position 2098 in EV-D68 [2]. Thus, alternative mechanisms
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might exist that account for the acid lability of rhinoviruses and early EV-D68 strains
that have a Tyr at position 2098. For instance, previous electrostatic calculations of
viral stability postulated a mechanism where a β-sheet at the pentamer-pentamer
interface regulates the accessibility of buried histidine residues to acid [465]. The
β-sheet appears to be unstable in rhinoviruses but is stable in polioviruses at low pH
conditions.
Sialic acid receptor and endosomal acidification probably assist EV-D68 entry into
host cells in a synergistic manner. Sialic acid receptor binding to the Fermon strain
caused ejection of the pocket factor that destabilizes the virus. The infectivity of the
Fermon strain was slighted impaired at pH 5-6, suggesting that endosomal acidifica-
tion alone would not be sufficient to result in uncoating of the strain. This observation
raises the possibility that sialic acid receptor binding increases the pH threshold for
triggering virus uncoating. Nevertheless, the synergistic action of receptor and low
pH depends on virus strains. Concerning strain MO (as probably also strain KY),
because of the absence of a pocket factor in the native structure and of the low stabil-
ity under acidic conditions, sialic acid receptor binding might not contribute to virus
destabilization or to prime virus uncoating.
In summary, cryo-EM studies of the acid sensitive EV-D68 have shown the in-
volvement of multiple structural intermediates in virus uncoating. The identification
of expanded 1 particles, a previously unknown intermediate, suggests the conforma-
tional fluctuation of enterovirus capsids.
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6. INHIBITION OF HUMAN ENTEROVIRUS D68
Part of the data and text in this chapter are taken from [2, 3] and are highlighted
by a black, vertical line in the right margin below. Macmillan Publishers Ltd: Na-
ture Communications [3], copyright 2015. Text and data from [2] are reprinted with
permission from AAAS.
6.1 Chapter abstract
Effective antiviral treatments are currently not available to combat respiratory
diseases and rare neurological diseases associated with EV-D68. Structural similarity
between EV-D68 and rhinoviruses opens up the possibility of re-purposing known
rhinovirus inhibitors for inhibiting EV-D68 infections. Here, pleconaril, a compound
that had been specifically developed for rhinoviruses, has been found to be a nanomo-
lar inhibitor against the prototype strain and two circulating strains of EV-D68. The
crystal structure of EV-D68 in complex with pleconaril showed that it replaces the
pocket factor in binding the VP1 pocket. Furthermore, pleconaril inhibits EV-D68
attachment onto host cells and prevents virus uncoating. These results suggest that
pleconaril represents a candidate antiviral approach for treatments of EV-D68 infec-
tions.
6.2 Introduction
Over the last several decades, the hydrophobic pocket of VP1 has been explored as
target for a variety of small hydrophobic molecules that are known as capsid-binding
inhibitors of enterovirus (EV) infection. They stabilize the virus [188] by filling the
pocket with a well-fitting hydrophobic molecule, thereby inhibiting uncoating of the
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virus and the release of the genome into the infected cell. These compounds also
prevent attachment to cells by altering the surface features of the canyon floor where
the virus attaches to a cellular receptor [183, 188]. In addition, it was also shown
that capsid-binding compounds impedes virus breathing, which refers to reversible
conformational changes of the virus [253,254].
In most enteroviruses that have been investigated these capsid binding antiviral
compounds displace the pocket factor (e,g. PVs and many rhinoviruses (RVs)). RV-
B14 [13,243] and RV-B3 [20] do not contain a pocket factor, and they have a collapsed
VP1 pocket. Either neither RV-B14 nor RV-B3 bind a pocket factor in vivo or it was
lost during the purification procedure. Much effort was made between 1985 and 2000
to design a compound that fits into the VP1 pocket and would inhibit the maximum
number of rhinoviruses [457]. The final optimal structure was pleconaril which not
only had good efficacy but was also stable enough to maintain good bioavailability in
clinical tests [466]. For instance, oral pleconaril treatment was effective in reducing
the duration of common colds among adults in phase III clinical trials [466]. However,
pleconaril was not licensed primarily because it put women using birth control drugs
at risk of conception.
Currently, there are two capsid binding anti-EV compounds that are in clinical
trials. Pocapavir (or V-073) [81] is now being developed specifically for polioviruses,
aiming for usage in the post-eradication era [467]. Vapendavir (or BTA-798) [80]
has passed several phase II clinical trials with asthmatic patients. It is in develop-
ment for treatment of human rhinovirus infections and rhinovirus induced asthma
exacerbations that can result in chronic obstructive pulmonary disease.
This chapter describes the discovery of pleconaril as an effective capsid binding
inhibitor against EV-D68. Structural and functional analysis also unraveled the mech-
anism of action of pleconaril. Pleconaril interferes with EV-D68 entry into host cells
by inhibiting virus attachment and uncoating.
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6.3 Materials and Methods
6.3.1 Co-crystallization and data collection
Highly purified EV-D68 virions (2-3 mg/ml in PBS) were incubated with 0.2
mg/ml (in PBS) pleconaril at room temperature for 6h. 0.6 µl of the resultant
solution were then mixed with 0.6 µl of the reservoir solution (0.1 M sodium acetate
(pH 4.5) with 3.5 M sodium formate) for crystallization using the hanging drop vapor
diffusion technique. Thick plate-like or cubic, shiny crystals were obtained in 2-3 days
at room temperature. Crystals were cryo-protected in the same cryo-solution (as in
Chapter 2) except that 0.2 mg/ml pleconaril was added. Data collection on single
crystals was performed in the same way as mentioned for native EV-D68 crystals
(Chapter 2).
6.3.2 Structure determination
The crystals for the EV-D68-pleconaril complex were isomorphous with the native
EV-D68 crystals (Chapter 2). Initial phases were calculated using the native EV-D68
structure (without the pocket factor or water) for reflections to 8.0 A˚ resolution.
Phase extensions were performed using a step size of 1/a A˚
−1
until 2.3 A˚ resolution
had been reached similar to the phase determination of the native EV-D68 crystals.
6.3.3 In silico docking
In silico docking was performed by Woong-Hee Shin in the Kihara laboratory
(Purdue). Pleconaril, pirodavir and BTA-188 were docked into EV-D68 using AutoDo-
ck4 [468]. The three-dimensional coordinates of pirodavir and BTA-188 were obtained
from the PubChem database [469]. The binding pocket in EV-D68 was defined as
a cube-shaped box that ranged 22.5 °C in each direction from the geometrical cen-
ter of the pleconaril molecule as observed in the crystal structure. Each compound
was treated as being fully flexible (all single bonds that are not in a ring structure
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or between two double bonds were allowed to rotate) while the surrounding protein
structure of the virus was kept rigid. The Lamarckian Genetic Algorithm [470] was
used for conformational searches of the compound. The parameters that described
the conformation of the compound and its orientation and position in the search box
were set to random values to initiate each run. These were then optimized to mini-
mize the calculated binding energy. One thousand runs were made. The resultant one
thousand structures were then clustered around the final structures with the lowest
calculated binding energy. In each cluster, all structures have an r.m.s.d. value of
less than 2.0 A˚ relative to the lowest energy structure in this cluster. The structure
with the lowest calculated binding energy from the largest cluster was finally selected
as the most likely structure.
6.3.4 Viral attachment assay
To test the effect of pleconaril on EV-D68 attachment, purified virus (the proto-
type strain) was incubated with pleconaril in a series of concentrations ranging from 0
14 µM at 33°C for 1h, where 0 µM represents the virus only control in which the virus
was incubated with only DMSO. The resultant mixture was cooled down on ice and
added to 90% confluent HELF cells in a 24-well plate right after blocking each well
with the blocking solution as mentioned above. The MOI was 20. After incubation at
4°C for 1h, the wells were washed three times with cold DMEM to remove unbound
virus. Similar results were obtained when the virus was incubated with pleconaril at
4°C overnight. Total RNA in each well was extracted using an RNeasy Mini Kit (Qia-
gen) per manufacturers protocol (RNA extraction was performed by Ju Sheng). The
viral RNA of the bound virus in each sample was quantified a quantitative real-time
RT-PCR assay (together with Ju Sheng). All experiments were done in triplicate.
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6.3.5 Thermal stability assay
Thermal stability assays were performed similarly as previously described [471,
472] with some modifications. This was done together with Ju Sheng. Briefly, 1.5
µg of EV-D68 virus were incubated with pleconaril (with a final concentration of
10 µg/mL or 50 µg/ml) at 33°C for 1h. The control virus was treated the same
way except that no pleconaril was added. 1% DMSO (v/v) was used consistently.
Sybr green II dye (Life Technologies) was added to reach a concentration of 6X and
RNAseOUT (Life Technologies) at a concentration of 1U/µl. For each sample, a
50 µl reaction was set up and the fluorescence intensity was recorded in triplicate
at 1°C intervals between 31°C and 95°C using a real time PCR system (Applied
Biosystems 7300). After heating to a given temperature and holding for 20s, the
sample temperature was then lowered to 30°C and held for 2 min. This ensured that
the fluorescence was recorded at a constant temperature. The fluorescence intensity
was plotted as a function of temperature and the data were fitted with a sigmoidal
curve.
6.3.6 Plaque reduction assay
Three EV-D68 strains were used for plaque reduction assays, including the pro-
totype strain and two strains (US/MO/14-18947 and US/KY/14-18953) from the
2014 outbreaks in the United States. Experiments were performed together with Ju
Sheng. The virus was incubated with a specific inhibitory compound that had been
dissolved in DMSO at 33°C for 1h. For each of the three compounds (pleconaril,
pirodavir, and BTA-188), a series of concentrations were assayed in at least tripli-
cate. For vehicle control, the same amount of DMSO was added without using a test
compound. Confluent HeLa cells in 6-well plates were infected with approximately
150 PFU (plaque-forming unit) EV-D68 with compounds or DMSO per well. An
overlay containing 0.8% agarose was added to each well. After 4 days of incubation
at 33°C, the plaques were counted in each well. The percent inhibition was calculated
118
by (Ncontrol −Ninhibitor)× 100/Ncontrol, where Ncontrol and Ninhibitor are plaque counts
for the control and inhibitor wells, respectively.
6.4 Results
6.4.1 Pleconaril inhibits EV-D86 infection
The structural similarity of EV-D68 and many RVs suggested that the EV-D68
VP1 pocket might be targeted by known capsid-binding inhibitors against RVs. The
anti-EV-D68 activity of two capsid binding compounds, pirodavir and BTA-188 (Fig.
6.1), that had significant anti-rhinovirus activity were compared with pleconaril us-
ing plaque reduction assays in HeLa cells (Fig. 6.2). The half maximal effective
concentration, EC50, value of these two compounds were found to be comparable
to previous results using cytopathic effect inhibition assays against EV-D68 [473].
However, pleconaril was found to be more potent against EV-D68 than pirodavir and
BTA-188 (Fig. 6.2). The inhibitory effect of pleconaril is similar against EV-D68,
RV-A16 and RV-B14 but better than against EV-A71. It is, therefore, noteworthy
that pleconaril was an effective inhibitor in extensive clinical tests for treatment of
common colds [466,474] .
6.4.2 Pleconaril interferes with virus entry
Furthermore, pleconaril was found to interfere with virus attachment and uncoat-
ing during cell entry of EV-D68. As described in Chapter 3, the structures of EV-D68
complexed with sialylated trisaccharides suggest that the receptor molecule and the
pocket factor compete to bind the virion in the initial step of EV-D68 entry into
host cells. Pleconaril inhibits sialic acid dependent viral attachment to HELF cells
(Fig. 6.2) because the bound pleconaril blocks the conformational change of the virus
that favors sialic acid binding. In addition, fluorescence-based thermal stability as-
says indicated that when EV-D68 was incubated with either 10 µg/ml or 50 µg/ml
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Fig. 6.1. Chemical structures of pleconaril [75] , BTA-188 [475],
and pirodavir [476].
pleconaril, 4°C higher temperatures were required to release the RNA genome than
when no pleconaril was present (Fig. 6.2). Thus, pleconaril stabilizes EV-D68 capsids
and prevents the virus from uncoating during viral entry.
6.4.3 Structure of EV-D68 in complex with pleconaril
The structure of EV-D68 was also determined to 2.3 A˚ resolution when co-
crystalized with pleconaril (Table 6.1). The crystallographic procedure was the same
as for the native structure determination. The R factor was 0.243 (Table 6.1). The
electron density of the ligand inside the hydrophobic pocket was of the same height
but much longer than that of the pocket factor in the native EV-D68 structure (Fig.
6.3) and could be easily fitted with the structure of pleconaril (Fig. 6.3). This demon-
strated that the native pocket factor was replaced by pleconaril. However, the density
of the ligand and of the pocket factor are slightly lower than that of the polypeptide
main chain. In part this is to be expected because the ligand or fatty acid pocket
factor are composed primarily of only carbon atoms as opposed to the heavier combi-
nation of carbon, nitrogen plus oxygen atoms of the main chain. In part the slightly
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Fig. 6.2. Pleconaril is effective against EV-D68. A. List of EC50
values. B. Plot of % plaque reduction of pleconaril as a function of
the log of its concentration. Error bars indicate SD. C. Preincubation
of EV-D68 (prototype) with pleconaril inhibits viral attachment onto
non-treated HELF cells. Data are represented as mean±SD. Exper-
iments were done in triplicate. D. Release of EV-D68 genome upon
increase in temperature as monitored by Sybr green II. The experi-
ments were done in triplicate. For each data point, the ratio between
mean fluorescence intensity and standard deviation is at least 7.6.
Shown are curves fitted with a sigmoidal function for the native virus
and for the virus after incubation with pleconaril. Panels A, B, and
part of panel C from [2]. Reprinted with permission from AAAS.
lower density of the ligand might be due to some variations of conformation within
the VP1 binding pocket.
Part of the VP1 GH loop (residues 212-215) that forms the entrance to the VP1
pocket had become less ordered. The Cα atom of residue 211 had moved 1.2 A˚
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Table 6.1
Data collection and refinement statisticsa
EV-D68 with pleconaril
Data collection
Oscillation angle (°) 0.2
No. of crystals (No. of frames) 2 (232)
Space group I222
Cell dimensions
a, b, c () 323.2, 346.1, 355.5
α, β, γ (°) 90.0, 90.0, 90.0
Resolution () 50.0-2.32 (2.40-2.32)b
No. of unique reflections 399300 (26345)
Completeness (%) 47.2 (31.3)
Redundancy 1.6(1.2)
Rmergec 0.077 (0.185)
I /σ(I ) 6.98 (2.35)
Refinement
Resolution () 50.0-2.32 (2.40-2.32)
No. of reflections 399130 (26181)






RMSD bond (A˚) 0.006
RMSD angle (°) 1.388
Mean B-factor (A˚2) 17.3





a From [2]. Reprinted with permission from AAAS










towards the inside of the pocket relative to that of the native structure, possibly
blocking the entrance to the pocket once pleconaril had entered (Fig. 6.3). Thus the
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Fig. 6.3. Structure of pleconaril bound into the VP1 pocket of
EV-D68. A. Pocket factor density (grey) compared to the pleconaril
density (magenta). B. Pleconaril (green) fitted to density in the struc-
ture of the complex. C. Conformational change of the VP1 GH loop
as a consequence of the presence of pleconaril. The native and com-
plex structures are shown in marine blue and baby blue, respectively.
Oxygen, nitrogen, sulfur and fluorine atoms are shown in red, dark
blue, yellow and light green, respectively. From [2]. Reprinted with
permission from AAAS.
dynamics of GH loop might be an important consideration for future structure-based
design of EV-D68 capsid-binding inhibitors.
A comparison of the EV-D68-pleconaril, RV-B14-pleconaril and RV-A16-pleconaril
structures showed a similar binding mode for pleconaril in the VP1 pocket of these
three viruses (Fig. 6.4). This may explain why pleconaril is similarly effective against
these three enteroviruses. To investigate why pleconaril is more effective against
EV-D68 than pirodavir or BTA-188, in silico docking was performed. The pres-
ence of trifluoromethyl substituted oxadiazole moiety in pleconaril, rather than a
more hydrophilic group in either pirodavir (ethyl carboxylate group) or BTA-188
(O-ethyloxime group) at structurally equivalent positions, likely contributes to more
favorable interactions of pleconaril with the hydrophobic residues deep inside the VP1
pocket of EV-D68.
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Fig. 6.4. Comparison of (A) RV-A16 complexed with pleconaril
(PDB accession number: 1NCR), (B) RV-B14 complexed with ple-
conaril (PDB accession number: 1NCQ) and (C) EV-D68 complexed
with pleconaril. Pleconaril and the protein structure are shown in
green and cyan, respectively. Oxygen, nitrogen, sulfur and fluorine
atoms are colored red, dark blue, yellow and light green, respectively.
Residues in the three structures are all numbered according to EV-D68
numbering. Residues shown are those within 4 A˚ to any pleconaril
atom in the corresponding structure. From [2]. Reprinted with per-
mission from AAAS.
More importantly, in addition to the prototype Fermon strain, pleconaril also
inhibited two strains from the 2014 outbreak in the United States. The EC50 values
for strains US/KY/14-18953 and US/MO/14-18947 were about 760 nM and 110 nM,
respectively (Fig. 6.2). US/KY/14-18953, a phylogenetically minor strain in the 2014
outbreak, has the the same set of pleconaril interacting residues as the Fermon strain
strain. US/MO/14-18947, a phylogenetically predominant strain in the outbreak,




The structure of EV-D68 has considerable similarities to the well-studied RVs for
which pleconaril was specifically designed. This chapter shows that pleconaril replaces
the pocket factor and is a potent inhibitor of EV-D68 strains. The size and location
of the pocket factor lodged in the VP1 pocket is similar to that found in other RVs
and different to the pocket factors found in poliovirus 1 and EV-A71. This correlates
with the observation that pleconaril is far more active when the natural pocket factor
is short as in the RVs and in EV-D68.
Pleconaril was found to be an effective inhibitor against not only the proto-
type strain (isolated in 1962) but also two circulating strains (isolated in 2014).
Furthermore, sequence alignment of 188 EV-D68 strains found between 1962 and
2013 indicates that residues in VP1 which interact with pleconaril, as identified from
the complex structure, are completely conserved with one exception. Additionally,
the activity of pleconaril to US/MO/14-18947 was not impaired by the presence of
two amino acid substitutions in the hydrophobic pocket. These results indicate that
pleconaril might be able to inhibit a broad spectrum of EV-D68 strains. In accor-
dance with this prediction, pleconaril recently proved to be effective against a range
of EV-D68 clinical isolates that were classified into three different clades [477] .
Consistent with the activity of pleconaril using a plaque assay in HeLa cells pre-
sented here, several other recent work reported overall similar results when using
cytophatic effect inhibition assays in HeLa cells [477–479]. Furthermore, the clini-
cal efficacy of pleconaril in treatment of common colds was shown to correlate with
the susceptibility (to pleconaril) of viruses that infect human subjects. The greatest
activity of pleconaril was observed in subjects infected with viruses that showed an
EC50 of less than 0.38 µg/ml (or better than about 1 µM) [474]. Thus, it is proba-
ble that pleconaril, a nanomolar inhibitor of EV-D68, would be clinically effective in
treatment of EV-D68 infections.
Nevertheless, some uncertainties have also been raised over the clinical efficacy of
pleconaril against EV-D68. One recent report found that the activity of pleconaril
against circulating strains depends on the cell lines used for inhibition assays [478].
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This observation makes it more complicated to predict clinical efficacy according to
cell-based inhibition data. Moreover, EV-D68 variants resistant to pleconaril were
readily selected in the laboratory. The variants shared one common substitution
(V1069A) that was proposed to weaken the interactions of pleconaril with the virus
[477]. Therefore, resistance of EV-D68 to pleconaril is another factor that would
possibly impair the clinical efficacy.
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7. SUMMARY
Enterovirus (EV) is an important genus of Picornaviridae, a family of non enveloped,
icosahedral viruses with a positive-strand RNA genome. The genus includes a number
of human pathogens, such as polioviruses, enterovirus A71 and many respiratory
viruses, including human enterovirus D68 (EV-D68) and isolates of a newly discovered
species rhinovirus C (RV-C). Specifically, EV-D68 was the causative agent of an
outbreak of respiratory infections among young children in the United States (US)
in 2014. It also occasionally causes neurological diseases. Nevertheless, there are
currently no effective antiviral treatments or vaccines available.
The crystal structures have been determined of the prototype strain of EV-D68 by
itself and in complex with a capsid-binding inhibitor, pleconaril, which was developed
as an anti-rhinovirus inhibitor. Antiviral compound screening shows that pleconaril is
an effective inhibitor against the prototype strain and circulating strains of EV-D68.
Structural analysis further demonstrates that pleconaril binds to EV-D68 capsids and
replaces the pocket factor, a fatty acid-like molecule that stabilizes the virus in its
native state. Thus binding of pleconaril enhances the stability of EV-D68 virions,
preventing the virus from releasing its genome. These results suggest that pleconaril
is a possible drug candidate to alleviate EV-D68 outbreaks.
Receptor dependent cell entry of EV-D68 has been studied through structural and
functional analyses. Attachment, infectivity, and inhibition assays show that sialic
acid on the cell surface is indispensable for EV-D68 to attach onto and infect host
cells. To analyze the interactions of EV-D68 with sialic acid, the crystal structures of
the virus have been solved when complexed with three sialylated trisaccharides that
are receptor analogues. Binding of sialic acid receptor analogues to a depression, the
canyon, on the virus surface causes a cascade of structural rearrangements of EV-
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D68 to eject the pocket factor. Thus the sialic acid receptor destabilizes the virus
and facilitates cell entry.
Isolates of RV-C are closely linked to childhood asthma exacerbations that can
lead to significant adult respiratory problems. The RV-C are difficult to be prop-
agated in vitro, representing a challenge for structure determination. Using cryo-
electron microscopy (cryo-EM), the atomic structure of a cell adapted rhinovirus C
has been determined. The RV-C structure highlights novel immunogenic surfaces, a
potential binding site for glycans on the RV-C receptor and antiviral drug resistance
properties. Thus structural analysis of an RV-C defines molecular determinants for
designing effective antiviral therapeutics and vaccines. More importantly, this study
has established a workflow for structure determination of related viruses by cryo-EM.
To characterize structural changes of EV-D68 during virus uncoating, cryo-EM
studies were performed using an EV-D68 strain, namely strain MO, from the 2014
US outbreak. A 2.3 A˚ resolution cryo-EM structure of the virus shows the absence of
a pocket factor in the hydrophobic pocket in viral protein 1. This structural feature is
consistent with an instability of strain MO under acidic conditions. Acid treatment of
strain MO leads to the formation of an uncoating intermediate, A(altered)-particles.
Pores are opened up at icosahedral two-fold axes in A-particles, which probably allows
for the exiting of viral RNA. Furthermore, cryo-EM structures of six conformational
states of the viral capsid have been determined using a single sample of strain MO
at neutral pH. These states exhibit differences concerning particle size and internal
regions of the capsid. Thus, the process of EV-D68 uncoating might proceed via the
involvement of multiple structural intermediates.
In summary, these studies have advanced the knowledge of receptor-mediated EV-
D68 entry into host cells and EV-D68 uncoating. The structures presented in this
thesis will facilitate the design and development of antiviral therapeutics and vaccines
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A. INTERACTIONS OF ENTEROVIRUS A71 WITH
HUMAN SCAVENGER RECEPTOR B2
Part of the text in this chapter is taken verbatim from [1] and is highlighted by a
black, vertical line in the right margin below.
A.1 Introduction
Enterovirus A71 (EV-A71) was first isolated from patients with neurological dis-
eases in California in 1969 [480]. It is one of the major causative agents of hand, foot
and mouth disease (HFMD) in infants and young children. It is also notable for se-
vere neurological complications, such as acute flaccid paralysis, aseptic meningitis and
encephalitis [481]. It also occasionally leads to fatal cases [481]. Recently, frequent
outbreaks have been reported particularly in Asia-Pacific region, raising significant
public health concerns [481]. Although there is no antiviral intervention available,
two vaccines using heat-inactivated whole virions have been approved for prevention
of EV-A71 infections among children in China [72,73].
Over the last few years, a number of cellular receptors and attachment factors
have been identified for EV-A71, including hSCARB2 (human scavenger receptor
B2), PSGL-1 (P-selectin glycoprotein ligand 1), heparan sulfate, sialylated glycans,
annexin II, vimentin, and nucleolin [164–166, 168, 169, 482–484]. These cell surface
molecules were shown to be indispensable for or only enhance EV71 infection in cell
culture. Specifically, hSCARB2 is a functional receptor for a broad range of EV-A71
strains [485]. It is expressed in a variety of human tissues, including neurons in the
central nervous system [486]. In addition, EV-A71 can not use mouse SCARB2 as a
receptor [165]. Thus, SCARB2 is a host factor that impacts the host range, tissue
tropism, and pathogenesis of EV-A71. More importantly, hSCARB2 plays crucial
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roles in virus attachment onto host cell surface, internalization through clathrin-
dependent endocytosis, and virus uncoating [193, 194, 199, 485]. In contrast, other
receptors or attachment factors have not been shown to induce EV-A71 uncoating
[194].
hSCARB2 is a glycoprotein also known as lysosomal integral membrane protein II,
which is an abundant protein in lysosomes [487]. It normally functions as a trafficking
receptor of beta-glucocerebrosidase, an important enzyme for glycolipid metabolism.
hSCARB2 is a type-III transmembrane protein with both termini spanning across
the membrane. It contains a large ectodomain (about 400 amino acids) when being
present on the plasma membrane (or a large lumenal domain when residing on the
lysosome membrane). The crystal structure of the hSCARB2 ectodomain showed a
twisted beta barrel core with an internal tunnel traversing the whole length of the
molecule [192, 487, 488]. Thus, hSCARB2 is structurally different from many known
EV receptors that possess repeated Ig-like domains [183]. Nevertheless, similar to
the interactions of Ig-like receptors with respective EVs, hSCARB2 was suggested to
bind into the canyon region of EV-A71, despite that the EV-A71 canyon is shallower
than many other EVs [30, 31]. Moreover, hSCARB2 triggers EV-A71 uncoating at
low-pH conditions [192–194].
Mutagenesis studies showed that residues 144-151 of a three-helix bundle at the
head region of hSCARB2 are directly involved in EV71 binding according to two
independent studies [193,489]. Nevertheless, there is some uncertainty whether there
are also other residues involved in virus attachment. It is also not known how glycans
on hSCARB2 contribute to virus-receptor binding. Moreover, the three-helix bundle
undergoes a pH-dependent conformational change and possibly regulates the accessi-
bility of the entrance to the aforementioned internal tunnel, which was proposed to
function as a lipid-transfer tunnel [192]. However, it remains obscure how such struc-
tural changes influence hSCARB2 induced EV-A71 uncoating at acidic conditions.
This chapter describes current progress towards a structural study of EV-A71 in
complex with hSCARB2. A major challenge of this study is that aggregates were
170
formed when purified EV-A71 were incubated with purified hSCARB2. This was
shown by two former members of the Rossmann laboratory, Dr. Pavel Plevka and
Dr. Steffanie Becker. Therefore, the major focuses of this chapter are analyzing the
interactions of purified EV-A71 with recombinant hSCARB2 proteins and forming a
virus-receptor complex in vitro that is suitable for cryo-EM structure determination.
A.2 Materials and Methods
A.2.1 Cells and viruses
SF9 cells (Spodoptera frugiperda) were kindly provided by Jue Chen (Rockefeller
University, US). These cells were maintained in Sf-900 III serum free medium (Gibco)
and incubated in a shaker at 27°C with a speed of 125 rpm. Human embryonic kid-
ney (HEK) 293T cells (ATCC CRL-11268) were maintained in DMEM supplemented
with 10% FBS and NEAA. These cells were grown at 37°C with 5% CO2. Stock
recommbinant baculoviruses for hSCARB2-Fc-His expression and for His-hSCARB2
expression were supplied by Ian Jones (University of Reading, UK) and by Sergio
Grinstein (University of Toronto, Canada), receptively. To amplify recombinant bac-
uloviruses for one more passage from the stock virus, SF9 cells (at 1.5-2.0 million
cells/ml) were inoculated with stock virus. At about 3 days post infection, super-
natants were harvested after spinning down the culture and stored at 4°C.
A.2.2 Virus growth and purification
Growth and purification of EV-A71 was performed using a similar protocol de-
scribed for EV-D68 in Chapter 2. The only modification was that EV-A71 (strain
MY104-9-SAR-97) infect RD cells at 37°C rather than at 33°C.
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A.2.3 Cloning
To produce the construct hSCARB2-His-Monomer, the ectodomain of hSCARB2
(residues 28-431) was cloned from the template pCAGGS-hSCARB2-F into the pHLsec
vector [490]. pCAGGS-hSCARB2-F is a construct that encodes full length hSCARB2
with a C-terminal FLAG-tag. It was kindly supplied by Satoshi Koike (Tokyo
Metropolitan Institute of Medical Science, Japan). The pHLsec vector was kindly
provided by Yuguang Zhao (Oxford University, UK). Briefly, the cloning procedure
included the following steps. DNA that encodes the ectodomain of hSCARB2 was
obtained by PCR using the plasmid pCAGGS-hSCARB2-F as a template. The
two primers were 5’-ATACCGGTGTCTTCCAGAAGGCTGTAG-3’(forward) and 5’-
ATAGGTACCAGTGTTAATCATAGACTTC-3’(reverse). The DNA fragment and
pHLsec vector were independently digested using restriction enzymes AgeI and KpnI.
The resultant insert and linearized vector were ligated. The ligation product was then
transformed into NovaBlue Singles competent cells (Novagen). Single colonies were
picked up, and cell culture was scaled up for plasmid extraction. The plasmid was
used for sequencing which confirmed the correctness of inserted sequences.
A.2.4 Protein expression and purification
For expression of hSCARB2-Fc-His or His-hSCARB2, SF9 cells (at 2.5-3.0 million
cells/ml) were inoculated with their respective recombinant baculoviruses. At about 3
days post infection, cell viability dropped down from more than 98% (before infection)
to about 50%. Supernantants were harvested after spinning down the culture. About
80 ml of 10X buffer A was added to 1000 ml of supernatant. 1X buffer A refers to
50 mM HEPES, 500 mM NaCl, 1 mM imidazole (pH 7.5), where HEPES is short for
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid. The adjusted supernatant was
then incubated with about 5 ml of Ni-NTA (nickel-nitrilotriacetic acid) agarose beads
(Qiagen) in a shaker at 80 rpm and 4°C, where the beads had been pre-equilibrated
with 1X buffer A. Beads were collected into a gravity flow column and washed with
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1X buffer A and then 20 mM imidazole in 1X buffer A. The proteins were eluted with
400 mM imidazole in 1X buffer A. After concentration, the proteins were loaded onto
a size exclusion chromatographic column, Hiload 16/600 Superdex 200 pg or Superdex
200 10/300 GL (GE Health), for further purification. The resultant fractions were
analyzed by SDS-PAGE.
hSCARB2-His-Monomer was expressed using a transient mammalian cell expres-
sion system. Protein expression level was first monitored for a small scale test by
western blot analysis, which allowed for optimization of the protein production yield.
The primary and secondary antibodies were Mouse Anti-6X His (Genescript) and
Goat Anti-Mouse antibody conjugated with an infrared fluorescent dye (hereafter,
the secondary antibody is named as GαM800) that has an emission peak at close
to 800 nm (LI-COR), respectively. Fluorescent intensities were recorded using an
Odyssey imaging system. For large scale expression, about 60% confluent 293T cells
were transfected with the plasmid DNA that was pre-complexed with the transfection
reagent PEI (polyethylenimine). For each 150mm dish, about 15µg plasmid was used,
and the ratio of plasmid to PEI was about 1:5. Supernatants were harvested at about
4 days post transfection. Purification procedures were similar to those for the two re-
combinant hSCARB2 forms mentioned above. Essentially, immobilized nickel affinity
chromatography and size exclusion chromatography were employed. The yield was
about 10-15 mg purified proteins per 500 ml culture.
For expression of hSCARB2-F, 297T cells were similarly transfected with the plas-
mid DNA using PEI as the transfection reagent. At about 48h post transfection, all
cells became detached. Proteins were purified per protocol offered by Satoshi Koike.
Briefly, after the culture was spun down, cell pellets were lysed in NTE buffer (20 mM
Tris, 120 mM NaCl, 1 mM EDTA, pH 8.0) with 1% (v/v) Triton X-100 (Sigma), where
Tris stands for tris(hydroxymethyl)aminomethane and EDTA stands for ethylenedi-
aminetetraacetic acid. The resultant mixture was spun down, and the supernatant
was used for immunoaffinity chromatography. Essentially, the supernatant was in-
cubated Anti-FLAG M1 beads (Sigma) in the presence of calcium cations (10 mM).
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After centrifugation and subsequently washing the beads, the proteins were eluted
from the beads using FLAG peptides (Sigma) in NTE buffer with 0.05% (v/v) NP-
40 (Sigma). NP-40 interferes with the UV absorbance of protein at the wavelength
of 280 nm. Thus protein concentration was assayed using Coomassie brilliant blue
R-250 dye that detects the presence of proteins and using BSA as a reference protein.
A.2.5 Enzyme-linked immunosorbent assay
Purified EV-A71 virions (with concentrations ranging from 0-9 µg/ml) in PBS
were coated onto a NUNC MaxiSorp 96-well plate (NUNC Inc.) at 4°C for overnight.
After washing with PBS and then blocking with blocking solution (2% (w/v) BSA in
PBS), wells were incubated at 4°C] for 1h with His-hSCARB2, PSGL-1-Fc, hSCARB2-
Fc-His, or hSCARB2-His-Monomer, all of which had a concentration of 20 µg/ml
and were in PBS with 1% (w/v) BSA. PSGL-1-Fc, a recombinant PSGL-1, had been
shown to bind EV-A71 and was kindly provided by Ian Jones. Then the plate was
washed with PBS for multiple times. The bound receptors were detected by the
primary antibody Mouse Anti-6X His (at a dilution of 1:750) and then by the sec-
ondary antibody Goat Anti-Mouse conjugated with alkaline phosphatase (Promega)
(at a dilution of 1:6000). After washing out unbound secondary antibodies, the activ-
ity of bound secondary antibodies were assayed using the substrate para-nitrophenyl
phosphate in 1M ethanolamine and 0.5 mM MgCl2 (pH 9.8). The absorbance of
the product para-nitrophenol in each well was recorded at a wavelength of 405 nm
using a SpectraMax M5 Microplate Reader (Molecular Devices). Experiments were
performed in triplicates. Non-specific binding of either the primary antibody or the
secondary antibody to coated virions was also assessed by including a series of nega-
tive controls. Coating of different concentrations of virions onto the plate was verified
by using Mouse Anti-EV-A71-VP1 (2 µg/mL, antibodies-online Inc.).
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A.2.6 Electron microscopy of negatively stained particles
Purified EV-A71 virions were incubated with or without hSCARB2-Fc-His (molar
ratio of receptor to virus was around 120:1) under in 20 mM citrate-phosphate buffer
with 150 mM NaCl (pH 4.5) at 4°C for 1h, subsequently at 37°C for 1.5h and soni-
cation (using an ultrasonic bath) for 3 min. For EM sample preparation, about 2.5
µl of sample was applied onto a thin layer of continuous carbon film supported by an
EM grid and incubated for about 2 min at room temperature. Excessive sample was
washed away with a large drop (about 8 µl) of 2% (w/v) uranyl acetate (pH about
4.5), followed by blotting. The grid was air dried and subsequently examined with
a Phillips CM200 microscope (FEI) operated at an accelerating voltage of 200 kV.
Electron micrographs were recorded at a nominal magnification of 38,000x using a
1K x 1K CCD camera.
A.3 Results and Discussion
Initial screening using electron microscopy of negatively stained particles was per-
formed with three forms of recombinant hSCARB2. These were hSCARB2-F (full
length hSCARB2 residues 1-478 with a C-terminal FLAG-tag), hSCARB2-Fc-His
(hSCARB2 ectodomain residues 30-434 with a C-terminal human IgG1 Fc-tag fol-
lowed by a 6X His-tag), and His-SCARB2 (hSCARB2 ectodomain residues 35-430
with an N-terminal 6 X His-tag). Electron micrographs showed that hSCARB2-
Fc-His induced EV-A71 uncoating under an acidic condition (pH 4.5) (Fig. A.1).
This observation suggested that hSCARB2-Fc-His is capable of binding EV-A71.
hSCARB2-Fc-His was predicted to be a dimeric protein based on gel filtration profile
(Fig. A.1). Nevertheless, His-hSCARB2 was not able cause aggregation of EV-A71.
Cryo-EM analysis of EV-A71 after incubation with His-hSCARB2 at 4°C for 2 min
showed no significant densities of bound His-hSCARB2 on the virus surface in the
reconstruction. These results suggested that His-hSCARB2 failed to bind EV-A71.
Furthermore, the production of hSCARB2-F, a membrane protein, had a low yield.
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Preliminary test with different kinds of detergents, including NP-40 and Tween-20,
indicated that they either impaired virus-receptor interactions or deteriorated the
contrast of cryo-EM images.
The dimeric hSCARB2-Fc-His proteins probably cross link EV-A71 particles, re-
sulting in the observed aggregation of the virus. Additionally, glycans on hSCARB2-
Fc-His (derived from insect cells) might not be favorable for virus-receptor bind-
ing [192,489]. Thus, a new construct, hSCARB2-His-Monomer, was designed, which
included the SCARB2 ectodomain (residues 28-431) and a C-terminal 6 x His-tag.
The protein was expressed in mammalian cells and purified to yield monomeric
hSCARB2, as was predicted based on gel filtration profile (Fig. A.2). ELISA anal-
ysis showed that hSCARB2-His-Monomer (as also PSGL-1-Fc) can bind to EV-A71,
whereas binding of hSCARB2-Fc-His with EV-A71 appeared to be fairly weak (Fig.
A.2). In contrast, His-hSCARB2 can not bind EV-A71, which is consistent with
the aforementioned cryo-EM analysis. Thus, hSCARB2-His-Monomer is a candidate
recombinant receptor that may alleviate the aggregation problem.
An early study reported that EV-A71 viruses tend to form aggregates [480]. Re-
ceptor triggered confromational change of the virus is probably also a reason that
explains hSCARB2 induced EV-A71 aggregation. Furthermore, the usual molar ra-
tio of hSCARB2 to EV-A71 in solution is more than 60:1. It is also probable that
excessive receptor is a factor that accounts for aggregation. Thus, there exist a
few potential approaches to work around the aggregation issue. Addition of sodium
deoxycholate, a reagent known for clearing EV-A71 aggregation [480], might be help-
ful. Alternatively, inclusion of capsid binding inhibitors (e.g., pirodavir [476]), may
prevent unnecessary conformational changes but still maintain virus-receptor inter-
actions. Another potential method is to take advantage of the recently developed
antibody-based affinity grid [491, 492]. The idea is to fix individual EV71 virions
with EV-A71 antibodies prior to complexing the virus with recombinant hSCARB2.
Finally, hSCARB2 might be incorporated into artificial membrane systems such as
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Fig. A.1. hSCARB2-Fc induces EV-A71 uncoating at low pH.
A. Size exclusion chromatographic profile of hSCARB2-Fc-His using
a Superdex 200 column shows an estimated dimeric form of the pro-
tein. B. SDS-PAGE analysis of hSCARB2-Fc-His. Fractions of the
left peak (at 11.7 ml) on the gel filtration profile was pooled up and
concentrated to yield the final protein (lane 4 from the left). Lanes 2-3
represent samples before gel filtration. C-D. Electron micrographs of
negative stained EV-A71 particles. C. EV-A71 alone was incubated
under pH 4.5 at 4°C for 1 h and then at 37°C for 1.5 h. D. EV-A71
and hSCARB2-Fc-His were incubated under pH 4.5 at 4°C for 1 h
and then at 37 °C for 1.5 h. Scale bar: 200 nm.
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Fig. A.2. A mammalian cell derived monomeric hSCARB2
binds EV-A71. A. Gel filtration profile of hSCARB2-His-Monomer
shows a predicted monomeric form of the protein. B. SDS-PAGE
analysis of hSCARB2-His-Monomer. The far right lane represents a
sample that was pooled up from the fractions of the peak (at 13.9
ml) shown in A. Other lanes correspond to fractions collected from
a previous run of gel filtration. C. Binding of SCARB2 to EV71
was analyzed by ELISA. Wells were coated with different concen-
trations of purified virus, followed by addition of hSCARB2. The
bound hSCARB2 was detected by using mouse anti-6X Histag and
subsequently anti-mouse conjugated with alkaline phosphatase. Ex-
periments were done in triplicates. Data are shown as mean±SD.
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liposomes [136] and nanodiscs [213]. This approach would bring the virus-receptor
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